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Abstract 
The next generation of monoclonal antibody (mAb) therapies are 
under increasing pressure from healthcare providers to offer cost effective 
treatments in the face of intensified competition from rival manufacturers and 
the looming loss of patent exclusivity for a number of blockbusters. To remain 
completive in such a challenging environment companies are looking to 
reduce R&D and manufacturing costs by improving their manufacturing 
platform processes whilst maintaining flexibility and product quality. As a 
result companies are now exploring whether they should choose 
conventional batch technologies or invest in novel continuous technologies, 
which may lead to lower production costs. This thesis explores the creation of 
a dynamic tool as part of a decision-support framework that is capable of 
simulating and optimising continuous monoclonal antibody manufacturing 
strategies to assist decision-making in this challenging environment. 
The decision-support framework is able to tackle the complex problem 
domain found in biopharmaceutical manufacturing, through holistic 
technology evaluations employing deterministic discrete-event simulation, 
Monte Carlo simulation and multi-attribute decision-making techniques. The 
hierarchal nature of the framework (including a unique sixth hierarchal layer; 
sub-batches) made it possible to simulate multiple continuous manufacturing 
scenarios on a number of levels of detail, ranging from high-level process 
performance metrics to low-level ancillary task estimates. The framework is 
therefore capable of capturing the impact of future titres, multiple scales of 
operation and key decisional drivers on manufacturing strategies linking 
multiple continuous unit operations (perfusion cell culture & semi-continuous 
chromatography). 
The work in this thesis demonstrates that the framework is a powerful 
test bed for assessing the potential of novel continuous technologies and 
manufacturing strategies, via integrated techno-economic evaluations that 
take proof-of-concept experimental evaluations to complete life-cycle 
performance evaluations.  
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Abbreviations 
 
AEX   Anion-Exchange Chromatography 
ATF  Alternating Tangential Flow perfusion cell culture 
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ATF-CC ATF perfusion, Continuous capture and Continuous polishing 
B&E   Bind and Elute 
BDS  Bulk Drug Substance 
BLA  Biological Licensure application 
CDR  Complementarity-Determining Regions 
CEX  Cation-Exchange Chromatography 
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CIP  Cleaning-in-Place  
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COG/g Cost of Goods per gram 
CPP   Critical Process Parameters  
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CQA   Critical Quality Attributes  
CV  Column Volumes 
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DSP  Downstream Processing 
EB  Environment Burden 
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FB  Fed-Batch cell culture 
FB-CB  Fed-Batch, Continuous capture and Batch polishing 
FB-CC Fed-Batch, Continuous capture and Continuous polishing 
Fc  Crystallisable Fragment 
FCI   Fixed Capital Investment 
FDA  United States Food and Drug Administration 
FT   Flow Through 
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FTE  Full Time Equivalent 
HCCF  Harvested Cell Culture Fluid 
HCP   Host Cell Proteins 
HIC  Hydrophobic Interaction Chromatography 
HMW  High Molecular Weight species 
HPLC  High Performance Liquid Chromatography 
ICH International Conference on Harmonisation Technical 
Requirements for Registration of Pharmaceuticals for Human 
Use 
IgG  Immunoglobulin G 
IND  Investigational New Drug application 
LMW  Low Molecular Weight species 
mAb  Monoclonal Antibody 
MADM Multi-Attribute Decision-Making  
MCDM Multi-Criteria Decision-Making  
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PCC  Periodic Counter Current chromatography 
PoC  Proof-of-Concept 
PoS  Probability-of-Success 
PPQ   Process Performance Qualification  
QbD  Quality by Design 
QCQA Quality Control and Quality Assuracne 
R&D  Research and Development 
SEC  Size Exclusion Chromatography 
SEM   Scanning Election Microscopy  
SIP  Sterilising-in-Place 
SPIN  Spin-Filter perfusion cell culture 
SQL   Structured Query Language 
UFDF  Ultrafiltration/Diafiltration 
UML  Unified Modelling Language 
USP  Upstream Processing 
VBA  Visual Basic for Applications 
VRF  Virus Retention Filtration 
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1 Introduction 
 Over 20 therapeutic monoclonal antibodies (mAb) have been approved 
to date accounting for 35% of the therapeutic market (Aggarwal 2011; Wang 
et al. 2009), with the top-selling eight mAbs accounting for greater than $18 
billion in annual revenue in the US (Aggarwal 2011; Yamane-Ohnuki and 
Satoh 2009). In addition, there are approximately 300 antibodies in clinical 
development increasing at an annual rate of 18% since 2004 (PhRMA 2004; 
PhRMA 2006; PhRMA 2008; PhRMA 2011) and with expected clinical 
success rates of 11-17% a significant number will make it market (DiMasi et 
al. 2010; Kelley 2009; Paul et al. 2010; Reichart 2009; Strohl 2009). 
Furthermore, ten licensed recombinant antibodies will lose patent exclusivity 
over the next eight years. In this climate of increasing competition and lower 
reimbursement levels, improving research and development (R&D) 
productivity whist reducing manufacturing costs is a major challenge for the 
biopharmaceutical industry (DiMasi et al. 2010; Farid 2009a; Morgan et al. 
2011; O'Hagan and Farkas 2009; Paul et al. 2010).  
 In the effort to reduce R&D and manufacturing costs biopharmaceutical 
manufacturers are looking to improve their manufacturing platform processes 
whilst maintaining flexibility and product quality (DiMasi et al. 2010; Farid 
2009a; Morgan et al. 2011; O'Hagan and Farkas 2009; Paul et al. 2010). 
However, the development and manufacture of biopharmaceutical drugs is a 
highly complex endeavour that is heavily regulated (DiMasi et al. 2010; Paul 
et al. 2010). This has stimulated controversial discussions within the industry 
on the best choice of mAb production technologies (Kelley 2009; Kelley 
2007). Companies are now asking whether they should choose conventional 
batch technologies or invest in novel continuous technologies, which may 
lead to lower production costs. These questions demonstrate that there is a 
significant opportunity for a decisional framework capable of comparing the 
new continuous technologies to existing platform technologies and guiding 
decision makers towards effective technology evaluations. Consequently, the 
aim of this thesis is the development of a decisional tool that is capable of 
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simulating and optimising continuous mAb manufacturing processes in this 
challenging environment. 
 This introductory chapter provides an overview of this challenging 
environment, by exploring the published literature on drug development, 
manufacturing norms and alternatives, the use of computational frameworks 
and the techniques they employ. Section 1.1 provides an overview of the 
economics, success rates and on-going paradigm shift in clinical trial strategy 
being experienced currently in biopharmaceutical drug development. Section 
1.2 explores biopharmaceutical manufacturing, providing an insight into the 
current technologies being employed and the resulting economic and 
environmental impacts of biopharmaceutical manufacturing processes. 
Sections 1.3 & 1.4 focuses on mAbs as therapeutic drugs and reviews the 
current state of mAb manufacturing combined with an overview of future mAb 
manufacturing processes. There is an overview of computational simulation 
tools and the techniques they employ when simulating and evaluating 
biopharmaceutical manufacturing processes in Section 1.5. Finally, in 
Section 1.6 the aims and organisation of the thesis are presented. 
 
1.1 Biopharmaceutical Drug Development 
Biopharmaceuticals are medical drugs produced by biotechnology 
processes. Examples include recombinant vaccines (attenuated or killed viral 
bodies, toxins or surface proteins), nucleic acids (DNA, RNA or antisense 
oligonucleotides) and recombinant proteins. Recombinant proteins are the 
leading category of biopharmaceuticals (Aggarwal 2011) and include 
hormones (e.g. Insulin for diabetes), growth factors (e.g. erythropoietin for 
anaemia), cytokines (e.g. Interferon beta-1a for multiple sclerosis), 
therapeutic enzymes (e.g. beta-glucoerebrosidase for Gaucher disease), 
blood factors (e.g. r.Factor VIII for haemophilia) and monoclonal antibodies 
(e.g. infliximab for Crohn’s disease etc.). This thesis takes a particular 
interest in monoclonal antibodies (mAbs); the development of which follows 
the same path as other biopharmaceuticals, including several stages of 
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clinical testing before approval. 
The development of a biopharmaceutical is a lengthy and expensive 
process that involves three distinct phases of development from drug 
discovery to clinical testing and eventual approval. Drug discovery can be 
broken down into four phases: target identification, target validation (Target-
to-hit), lead identification (hit-to-lead) and lead optimisation (Bogdan and 
Villiger 2010; Paul et al. 2010). During target identification both the healthy 
and pathological states are compared to allow possible drug targets to be 
found. Once a target has been found its biochemical functions are assessed 
in a disease model; this is created from either cultured human cells or an 
animal model (usually mouse). After the identification of multiple promising 
targets and the successful creation of a disease model, the chosen targets 
are validated; the most promising targets are then selected for further 
development. These promising targets feed into the lead identification phase 
where large libraries of molecules are screened. The molecules that show 
specificity for the target and exhibit the desired changes are selected (leads). 
The leads are then optimised; this is where an attempt at made to improve 
the activity of the lead without compromising safety and bioavailability, which 
are tracked by in vivo and in vitro studies. 
Once the optimal lead (drug candidate) is selected it then enters the 
clinical testing phase of development, which is designed to test the safety, 
biological activity and effectiveness of the drug candidate (DC). Pre-clinical 
testing is the last stage prior to human testing and therefore the principle aim 
of the study is to assess if the DC is safe to administer to humans. To start 
human clinical trials an investigational new drug application (IND) must be 
submitted to the FDA. The IND details all the experimental results from drug 
discovery; the chemical structure of the DC; how it is thought to work in the 
body; any toxicity findings from pre-clinical studies and how the DC is 
manufactured (PhRMA 2011). Table 1.1 illustrates how the principle aim of 
Phase I clinical trials are to establish the safety of the DC in humans; this is 
achieved by studying the DCs safety profile and the safe dosage range. 
These studies also address the bioavailability of the DC by monitoring its 
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biochemical and physiological effects on the healthy test population. Phase II 
studies use a patient test population; these are divided into two streams of 
studies, with IIa studies designed to define dosage and IIb designed to prove 
effectiveness. The goal of Phase II trials is to show the proof-of-concept of 
the DC i.e. showing that it is effective in treating the target indication (Bogdan 
and Villiger 2010). If the DC is successful it progresses to Phase III clinical 
trials. Phase III trials encompass a large patient test population, the aim of 
which is to confirm effectiveness, establish the correct dosage and disclose 
any side effects seen. Following the completion of all three phases of clinical 
trials the company files a biological licence application (BLA). The FDA or 
EMEA reviews the data and decides if it will grant the company marketing 
approval, ask for further clinical trials or even refuse marketing approval. 
After approval a company is required to submit periodic reports focusing on 
continued product quality and any adverse side effects reported. In some 
cases a company may have to carry out further clinical studies (Phase IV) 
that evaluate the long-term effects of the DC.  
 
Table 1.1. Stages of Biopharmaceutical Development 
  Clinical Trials 
 Discovery & 
Pre-clinical Phase I Phase II Phase III 
Test 
Population 
Laboratory 
and animal 
studies 
20 to 100 
healthy 
volunteers 
100 to 500 
patient 
volunteers 
1000 to 5000 
patient 
volunteers 
Purpose 
Assess safety 
and biological 
activity 
Determine 
safety and 
dosage 
Evaluate 
effectiveness 
and define 
dosage 
Confirm 
effectiveness, 
dosage and 
monitor any 
adverse 
reactions 
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1.1.1 Economics & Success of Development 
 The average capitalised and risk-adjusted R&D cost to bring a new 
biopharmaceutical to market has recently been estimated to be between 
$1.2-1.8 billion (DiMasi and Grabowski 2007; Paul et al. 2010). The 
substantial development cost can be attributed to the high attrition rate of 
new drug candidates from preclinical discovery to BLA submission and 
launch. Estimated success rates of 11-17% mean that 6-9 DCs must enter 
Phase I clinical trials to generate a single successful launch (DiMasi et al. 
2010; Paul et al. 2010; Reichart 2009). This translates into an average cash 
outlay of approximately $210 million ($170 - $250 million) per drug as it 
proceeds from preclinical development to launch (DiMasi and Grabowski 
2007; Paul et al. 2010). Table 1.2 highlights how the highest level of attrition 
occurs at the transition of the DC from Phase II to Phase III trials; this is 
when the DC must prove efficacy before being enrolled in expensive Phase 
III trials. The resulting successful DCs have to recover the cost of the failed 
DC projects, with the majority of which have incurred Phase I and Phase II 
clinical trial costs. 
Table 1.2. Probabilities of Success for Clinical Phase Transition 
 DiMasi et 
al, 2010 
Paul et 
al, 2010 
Reichert, 
2009 Nelson et al, 2010 
Drug 
Candidate 
Categories 
Biotech1 Biotech Humanised mAbs2 
Humanised 
mAbs3 
Human 
mAbs4 
Phase I-II 64% 54% 80% 80% 89% 
Phase II-III 39% 34% 46% 47% 51% 
Phase III-
BLA 66% 70% 80% 86% 75% 
BLA-
Launch 100% 91% 100% 100% 100% 
Overall 
success 16% 12% 29% 32% 33% 
1 Phase success rates from 1999 to 2004 
2 Phase success rates from 1997 to 2008 
3 Phase success rates from 1997 to 2008 (n = 133) 
4 Phase success rates from 1997 to 2008 (n = 131) 
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 Probabilities of success (PoS) play a key role in determining how 
companies allocate resources; for example resources are more likely to be 
directed towards development programs deemed to have a higher chance of 
success. Table 1.2 highlights the PoS for general biopharmaceuticals 
alongside humanised and human mAbs. Both exhibit the same high attrition 
rates between Phase II and Phase III transitions, however, nearly half of all 
humanised and human mAbs (46-51%) will move onto Phase III studies 
compared to just over a third of general biopharmaceuticals (34-39%). A 
significant majority of humanised and human mAbs (80-89%) also 
demonstrate a superior Phase I to Phase II transition success compared to 
general biopharmaceuticals (54-64%). The higher PoS shown for humanised 
and human mAbs is due to their highly specific nature and reduced likelihood 
of generating an adverse immune response. This in turn leads to improved 
safety (Phase I success) and efficacy (Phase II success) profiles compared 
to other biopharmaceuticals.  
 The high success rates shown have made companies more likely to 
champion mAb drug candidates over other biopharmaceuticals. Today mAbs 
and Fc fusion proteins account for 35% of the therapeutic market (Strohl 
2009) and this is likely to increase significantly, with approximately 300 
candidates currently under development (PhRMA 2011). This trend 
demonstrates a common approach by companies to de-risk their candidate 
pipeline in an attempt to reduce development costs by having to recuperate 
fewer failed DCs. However, numerous studies have demonstrated that 
development costs have been trending upwards significantly over the last 
couple of decades (DiMasi et al. 2010; DiMasi et al. 2003; Morgan et al. 
2011). The principle factors routinely identified as primary drivers of 
development costs are the risk and time involved in drug development. Real 
development times have remained relatively stable during the last two 
decades, but the ‘time costs’ associated with development are increasing 
above inflation as clinical trials become larger and more complex, demanding 
increased investment of resources (DiMasi et al. 2010; Paul et al. 2010). 
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1.1.2 Future Development Paradigms 
Over a decade ago the increase in R&D costs was shown to be occurring 
at a significantly higher rate in comparison to the number of new approvals 
(DiMasi et al. 2003). The overall R&D productivity, as measured by IND & 
BLA applications per dollar invested, has declined 21% annually in the 
ensuing time period (O'Hagan and Farkas 2009). Biopharmaceutical 
companies are now struggling to make the same level of returns on invested 
capital previously seen for new DC development; due to a drop from 9% in 
1995-2000 to only 4% in capital returns today (O'Hagan and Farkas 2009). In 
addition, ten licensed recombinant antibodies will lose patent exclusivity over 
the next eight years. This will affect the amount of capital these companies 
have at their disposal to invest. In this climate, improving research and 
development (R&D) productivity whist reducing R&D costs is a major 
challenge facing the biopharmaceutical industry. This has led to some 
questioning the business model of larger biopharma, with many even 
predicting its imminent demise (O'Hagan and Farkas 2009; Paul et al. 2010). 
Efforts are being made to improve R&D productivity by the 
biopharmaceutical companies, including experimenting with new R&D 
organisations, partnerships and technologies (O'Hagan and Farkas 2009). 
However, most companies are still employing the traditional R&D paradigm, 
using the scale-more tactic, hoping the number of “shots on goal” will 
translate into more successful launches (O'Hagan and Farkas 2009; Paul et 
al. 2010). An alternative paradigm gathering support employs the scale-more 
tactic, but attempts to reduce the incurred development costs caused by 
failed DCs. 
Current R&D costs are dominated by clinical expenditure, which typically 
accounts for 70% of the $210 million R&D cost per successful DC (Bogdan 
and Villiger 2010; DiMasi and Grabowski 2007; Paul et al. 2010). Therefore, 
approximately $145 million can be attributed to clinical activities, with a 
further $65 million spent on process development and manufacturing. The 
quick win, fail fast development paradigm targets a reduction in the clinical 
expenditure by reducing uncertainty from the expensive later development 
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stages (Phase II & III) through the establishment of proof-of-concept (PoC) 
(Cartwright et al. 2010; Paul et al. 2010). Where proof-of-concept is defined 
as “The earliest point in the drug development process at which the weight of 
evidence suggests that it is reasonably likely that the key attributes for 
success are present and the key causes of failure are absent” (Cartwright et 
al. 2010).  
 
Figure 1.1.  A comparison of the differences between (a) the traditional 
development paradigm and (b) quick win, fail fast paradigm. The alternative 
paradigm demonstrates the use of proof-of-concept (PoC) to reduce the 
number of expensive late-stage R&D failures. The savings are re-invested in 
drug discovery generating more drug candidates to feed into the PoC model, 
this referred to as the “R&D sweet spot”. FED, first efficacy dose; FHD, first 
human dose; PD, product decision. Adapted from Paul et al, 2010. 
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Figure 1.1 highlights the key difference between the traditional R&D 
paradigm (Figure 1.a) and the quick win, fail fast paradigm (Figure 1.b). In 
this alternative paradigm the early development stages (Phase I & IIa) are 
designed to include the ability to monitor the efficacy, safety and 
differentiation of the DC, allowing the termination of ineffective DCs as early 
as possible and therefore reducing the incurred development costs for the 
successful DCs (Cartwright et al. 2010; Paul et al. 2010). This approach 
reduces the number of DCs progressing to Phase II & III, but the ones that do 
progress have a much higher PoS and Launch. The reduction in resource 
investment into late-stage development (Phase III & IV) for just one product 
has been estimated to be sufficient to fund the early-development of almost 
10 Phase 1 DCs (Paul et al. 2010). The paradigms two pronged approach to 
increase R&D productivity, by killing-off DCs destined to fail early-on and 
invest the resulting saved resources into further lead development, is 
projected to offer a 28% reduction in the cost in bringing a new DC to market 
(Paul et al. 2010). 
 
1.2 Biopharmaceutical Manufacture 
 Manufacturing processes for biopharmaceuticals can vary greatly, 
especially for non-antibody products. However, they do share a number of 
common features and processes, which are highlighted in Table 1.3. The 
manufacturing process usually involves a product synthesis step, where the 
protein is produced by fermentation. Mammalian cells are the dominant 
expression system used in recombinant protein production due to their ability 
to assemble, fold and apply the correct post-translational modifications 
(Marichal-Gallardo and Álvarez 2012). The fermentation step is followed by a 
series of processing operations designed to recover and purify the target 
protein, commonly referred to as downstream processing (DSP). The post-
fermentation solution contains large number of impurities, including chemical 
reagents, host cell components (e.g. proteins, DNA) and various product 
related impurities (e.g. aggregates, product fragments). The principle aim of 
the DSP is to remove these impurities, however the diverse nature of these 
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impurities can lead to complex DSP configurations that dominate the overall 
manufacturing process. 
 
Table 1.3. Overview of Biopharmaceutical Manufacturing Operations 
Product Synthesis 
Cell Culture 
• Bacteria (e.g. E. coli), yeast or fungi cell culture for non-antibody proteins 
• Mammalian cell culture for production of antibodies 
 
Product Purification 
Isolation / Recovery 
• Product in fermentation broth:  
− Cell removal and volume reduction 
• Product inside cells: 
− Soluble form: cell disruption, solids removal and volume reduction 
− Insoluble form (inclusion bodies): homogenization, differential 
centrifugation, wash and dissolution 
Purification / Reaction 
• Bulk & Intermediate Purification:  
− Primarily for removal of process-related impurities, e.g. reagents, host 
cell proteins, DNA, endotoxins; some product-related impurities; 
common methods: 
• Precipitation, adsorption, extraction 
• Chromatography (bind & elution, flowthrough) 
• Ultrafiltration/Diafiltration (UF/DF):  
− Used as needed for product concentration (volume reduction) and 
buffer exchange (prepared for next step or for storage) 
• Reaction/product modification:  
− Used at an appropriate point in purification train for conversion to 
bioactive forms (e.g. refold / oxidation, dimer formation, PEGylation) 
• Polishing:  
− Final purification step (invariably using chromatography) to remove 
close product-related impurities and residual of host cell proteins 
(HCPs). 
• Final UF/DF & Sterile Filtration: 
− Concentration & buffer exchange for long-term product storage or 
preparation for drug product formulation 
 
Adapted from Ho et al. 2011. 
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 Section 1.1.1 highlighted the inherent risks associated with 
biopharmaceutical development. This uncertainty leads to companies having 
to devise manufacturing schedules and strategies with insufficient 
information, such as the product dosage, cell line productivity and projected 
market demands (Farid 2009b). This can lead to companies having unused 
manufacturing capacity in their facilities or insufficient reservations with a 
contract manufacturer (CMO) to generate the required clinical material on 
time. These scenarios can lead to significant financial losses and have 
placed a growing emphasis on improving the cost-effectiveness of 
biopharmaceutical manufacturing. Manufacturing costs are often split into two 
classes with a distinction being made between the invested costs (capital 
investment) and the operating costs (cost of goods). 
 
1.2.1 Capital Investment 
 Capital investment is often described as the capital required to construct, 
validate and licence a manufacturing facility. This includes the base building 
cost with all the process equipment costs, HVAC systems, process piping, 
instrumentation and utilities included; plus the indirect costs associated with 
design, engineering, validation and licensure. Investment costs for cGMP 
facilities are reported to range from $25 to $750 million (Farid 2007) 
(Pavlotsky 2004) with construction times of 4-5 years to build, validate and 
licence the resulting facility (Farid 2009b; Kamarck 2006). The most recent 
construction activity has been for multiproduct manufacturing facilities for the 
production of antibodies (Pfizer, Grange Castle, Ireland & MedImmune, 
Frederick, USA). Table 1.4 highlights the estimated investment cost, facility 
size and bioreactor capacity for a number of these facilities. The table also 
allows a number of benchmark costs to be calculated, with investment costs 
shown relative to facility size of $660 to $1780 per square foot and to 
bioreactor capacity of $1,765 to $12,000 per litre (in the range of 20,000 to 
200,000L) dependant on the facility design and level of plant automation 
(Farid 2007).  
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Table 1.4. Benchmarks for Antibody Manufacturing Facilities 
Manufacturing 
Facility 
Date 
Facility 
Completed 
Capital 
Investment 
($ million) 
Area 
(sq ft) 
Bioreactor Capacity 
Number Size (L) Total (L) 
Genetech, 
Vacaville, CA 2000 250 310000 8 12000 96000 
Imclone, 
Branchburg, 
BB36, NJ 
2001 53 80000 3 10000 30000 
Biogen, 
LSM, RTP, NC 
2001 175 245000 6 15000 90000 
Boehringer 
Ingelheim, 
Bibreach, 
Germany 
2003 315 - 6 15000 90000 
Lonza Biologics, 
Portsmouth, NH 2004 207 270000 3 20000 60000 
Amgen,  
BioNext, West 
Greenwich, RI 
2005 500 500000 9 20000 180000 
Genentech 
Expansion, 
Oceanside, CA 
2005 380 470000 6 15000 90000 
Imclone 
Expansion, 
Branchburg, 
BB36, NJ 
2005 260 250000 9 11000 99000 
Biogen Idec, 
Hillerod, 
Denmark 
2007 350 366000 6 15000 90000 
Lonza Biologics, 
Tuas, Singapore 2009 250 - 4 20000 80000 
Genetech, 
Vacaville, CA 2009 600 380000 8 25000 200000 
Bristol-Myers 
Squibb – 
Devens, MA 
2011 750 - 6 20000 120000 
Pfizer Biotech 
Campus, 
Grange Castle, 
Ireland 
2011 18001 - 6 12500 75000 
MedImmune, 
Frederick, MD 2011 600 337000
2 4 12500 50000 
Adapted from Farid, 2007. 
1 Investment cost includes finish and fill and other auxiliary facilities. 
2 Extra 100,000 sqft of production capability available. 
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 Cost benchmarks are commonly employed to estimate the investment 
required for future cGMP manufacturing facilities. For example, Pavoltsky 
(2004) utilises facility size benchmarks to derive the projected investment 
cost. Werner (2004) relates the investment cost to the required output of 
facility, deriving his cost estimates from benchmarked bioreactor capacity 
costs (Werner 2004). Although benchmark investment costs are useful, Farid 
(2007) highlights a number of limitations of datasets used to derive 
benchmark investment costs. For example, facility costs and areas are often 
quoted without clarification of whether they account for warehouses and 
support facilities or without specification of the exact set-up of the processing 
equipment in the facility (for example the number of purification trains or level 
of automation). Better-cost estimates can be derived using factorial estimates 
but these require more detailed knowledge of factors, such as the type and 
number of key process equipment. Factorial estimates use a cost factor 
derived from previous construction projects, relating the capital outlay used in 
facility construction to the cost of equipment in the facility. The factorial 
method is often attributed to Lang (1948) and has been used to estimate 
capital investment in chemical facilities, water treatment plants and 
biopharmaceutical facilities (Lang 1948). Chemical facilities often use values 
in the range of 3-5 (Peters et al. 2006; Sinnott et al. 2005), with 
biopharmaceutical facilities using much larger values, ranging from 3.3-8.1 
for stainless steel based facilities and values up to 23.7 for single-use based 
facilities (Farid 2007; Novais et al. 2001; Pollock et al. 2013b). The high Lang 
Factors used in biopharmaceutical facilities are due to the requirement to 
maintain higher cGMP suite contaminant level ratings, which result in 
increased HPAC/HVAC and SIP costs. 
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1.2.2 Cost of Goods 
 Operating costs are often described as any cost associated with the 
production of the product (goods) and hence referred to as `Cost of Goods`. 
The Cost of Goods (COG) typically comprise of direct costs related to 
production, such as raw materials and utilities, and indirect costs which 
account for the depreciation and maintenance of the manufacturing facility. 
Labour costs are often reported as direct (hourly rate related to 
manufacturing activities) or indirect costs (FTE annual labour cost) 
depending on the reporting methods preferred. The exact impact of each cost 
parameter on the overall COG varies with both the scale of operation and cell 
culture titre. The relationships between each cost factor are succinctly 
summarised by Farid (Farid 2009b). Figure 1.2 highlights how the overall 
COG per gram (COG/g) declines with increased annual production capacity 
(Figure 1.2.a), while the ratio of indirect and direct costs shifts so that the 
material costs dominate the COG/g and the labour and indirect costs fall and 
therefore represent a reduced fraction of the COG/g (Figure 1.2.b). The 
relationships presented highlight how at small-scales of production indirect 
costs tend to dominate and thus any change in material costs will have 
minimal impact. In contrast, any reduction in material cost at larger scales will 
significantly impact COG/g, particularly the DSP raw materials (Figure 1.2.c). 
Figure 1.2.c presents a phenomenon often reported as the `downstream 
bottleneck` (Langer 2012), where the increase in cell culture titre increases 
the mass of product requiring purification. The increase in material requiring 
purification in turn increases the DSP costs, due to the principal purification 
technology, `chromatography` being linearly scalable. Therefore, larger 
columns are employed to process the extra product impacting raw material 
costs (Figure 1.2.b), in place of extra column cycles due to time constraints. 
The trends highlighted in Figure 1.2 are expected to become even more 
pronounced if the increase in annual output is accompanied by an increase in 
titre (Farid 2009b). 
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Figure 1.2.  Typical cost trends seen as scale increases for a) total cost of 
goods per gram (COG/g); b) material, labour and indirect costs; c) upstream 
and downstream operating costs. Adapted from Farid 2009. 
 
 Manufacturing COG are reported to represent 15-25% of sales (Farid 
2009b), with the recovery of development costs and sales related costs 
dominating sales price. This trend has made biopharmaceutical companies 
reluctant to publicise representative COG values. A literature review of COG 
is further complicated by the fact that annual production rate, titre or 
fermentation capacities are not always available (Farid 2007; Kelley 2009). 
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246 PROCESS ECONOMIC DRIVERS IN ANTIBODY MANUFACTURE
 12.4  ECONOMIES OF SCALE 
 The relative importance of key process parameters on the overall economic 
feasibility of a process varies with both the scale of operation and the assumed 
titer. As annual output and scale increase at a given titer or combined with 
titer increases, the relative importance of different cost categories is expected 
to change as shown in Fig.  12.5 . The overall COG per gram decreases, while 
in terms of the ratio of direct and indirect costs, the material costs rise consid-
erably and dominate the COG per gram, whereas labor and capital - dependent 
costs (overheads) fall and hence represent a less - signifi cant proportion of 
COG per gram. Similarly in terms of the ratio of upstream processing  (USP) 
and DSP costs, the DSP costs become a major component of the COG 
per gram. 
 If the increase in annual output is also accompanied by titer increases, then 
the trends are expected to become even more pronounced. At small scales, 
fi xed costs tend to dominate, and thus any changes in raw material costs will 
 FIGURE 12.5  Economies of scale. Typical cost trends as scale increases for ( a ) total 
COG per gram; ( b ) mater al, labor, an  indirect (capital - related) costs; and ( c ) USP 
and DSP operating costs. 
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Historic published estimates of COG per gram for antibodies range from 
$1000s per gram to $100s per gram, with more recent estimates from 
conference proceedings and publications suggesting $50 - $100 per gram for 
current processes with titres ≥ 2 gram per litre (Farid 2007; Kelley 2009). 
 
1.2.3 Environmental Sustainability 
 Biopharmaceutical manufacturing has a unique environmental footprint 
compared to other manufacturing sectors, these environmental 
characteristics are summarised below (Ho et al. 2011).  
 
• The manufacturing processes use very large amounts of water; 
• Significantly more water is used in the supporting operations, such as 
CIP, SIP and facility maintenance; 
• The majority of process buffers contain large amounts of common 
salts such as NaCl which end up as aqueous waste; 
• The majority of waste is aqueous and innocuous in nature (very low 
solvent use); 
• Solid wastes in the form of consumables (resins, membranes, filters, 
single-use bags and tubing/connectors) are on the increase due to rise 
in single-use technology use. 
 
 The major characteristic of biopharmaceutical manufacture is the vast 
amounts of water used during manufacturing. The fermentation step is 
responsible for a large amount of this water use. Productive fermentation 
operations can now achieve protein concentrations of 5-10 g/L, which is only 
equal to 0.5-1 wt% of the solution (Ho et al. 2011). The fermentation steps 
therefore consume between 20-25% of the total water used, however, the 
chromatographic operations are the principle water using steps often 
surpassing 50% of the total (Ho et al. 2011). 
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 The amount of water and consumables used in the manufacture of a 
product can be used to establish the environmental burden of a given 
manufacturing strategy. A widely utilised concept called the E factor was 
originally developed by Sheldon for the chemical industry to assess the 
overall environmental impact or greenness of production (Sheldon 1994; 
Sheldon 1997; Sheldon 2007). The E factor is defined as the total amount of 
reagents, water and consumables used per kilogram of product produced. 
The E factor could serve as a very useful environmental index for the 
production of biopharmaceuticals simply because every manufacturing step 
uses aqueous solutions and is processed via a range of consumable 
components (resin, filters, single-use bags and tubing). The E factor can also 
be used to monitor the water usage for the non-process operations. Typical 
antibody manufacturing strategies consume water (process and non-process) 
from 3000 to over 9000 kg water per kilogram of antibody produced and 1 to 
16 kg of consumables per kilogram of antibody produced (Ho et al. 2011; 
Pollock et al. 2013b). 
The E factor does have its limitations, namely its inability to highlight the 
environmental impact of toxic substances. This is not a particular concern for 
biopharmaceutical manufacture due to the innocuous nature of the aqueous 
waste streams generated, which are readily discharged as municipal waste 
(after minor treatment). The solid waste streams from consumable use are 
typically autoclaved prior to landfill or incineration. In contrast the chemical 
industry generates more exotic and environmental unsustainable waste 
streams including large volumes of organic solvents. Irabien et al propose a 
new index called the Environmental Burden (EB), which addresses pollutant 
release via air (emissions), water (effluents) and soil (wastes) (Irabien et al. 
2009). Each substance monitored is weighted by a “potency factor” that 
captures the environmental impact of the substance release rather than just 
the quantity discharged. 
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1.3 Monoclonal Antibodies 
 Therapeutic monoclonal antibodies (mAb) are the best-selling biologics 
accounting for 5 of the top 10 selling drugs in 2012 and 51.8% of total 
biologic sales (Aggarwal 2011; Merie 2013; Reichart 2013). The top-selling 
five mAbs account for greater than $37 billion in annual revenue (Merie 
2013). In addition, there are currently approximately 300 antibodies in clinical 
development (PhRMA 2011). The number of licensed antibodies is growing 
at a rate of about 11% per annum (Kelley 2009) and the number of clinical 
antibody candidates has been growing at a rate of 18% since 2004 (PhRMA 
2004; PhRMA 2006; PhRMA 2008; PhRMA 2011). Monoclonal antibodies 
have been the principle drivers of the recent biopharmaceutical sales and are 
likely to remain so for the foreseeable future with the mAb market expected 
to increase to $70 billion in sales by 2015 (Aggarwal 2011; Marichal-Gallardo 
and Álvarez 2012). 
 
1.3.1 Structure 
 MAbs are a general class of compounds with a molecular weight around 
150 kDa and a defined structure. Figure 1.3 shows the structure of 
immunoglobulin G (IgG) a common class of therapeutic mAbs, which also 
includes IgA, IgD, IgE, and IgM types. Each IgG molecule comprises of a 
disulphide-bonded pair of heavy chains, each linked to a disulphide-bonded 
light chain. Each heavy and light chain has two domains, the `constant` 
domain and `variable` domain. The variable domains are the primary 
difference between mAbs and contain the complementarity-determining 
regions (CDR) that are responsible for binding impurities, toxins or antigens 
with high specificity. The Fc region consists of two heavy chains and may 
have sugar groups (glycans) attached to the heavy chain by a process called 
glycosylation, which increases the products heterogeneity and can mediate 
the appropriate immune response.  
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Figure 1.3. General Structure of IgG monoclonal antibody, highlighting the 
key structural properties including the antigen binding fragment (Fab), 
crystallisable fragment (Fc), light chain (L), heavy chain (H), constant regions 
(C) and variable regions (V). 
 
 MAbs were first produced from mouse genes and referred to a murine 
mAbs (denoted with the suffix “-momab”), which were not particularly 
effective in clinical trials (Marichal-Gallardo and Álvarez 2012). Further 
genetic engineering resulted in chimeric (“-ximab”) and humanised (“-
zumab”) mAbs, with Rituxan® (Rituximab) the first chimeric mAb to market in 
1997 and Zenapax® (Dacalizumab) the first humanised mAb in 1997. Fully 
human mAbs ("-umab”) are now the focus due to their ability of generating 
negligible secondary effects to the patient (Marichal-Gallardo and Álvarez 
2012). In 2002, Humira® (Adalimumab) was launched as the first fully human 
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mAb and is currently the top-selling biopharmaceutical with sales of $9.534 
billion USD in 2012 (Merie 2013). Table 1.5 provides a detailed breakdown of 
mAb nomenclature, demonstrating how the generic mAb name is used to 
describe its structure and target. For example adalimumab is a human mAb 
(-umab) targeting an immune response (-lim-) and this is reflected in its 
primary target indications being autoimmune disorders (e.g. rheumatoid 
arthritis, Crohn’s disease and chronic plaque psoriasis). 
 
Table 1.5. MAb suffix nomenclature based on source and target 
Target 
   Non-tumour target Viral -vir- 
 Bacterial -bac- 
 Immune -lim- 
 Infectious lesions -les- 
 Antifungal -fung- 
 Cardiovascular -ci(r)- 
 Neurologic -ne(r)- 
 Interleukins -kin- 
 Musculoskeletal -mul- 
 Bone -os- 
 Toxin target -toxa- 
Tumour target Colon -col- 
 Melanoma -mel- 
 Mammary -mar- 
 Testis -got- 
 Ovary -gov- 
 Prostate -pr(o)- 
 Miscellaneous -tu(m)- 
   
Source 
    Human -umab 
 Murine -omab 
 Rat -amab 
 Hamster -emab 
 Primate -imab 
 Chimeric -ximab 
 Humanised -zumab 
 Rat/murine hybrid -axomab 
 Chimeric + humanised -zixumab 
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1.3.2 Application of Monoclonal Antibodies 
 There are currently 35 mAbs approved for EU or US markets, with a third 
having achieved blockbuster status (over $1 billion USD in sales). Table 1.6 
lists all the approved therapeutic mAbs to date. Of the 35 approved mAbs 15 
(43%) target cancer indications, 11 (31%) inflammatory/autoimmune 
diseases, 3 (9%) transplant rejection, 2 (6%) infectious diseases and 4 (11%) 
target other indications. Approximately a third of the marketed mAbs (11) are 
human derived, 14 (40%) are humanised, 6 (17%) are chimeric and 4 (11%) 
are murine derived. 
 
Table 1.6. Monoclonal antibodies approved or in review in the EU or US  
International 
non-proprietary 
name 
Trade name Type Indication first approved 
Approval 
year  
EU (US) 
Muromonab-CD3 Orthoclone 
Okt3 
Anti-CD3; Murine 
IgG2a 
Reversal of 
kidney transplant 
rejection 
1986 (1986)1 
Abciximab Reopro Anti-GPIIb/IIIa; 
Chimeric IgG1 
Fab 
Prevention of 
blood clots in 
angioplasty 
1995 (1994) 
Rituximab MabThera, 
Rituxan 
Anti-CD20; 
Chimeric IgG1 
Non-Hodgkin's 
lymphoma 
1998 (1997) 
Basiliximab Simulect Anti-IL2R; 
Chimeric IgG1 
Prevention of 
kidney transplant 
rejection 
1998 (1998) 
Daclizumab Zenapax Anti-IL2R; 
Humanized IgG1 
Prevention of 
kidney transplant 
rejection 
1999 (1997)1 
Palivizumab Synagis Anti-RSV; 
Humanized IgG1 
Prevention of 
respiratory 
syncytial virus 
infection 
1999 (1998) 
Infliximab Remicade Anti-TNF; 
Chimeric IgG1 
Crohn disease 1999 (1998) 
Trastuzumab Herceptin Anti-HER2; 
Humanized IgG1 
Breast cancer 2000 (1998) 
Gemtuzumab 
ozogamicin 
Mylotarg Anti-CD33; 
Humanized IgG4 
Acute myeloid 
leukemia 
N/A (2000)1 
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International 
non-proprietary 
name 
Trade name Type Indication first approved 
Approval 
year  
EU (US) 
Alemtuzumab MabCampath, 
Campath-1H 
Anti-CD52; 
Humanized IgG1 
Chronic myeloid 
leukemia 
2001 (2001) 
Adalimumab Humira Anti-TNF; Human 
IgG1 
Rheumatoid 
arthritis 
2003 (2002) 
Tositumomab-
I131 
Bexxar Anti-CD20; 
Murine IgG2a 
Non-Hodgkin 
lymphoma 
NA (2003) 
Efalizumab Raptiva Anti-CD11a; 
Humanized IgG1 
Psoriasis 2004 (2003)1 
Cetuximab Erbitux Anti-EGFR; 
Chimeric IgG1 
Colorectal cancer 2004 (2004) 
Ibritumomab 
tiuxetan 
Zevalin Anti-CD20; 
Murine IgG1 
Non-Hodgkin's 
lymphoma 
2004 (2002) 
Omalizumab Xolair Anti-IgE; 
Humanized IgG1 
Asthma 2005 (2003) 
Bevacizumab Avastin Anti-VEGF; 
Humanized IgG1 
Colorectal cancer 2005 (2004) 
Natalizumab Tysabri Anti-a4 integrin; 
Humanized IgG4 
Multiple sclerosis 2006 (2004) 
Ranibizumab Lucentis Anti-VEGF; 
Humanized IgG1 
Fab 
Macular 
degeneration 
2007 (2006) 
Panitumumab Vectibix Anti-EGFR; 
Human IgG2 
Colorectal cancer 2007 (2006) 
Eculizumab Soliris Anti-C5; 
Humanized 
IgG2/4 
Paroxysmal 
nocturnal 
hemoglobinuria 
2007 (2007) 
Certolizumab 
pegol 
Cimzia Anti-TNF; 
Humanized Fab, 
pegylated 
Crohn disease 2009 (2008) 
Golimumab Simponi Anti-TNF; Human 
IgG1 
Rheumatoid and 
psoriatic arthritis, 
ankylosing 
spondylitis 
2009 (2009) 
Canakinumab Ilaris Anti-IL1b; Human 
IgG1 
Muckle-Wells 
syndrome 
2009 (2009) 
Catumaxomab Removab Anti-
EPCAM/CD3;Rat/
mouse bispecific 
mAb 
Malignant ascites 2009 (NA) 
Ustekinumab Stelara Anti-IL12/23; 
Human IgG1 
Psoriasis 2009 (2009) 
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International 
non-proprietary 
name 
Trade name Type Indication first approved 
Approval 
year  
EU (US) 
Tocilizumab RoActemra, 
Actemra 
Anti-IL6R; 
Humanized IgG1 
Rheumatoid 
arthritis 
2009 (2010) 
Ofatumumab Arzerra Anti-CD20; 
Human IgG1 
Chronic 
lymphocytic 
leukemia 
2010 (2009) 
Denosumab Prolia Anti-RANK-L; 
Human IgG2 
Bone Loss 2010 (2010) 
Belimumab Benlysta Anti-BLyS; 
Human IgG1 
Systemic lupus 
erythematosus 
2011 (2011) 
Ipilimumab Yervoy Anti-CTLA-4; 
Human IgG1 
Metastatic 
melanoma 
2011 (2011) 
Brentuximab 
vedotin 
Adcetris Anti-CD30; 
Chimeric IgG1; 
immunoconjugate 
Hodgkin 
lymphoma 
2012 (2011) 
Pertuzumab Perjeta Anti-HER2; 
humanized IgG1 
Breast Cancer 2013 (2012) 
Raxibacumab (Pending) Anti-B. anthrasis 
PA; Human IgG1 
Anthrax infection NA (2012) 
Trastuzumab 
emtansine 
Kadcyla Anti-HER2; 
humanized IgG1; 
immunoconjugate 
Breast cancer In review 
(2013) 
Vedolizumab (Pending) Anti-alpha4beta7 
integrin; 
humanized IgG1 
Ulcerative colitis, 
Crohn disease 
In review 
(NA) 
Source: The Antibody Society. 
1 Voluntarily withdrawn from the market 
 
 Sales per gram of mAb range from $1000 per gram to $50,000 per gram 
depending on dosage (Kelley 2009; Marichal-Gallardo and Álvarez 2012). 
Anti-TNF and other anti-inflammatory antibodies generated sales of $45.6 
billion USD in 2012, over a third of the biologics market total sales (Merie 
2013).  Cancer antibodies sales in 2012 were $23.7 billion USD accounting 
for approximately 20% of the biologics market (Merie 2013).  The only other 
product class to generate a market share in double digits was insulin and 
insulin analogs with $18.9 billion USD (15%) in sales (Merie 2013). 
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1.4 Manufacture of Monoclonal Antibodies 
 Early IgG products were sourced from human plasma and purified by 
multiple fractionation steps based on the Cohn process (Cohn et al. 1946). 
The Cohn process was initially developed for the production of albumin 
during World War II to aid the recovery of soldiers suffering from blood loss. 
The Cohn process is not dissimilar to crude oil fractionation, where crude oil 
is refined into to various products. Human plasma is fractionated by taking 
advantage of the differential solubility of the plasma proteins and utilises 
ethanol to precipitate the proteins based on their isoelectric points (Cohn et 
al. 1946). The Cohn process produces five fractions with the final fraction 
being enriched in albumin. However the other fractions were found to contain 
more than 20 valuable proteins including coagulation factors, protease 
inhibitors and IgGs (Burnouf 2007). Figure 1.4.a shows a traditional IgG 
purification process based on Cohn fractional precipitation; where fractions II 
and III are collected for further purification via a number of chromatographic 
steps to yield clinical grade IgG. The first human plasma sourced IgG was 
launched on the US market in the early 1980s to treat patients with idiopathic 
thrombocytopenic purpura, an autoimmune disease causing platelet 
deficiency (Pyne et al. 2002). 
 
1.4.1 Current platform processes 
 Current recombinant mAb purification processes have borrowed very 
little from plasma fractionation processes, apart from the virus inactivation 
steps and ultrafiltration/diafiltration operation. The first cGMP processes for 
mAb purification were based on 1980s and early 1990s technologies (Kelley 
et al. 2009). These early processes were highly diverse, employing multiple 
technologies and a variable number of chromatographic steps. In addition, 
early chromatographic operations provided low binding capacities and were 
often operated in the cold (Kelley et al. 2009). The diversity found in early 
mAb manufacturing processes can be attributed to the lack of substantial 
process knowledge at the time and the historical progression from murine to 
fully humanised mAbs. The high degree of equivalence found among 
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humanised mAbs CDRs and constant domains have made it possible to 
develop platform-manufacturing processes capable of processing many 
different mAbs with only minor changes to the operating conditions (Shukla et 
al. 2007).  
 Figure 1.4.b presents a typical recombinant mAb platform process. The 
target mAb is expressed recombinantly in mammalian cells due to their ability 
to assemble, fold and apply the correct post-translational modifications 
(Marichal-Gallardo and Álvarez 2012). In the past, cell culture mAb titres 
reached only mg/L values, but now the norm is 2–3g/L with processes in 
development with reported titres of 5 g/L and higher (Bisschops et al. 2009b; 
Kelley 2009). The harvested cell culture bulk is processed by centrifugation, 
followed by depth filtration to remove the mammalian cells. The resulting 
harvested cell culture fluid (HCCF) is then clarified by Protein A 
chromatography, the first DSP step. Protein A chromatography offers direct, 
high-capacity mAb capture from the HCCF and achieves excellent purity 
(>95%), recovery, plus several logs of DNA & HCP clearance and a partial 
reduction in product aggregates (Gagnon 2012). The low-pH elution also acts 
as a virus inactivation step by denaturing enveloped viruses. Two further 
chromatographic polishing steps are used to reduce host cell proteins (HCP), 
DNA, process related impurities (leached Protein A) and product aggregates. 
Anion-exchange (AEX) chromatography is regularly used as a polishing step 
due to its ability to offer several logs of clearance for DNA, viruses, 
endotoxin, leached Protein A, and acidic HCP (Gagnon 2012). The second 
polishing step often employs cation-exchange (CEX) chromatography to 
remove any remaining HCP and remove product aggregates. CEX is 
occasionally replaced with hydrophobic interaction chromatography (HIC) but 
its use is restricted due to the high salt conditions required to elute the mAb 
(Gagnon 2012). The product stream is then processed by virus retention 
filtration (VRF), the second dedicated virus reduction step, which utilises 
nanofiltration techniques to remove viruses by size exclusion. 
Ultrafiltration/diafiltration (UF/DF) is the final step in drug substance 
manufacture and is used to concentrate and formulate the mAb. The efficacy 
and robustness of the current mAb platform process, shown in Figure 1.4.b, 
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has made process yields of 60-80% routine (Marichal-Gallardo and Álvarez 
2012). 
 
Figure 1.4. Typical manufacturing processes for a) Cohn-based IgG platform 
and b) typical recombinant mAb platform. UFDF, ultrafiltration/diafiltration.  
 
1.4.2 Future platform processes 
 The next generation of mAbs are under increasing pressure from both 
public and private healthcare providers to offer cost effective treatments and 
contend with the intensified competition from rival manufacturers (novel and 
biosimilars). The success of these new mAb therapeutics will be highly 
dependent on their economic performance (Cohen 2009; Mitchell 2005). As a 
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result production cost, capacity utilisation and the ability to rapidly 
accommodate fluctuating market conditions are becoming critical success 
indicators (Farid 2009a; Kamarck 2006; Pellek and Arnum 2008). This is 
increasing the pressure on companies to produce more economically 
sustainable therapies and hence, adopt more cost-effective manufacturing 
strategies. The current platform processes are able to fulfil a number of these 
aims, however, they can only be reached if the process does not undergo 
significant changes for a reasonably long period of time (Shukla et al. 2007). 
However, this does not mean that the purification of mAbs is a mature 
engineering field and that no further process improvements can be made. In 
reality, since the emergence of the three-column purification platform in the 
early 1980s, the platform has been constantly evolving with minor updates. 
For example, over the years Protein A resins have become more rigid, 
allowing faster flow rates and shorter residence times, plus higher capacity 
variants have been available since 2003 (Curling 2009). This is a major 
benefit to the platform purification, but its cost overshadows its performance 
and inspires motivation to replace it (Gagnon 2012).  
 The economic burden associated with Protein A has led to suggestions 
that the next generation of platform purification processes should look for an 
alternative capture step. CEX is becoming a popular alternative due to it 
being an order of magnitude cheaper and its ability to offer dynamic binding 
capacities higher than 100mg IgG/ml resin (Gagnon 2012; Marichal-Gallardo 
and Álvarez 2012). Typical HCCF has a pH between 6.5-7.6 and conductivity 
around 10-20 mS/cm (Li et al. 2009), this latter factor will need to be reduced 
to achieve the high binding capacities reported (Gagnon 2012). The 
introduction of a new conditioning step negates some of the proposed 
savings offered by changing resin, plus the non-Protein A elution pool is 
unlikely to be purer than the Protein A pool (Curling 2009). A number of non-
chromatographic operations have been suggested including precipitation, 
positively charged ultrafiltration membranes and aqueous two-phase 
extraction to name a few. Prevailing opinion is that if these technologies were 
going to mount a serious challenge to Protein A as a capture operation, it 
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would have happened already (Curling 2009; Gagnon 2012; Marichal-
Gallardo and Álvarez 2012). 
 The majority of second-generation purification platforms are still reliant 
on Protein A chromatography (Gagnon 2012) and any change in capture 
technology will follow a path of evolution (increased capacity & reduced cost) 
rather than revolution (adoption of CEX). The principle developments are 
likely to occur to the polishing chromatographic steps, with the introduction of 
new chromatographic resins and modes of operation. The high purity of 
Protein A pools make the use of a single polishing step possible with the 
latest technologies. Figure 1.5 shows two leading contenders for the 
emerging two-column purification platform. These emerging platforms will 
have significant benefits for facility fit, operational ease and savings in COGs, 
development and validation costs (Kelley et al. 2008). 
 AEX chromatography’s high impurity clearance properties make it the 
logical choice from which to develop a single superior polishing step enabling 
two-column purification processes (Gagnon 2012; Kelley et al. 2008). New, 
mixed-mode chromatographic resins represent a diverse range of ligands 
that harness two or more chemical functions. Mixed-mode resins can be 
divided into three subsets based on their dominant characteristic; augmented 
anion-exchangers with hydrogen bonding, augmented metal coordination 
with electrostatic interactions and augmented hydrophobic interactions with 
other functions (Gagnon 2012). Anion-exchangers enhanced with hydrogen 
bonding are likely candidates to replace both AEX and CEX, by offering the 
contaminant and viral clearance of AEX and the aggregate clearance of the 
CEX.  
 An alternative to changing to a new chromatographic matrix is to utilise 
the current AEX matrix in a new mode of operation, namely weak partitioning. 
Weak partitioning refers to the binding strength of the product to the resin 
during isocratic operations and is a combination of bind and elute mode, and 
flowthrough mode (Kelley et al. 2008). When AEX is operated in flowthrough 
the product partition coefficient (Kp) is very low (Kp <0.1), in contrast a high 
Kp >100 would signify a bind and elution mode of operation (Kelley et al. 
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2008). Weak partitioning is defined under conditions where the product and 
aggregates starts to bind to the resin (Kp is between 0.1-20), this would lead 
to significant product loss, but by significantly increasing the loading (x5 mg 
mAb/mL resin) yields are bought back to acceptable levels. The result is a 
step that offers the contaminant clearance seen in AEX flowthrough mode 
augmented with aggregate removal.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Emerging two-column recombinant mAb manufacturing 
platforms. UFDF, ultrafiltration/diafiltration. 
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1.4.3 Continuous unit operations 
 MAb manufacturing and general biopharmaceutical manufacture is 
synonymous with batch processing in the way that each manufacturing 
process step is operated independently to the preceding and subsequent 
process steps (Gagnon 2012; Godawat et al. 2012; Kelley 2007; Marichal-
Gallardo and Álvarez 2012; Warikoo et al. 2012). This approach has been 
the prevailing mode of biopharmaceutical manufacture over the last decades 
due to the support by the industry and regulatory bodies for the tried and 
tested approach. By contrast, a number of other industries have undergone 
continued process intensification through their conversion from batch to 
continuous manufacturing, such as the petrochemical, chemical, polymer, 
pharmaceutical, and food industries (Godawat et al. 2012; Mollan and 
Lodaya 2004; Warikoo et al. 2012). The common advantages offered by 
continuous manufacturing regardless of industry are always the same. 
Namely steady state operations, reduced equipment sizes, high volumetric 
productivity, streamlined process flow, low cycle times and reduced capital 
and operating costs (Schaber et al. 2011; Warikoo et al. 2012). 
 Continuous processing is making inroads into the biotech industry, with 
the resurgence of perfusion cell culture technologies and the emergence of 
semi-continuous chromatography. Continuous manufacturing technologies 
have long been perceived to be more complex to implement and validate in 
the biotech sector. However, more recent continuous systems aim to 
overcome these obstacles with the promise of higher productivities and lower 
failure rates. This has led to various companies evaluating the potential 
continuous processing for the next generation of future high-efficiency 
platforms for mAb manufacturing (Hou 2012; Warikoo et al. 2012). A number 
of companies are publically increasing their investment in continuous 
processing evaluations; with Novartis, for example, investing $65 million USD 
in a combined research project with MIT called the Novartis-MIT Centre for 
Continuous Manufacturing (Palmer 2013). Some companies are even looking 
to build first of its kind continuous manufacturing facilities, with 
GlaxoSmithKline reportedly investing over 50million USD in a Singapore 
facility (Palmer 2013). The remaining big biopharma companies may not be 
53 
 
actively declaring their investments or strategies in the area, but Genzyme, 
Amgen, Pfizer, Bayer, Genentech and Merck have all been presenting their 
own work actively on the conference scene in the last year (Brower 2013; 
Mahajan et al. 2012; Palmer 2013; Pollock et al. 2013a; Vester 2013; 
Warikoo et al. 2012). These efforts are being actively encouraged and 
supported by the FDA and ICH who are paving the way for the 
implementation of continuous manufacture by removing regulatory obstacles 
and introducing new Quality by Design initiatives necessary to foster 
continuous processing in a cGMP environment (ICH Q8, Q9 & Q10).  
 
1.4.3.1.1 Perfusion 
Perfusion cell-culture-derived biopharmaceuticals offer the potential of 
greater daily productivities and hence smaller facility footprints than batch 
and fed-batch culture manufacturing strategies (Bosch et al. 2008; Lim et al. 
2006; Lim et al. 2005; Pollock et al. 2013b; Voisard et al. 2003). However, 
their use has been hampered historically by perceived greater logistical and 
validation complexity as well as higher likelihoods of technical failures (Lim et 
al. 2005). More recent perfusion culture systems aim to overcome some of 
these obstacles with the promise of higher productivities and lower failure 
rates (Centocor 2006; Crowley et al. 2008). This combined with the 
introduction of single-use technologies for cell culture operations have 
triggered renewed interest in the potential of bioprocesses based on 
perfusion culture systems.  
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 Table 1.7 highlights 10 commercial therapeutic biologics that utilize 
perfusion culture systems for their manufacture. These include recombinant 
blood factors, enzymes, and mAbs. The choice of perfusion culture has 
sometimes been a necessity in cases with labile products (e.g., Xigris® [Eli 
Lilly], Kogenate® [Bayer], Cerezyme® [Genzyme]). Historically for mAbs the 
choice has been due to company experience and low titres. For example, 
perfusion culture was the basis of Centocor’s (now Janssen Biotech) platform 
process in the 1980–1990s for both low dose products such as Reopro® 
(30mg) and high dose products such as the blockbuster Remicade® (≤1,050 
mg). However, the increase in fed-batch titres combined with their ease of 
operation has established fed-batch cell culture as the platform choice for 
most mAbs in recent years (Gagnon 2012; Godawat et al. 2012; Kelley 2007; 
Marichal-Gallardo and Álvarez 2012; Warikoo et al. 2012). Table 1.7 also 
reveals that the most common perfusion systems adopted in commercial 
processes are spin-filters (Deo et al. 1996; Yabannavar et al. 1992) and 
gravity settlers (often bespoke; Voisard et al., 2003), with up to 4,000L 
bioreactors. However, examination of the post-launch process changes for 
Remicade® revealed modifications to the perfusion systems used from 500 L 
internal spin-filter perfusion culture at the Leiden (Netherlands) site to 1,000 L 
bioreactors with external spin-filters at the Malvern (Pennsylvania) site in an 
effort to minimize culture failure due to adverse filter fouling (Wojciechowski 
et al. 2007). In its Ringaskiddy (Cork) site, Janssen Biotech has switched to a 
newer perfusion technology, alternating tangential flow (ATF) perfusion 
(Refine Technology, Edison, NJ) for the production of more recent mAbs, 
such as Simponi® (Centocor 2006). The ATF system achieves media 
exchange by circulating the broth back and forth between the bioreactor and 
an external hollow-fibre filter via the action of a diaphragm pump (Crowley et 
al. 2008; Shevitz 2000). The vendors report that the pulsating motion allows 
greater media perfusion rates, reduces the dead volume outside the reactor 
and minimizes the shear stress the cells are exposed to. These multiple 
effects allow the ATF perfusion system to minimize filter fouling and achieve 
higher cell densities and therefore reach higher productivities compared to 
earlier perfusion systems.  
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 There are a few contributions in the literature that compare the process 
economics of perfusion and fed-batch manufacturing strategies. Cacciuttolo 
(2007) concluded that fed-batch culture would be cheaper than perfusion 
culture as the cost of larger media and harvest tanks in perfusion were 
considered to outweigh the benefits of higher productivity. The analysis 
focused on the changes to the cell culture stages rather than the whole 
bioprocess. Bosch et al. (2008) took into account the complete bioprocess 
from seed train to final bulk drug substance. Comparing a microcarrier-based 
perfusion strategy to a fed-batch strategy generating a tonne of mAb with an 
expected titre <1 g/L. Bosch et al. (2008) found that the perfusion 
manufacturing strategy offered savings in COG/g due to the 10-fold increase 
in productivity relative to the fed-batch bioreactor. The analysis did not 
consider the consequences of bioreactor failure and focused on a single 
scale of production. Lim et al. (2005, 2006) compared a spin-filter perfusion 
to a fed-batch strategy under uncertainty, for an output of 50 kg/year and a 
titre of 1 g/L. No significant difference in COG/g was seen at this scale in the 
deterministic analysis. However, the authors used a stochastic analysis to 
demonstrate the reduction required in the failure rate of the spin-filter 
perfusion strategy for it to compete with the fed-batch strategy at this scale. 
 
1.4.3.1.2 Semi-continuous chromatography 
 Over the last decade mAb manufactures have been looking to increase 
upstream capacity, productivity and yields (Bisschops et al. 2009b; Holzer et 
al. 2008). This has led to a rapid increase in cell culture mAb titres from only 
mg/L values, to the current norm of 2–3g/L and with processes in 
development with reported titres of 5 g/L and higher this is likely to rise 
further (Bisschops et al. 2009b; Kelley 2009). The notable successes in 
upstream development has placed increased burden on downstream 
operations and improvements are urgently needed to tackle the growing 
`downstream bottleneck` (Bisschops et al. 2009b; Holzer et al. 2008; Langer 
2012). The current and future mAb purification platforms are still dominated 
by chromatographic methods and Protein A as the preferred primary capture 
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step (Gagnon 2012; Marichal-Gallardo and Álvarez 2012). Protein A resins 
are the leading material cost contributor in the current and future platforms 
(Pollock et al. 2013a; Pollock et al. 2013b). During commercial manufacture 
Protein A contributes to 10% of the direct costs, however, in early 
development Protein A can account for 53% of the direct manufacturing costs 
(Pollock et al. 2013a). During clinical manufacture product specific 
chromatographic resins are often used for just a few cycles, particularly if the 
DC is unsuccessful, leading to the resin being discarded before reaching its 
full potential cycle lifetime. The impact of poor resin utilisation is a particular 
concern in mAb development and improving utilisation of these expensive 
resins can have a significant effect on the manufacturing and development 
costs by reducing the cost burden associated with failed DCs. 
 Typically, the protein A column is loaded up to 90% of 1% breakthrough 
capacity, underutilising the resin’s capacity. This loading regime results in the 
entry (top) of the column being saturated and the exit (bottom) unsaturated 
upon completion of loading, leading to an excess buffer consumption caused 
by washing, elution and cleaning of the unsaturated column portion. Various 
methods have been employed to increase the productivity and utilisation of 
Protein A columns, including the use of dual flowrate loading strategies 
(Ghose et al. 2004) and flow-through recycling in an effort to fully saturate  
the whole resin (Mahajan et al. 2012). An alternative approach to increase 
utilisation is to divide the column into multiple portions and wash and elute 
the saturated top portion of the column and continue loading the unsaturated 
portion of the column until saturated. This principle is applied in semi-
continuous chromatography, which allows the columns to be loaded to a 
higher binding capacity, reducing the resin volume required and the overall 
buffer consumption. Semi-continuous chromatography has been shown by 
Mahajan et al (2012) to be an effective way to increase resin utilisation. This 
concept is similar to the simulated moving bed concept commonly used in the 
chemical and pharmaceutical industries (Juza et al. 2000; Pellek and Arnum 
2008; Strohlein et al. 2007), but to date this concept is not widely used in 
mAb purification. The expertise from these industries is now being applied to 
biopharmaceutical processes, with companies including Novasep (Pompey, 
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France) offering BioSC (2-6 columns) and Tarpon (Leiden, Netherlands) with 
BioSMB (6-12 columns). This has also led companies already supplying the 
biopharmaceutical industry to develop their own systems based on the SMB 
concept, such as GE Healthcare (Uppsala, Sweden) with its periodic counter 
current (PCC) system (3-4 columns). Recent papers have provided a proof-
of-concept for semi-continuous chromatography linked to a fed-batch process 
(Mahajan et al. 2012) and to an alternating tangential flow perfusion process 
(Godawat et al. 2012; Warikoo et al. 2012) for mAbs. These publications 
highlight the operational benefits of semi-continuous chromatography 
systems with resin volume reductions ranging from 40-50% and buffer usage 
decreases of 40-49% causing total reduction in total process buffer usage of 
12-15% (Mahajan et al. 2012; Pollock et al. 2013a; Warikoo et al. 2012).  
 While the proposition of continuous processing in biopharmaceutical 
manufacture is likely to face continued scepticism, this does not mean its 
benefits will not be realised. Continuous processing in other industries faced 
similar concerns and scepticism before its successful implication (Mollan and 
Lodaya 2004; Schaber et al. 2011; Warikoo et al. 2012). This is reflected in 
the disclosed activities and publications by a number or biopharmaceutical 
manufactures on their use and assessment of semi-continuous 
chromatography as shown in Table 1.8. The majority of large 
biopharmaceutical manufactures and semi-continuous chromatography 
system manufactures are included in Table 1.8. However based on this 
analysis there will also be a further number who have not disclosed their 
intentions. This hypothesis is based on the most notable omission of 
Novasep’s BioSC system, which has been available since 2007 yet no 
notable disclosures were found. To date no semi-continuous chromatography 
systems have been used to purify mAbs destined for clinical trials or 
commercially available product (no public disclosures). 
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Table 1.8. Current commercial use of semi-continuous chromatography 
 
1.5 Computational Decision Making Tools 
 This chapter has highlighted how the maturing biopharmaceutical 
industry is under increasing economic and regulatory pressure when 
developing and manufacturing mAbs and other biopharmaceuticals. 
Consequently, biopharmaceutical companies have to make many strategic 
decisions in multiple business areas such as the design of manufacturing 
processes and facilities, as well as capacity sourcing and portfolio 
management (Farid 2012). Many of these strategic decisions involve large 
capital expenditures that are further complicated by a number of sector 
specific constraints, namely tight regulatory requirements and increasing cost 
pressures (Farid 2012; Velayudhan and Menon 2007). Figure 1.6 presents 
the complex decisional domain biopharmaceutical companies have to 
operate within and highlights the most common constraints and uncertainties 
Company Systems Evaluated / Employed Reference 
Amgen GE AKTA PCC 
Jocelyn Materie et al, 
ACS 2010 San 
Francisco, CA. 
Bayer Undisclosed Thomas Daszkowski PIMS, London, UK. 
Biogen-Idec Tarpon BioSMB Bisschops et al, 2009 
Centocor GE AKTA PCC Karol Lacki et al, Gab 2004, Nice, France. 
Genentech GE AKTA PCC Mahajan et al, 2012 
Genzyme GE AKTA PCC Warikoo et al, 2012 Godawat et al 2012 
Lonza Tarpon BioSMB Allen et al 2010 
Merck Tarpon BioSMB 
Bisschops et al, Prep 
Symposium 2012, 
Boston, MA 
Pfizer (formerly Wyeth) Tarpon BioSMB GE AKTA PCC 
Stephen Lyle, M.S. IBC 
Antibodies 2010, 
Carlsbad, CA. 
Pollock et al, 2013 
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seen. To successfully operate in this environment a detailed understanding of 
how these decisions and their inherent constraints and uncertainties affect 
the companies’ key financial and operational performance are required (Farid 
2012). Advanced simulation tools are becoming essential in achieving this 
goal and are now available in a number of key decisional domains in the 
biopharmaceutical industry from portfolio management (George and Farid 
2008a; George and Farid 2008b; Rajapakse et al. 2005; Rajapakse et al. 
2006) to capacity planning (Lakhdar et al. 2007; Simaria et al. 2011; Stonier 
et al. 2011) and finally process and facility design (Farid et al. 2005; Lim et al. 
2006; Lim et al. 2005; Pollock et al. 2013a; Pollock et al. 2013b; Stonier et al. 
2012). 
 
 
Figure 1.6. Key constraints and uncertainties in biopharmaceutical drug 
development. Sourced from Farid, 2012. 
 
 The purpose of an advanced simulation tool is to enable the user to 
predict the impact of the desired changes on the real-world system (existing 
or proposed); this is usually impractical, too expensive or even impossible to 
conduct with the actual system of interest (Banks 1998; Maria 1997). These 
advanced tools offer a simulated system that includes multiple models, which 
are similar but simpler than the real-world system they represent (e.g. 
manufacturing equipment models in a manufacturing facility system) (Maria 
 718  22 Evaluating and Visualizing the Cost-Effectiveness
     Figure 22.1  Key decisions, constraints, uncertainties, and metrics in biopharmaceutical drug development. 
Critical Path Drug Development Cycle (Preclinical, Phase I - III)
Process development Process characterisation Post-approval changesScale-up development‡ ‡
Pilot scale cGMP manufacturing batches
Portfolio selection? Process design? Capacity Sourcing? Build single / multi-product facility?
Large-scale cGMP manufacturing batchesTech transfer & Facility fit‡ ‡
Market
Process
Development
Manufacturing
Decisions
Uncertainties Clinical (e.g. doses, transition probabilities) Technical (e.g. titres, equipment failure) Commercial (e.g. sales forecasts)
Constraints Time Capacity Budget Regulatory Skilled labour
Metrics Speed Ease of scale-up Cost of goods Fit to facility Robustness
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1997). This is because most real-world systems are too complex to allow 
realistic models to be evaluated analytically and therefore these models are 
studied by simulation (Kelton and Law 2000). In essence, a simulation tool 
simulates the real-world system via the operation of a model or models of the 
real-world system and infers the behaviour of the real-word system and sub-
systems (Banks 1998; Kelton and Law 2000; Maria 1997). 
 Simulation systems can be divided into two classes, discrete and 
continuous. A discrete system is a system for which the states of the 
simulated variables remain constant over intervals of time and change 
instantly at defined points in time, often referred to as `events` (Banks 1998; 
Kelton and Law 2000). An example of a discrete system would a queuing 
event, such as the number of customers in a shop (simulated variable), 
where the number of customers only changes when a customer is served 
and departs or a new one joins the queue (time events). In contrast, the 
states of the simulated variables in a continuous system change continuously 
over time and are defined by differential or difference equations (Banks 1998; 
Kelton and Law 2000). An example of a continuous system would be the 
movement of a projectile, for which position and velocity (simulated variables) 
are changing continuously over time.  
 The simulation models used within the two classes of system can be 
classified along three different dimensions, static vs. dynamic; deterministic 
vs. stochastic; and continuous vs. discrete (Kelton and Law 2000). Static and 
dynamic simulation models can be separated based on their use of time 
(Banks 1998; Kelton and Law 2000). A static simulation model is a `snap 
shot` of a system at a given point in time or one in which time plays no role 
(e.g. spreadsheet derived models). In dynamic simulation models time plays 
a crucial role; they represent a system as it evolves over time. Deterministic 
and stochastic simulation models can be distinguished by their use of 
probabilistic variables (Kelton and Law 2000). Deterministic simulation 
models do not use any probabilistic variables; the output of the model is 
determined by the input values and relationships in the model and will 
therefore be constant. Whereas stochastic models utilise probabilistic 
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variables; the output will be random and is only an estimate of the many 
possible outputs. Continuous and discrete simulation models are defined in 
the same way as continuous and discrete systems were defined previously. 
However, discrete simulation models are not always used to model discrete 
systems and vice versa (Kelton and Law 2000). For example, in a discrete 
system the variables can be treated as a flow using differential equations in a 
continuous model if the characteristics and movement of individual variables 
are not important (Kelton and Law 2000). Discrete-event simulation models, 
which are discrete, dynamic and stochastic, are one of the most common 
types of simulation models used (Banks 1998; Kelton and Law 2000; Maria 
1997). 
 
1.5.1 Process Simulations Tools for the Biotech Industry 
 Simulation tools have been actively utilised for process design and 
simulation in both the chemical and petrochemical industry since the early 
1960s (Petrides et al. 2002; Toumi et al. 2010). Computer-aided process 
simulation tools are now standard tools used to plan, design, optimise and 
evaluate chemical and petrochemical process (Farid 2007). Simulation tools 
used in these industries are designed to capture continuous processes, 
however, most biopharmaceutical processes are operated in a batch-to-batch 
manner. Biopharmaceutical processes are therefore represented more 
realistically with batch process simulators that account for time and event 
scheduling (Toumi et al. 2010). However, batch based simulation models 
tend to be more challenging to develop due to their time-dependant 
behaviour and therefore early biopharmaceutical simulation tools were 
adaptions of available chemical process simulation tools (Farid 2007; 
Petrides et al. 2002; Toumi et al. 2010). The first simulation tool capable of 
simulating biopharmaceutical processes was `Batches` from Batch Process 
Technologies (West Lafayette, IN), which entered the market in the mid-
1980s (Petrides et al. 2002). The tool employed continuous models that 
utilised differential equations between defined event times (Petrides et al. 
2002).  
63 
 
 The first simulation tools utilising batch time-dependant models targeted 
at biopharmaceutical manufacturing processes did not arrive until the mid-
1990s. Aspen Technology, Inc. (Cambridge, MA) introduced Batch Plus®; a 
recipe-driven modelling technology for batch processes (now called Aspen 
Batch Process Developer®) built on Aspen`s chemical process simulator 
Aspen Plus®. Early versions of the simulation tool proved to be difficult to 
adapt to biopharmaceutical processes, due to the lack of specific 
biopharmaceutical unit operations and the retained chemical process 
characteristics from Aspen Plus® (Kahn et al. 2001; Shanklin et al. 2001). 
Recent simulation model add-ons from Aspen Technology, Inc. include 
Aspen Chromatography®; this has the capability to model individual 
chromatographic steps and to capture multiple chromatographic operations in 
a manufacturing process when linked with Aspen Batch Process Developer® 
(Evans et al. 2010).  
 Intelligen, Inc. (Scotch Plains, NJ) introduced BioPro Designer® (now 
called SuperPro Designer®) around the same time as Aspens Batch Plus®. 
It was initially developed within the Massachusetts Institute of Technology 
(Cambridge, MA) in the late 1980s before Intelligen Inc. acquired and further 
developed the simulation tool prior to launch. SuperPro Designer® is built 
around a static model which the users access via a graphical interface. The 
tool has a large library of in-built unit operations to address the needs of the 
biopharmaceutical industry (Petrides et al. 1996). Early versions of SuperPro 
demonstrated its capability to perform detailed mass and energy balances, 
and equipment scaling and costing (Petrides et al. 1996). The release of a 
number of extension modules (e.g. EnviroPro®, SchedulePro®) improved the 
capabilities of the tool allowing it to capture the environmental footprint of a 
process and select production schedules based on process and facility 
constraints (Gosling 2005; Shanklin et al. 2001; Toumi et al. 2010). Toumi et 
al (2010) demonstrated how SuperPro Designer® and SchedulePro® were 
used in the successful technology transfer of a mAb manufacturing process; 
highlighting process improvements and establishing equipment and utility 
requirements for the transfer. 
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 The most recent simulation tool designed specifically for 
biopharmaceutical industry was released by Biopharm Services (Bucks, UK) 
in the early 2000s. BioSolve® is a static simulation tool created in Microsoft 
Excel (Microsoft Corporation, Redmond, WA, USA) which captures the time-
dependant nature of batch processing with extensive coding in Visual Basic 
for Applications (VBA). The tool, like other static spread-sheet based models 
is capable of conducting material balances, equipment sizing and cost 
analysis (Sinclair 2008; Toumi et al. 2010). Biosolve® has an inbuilt library of 
biopharmaceutical unit operations and an extensive cost and process 
database which, in contrast to other cost models is regularly updated 
(Sinclair 2008). 
 Alongside the simulation tools targeted specifically at the 
biopharmaceutical industry there are a number of discrete-event simulators, 
which are highly utilised in the other industries are now being readily used in 
biopharmaceutical process modelling. Discrete-event simulations are usually 
employed when a detailed understanding of time-dependency events is 
required, often on the minute-by-minute level (Paz and Puich 2004; Toumi et 
al. 2010). Due to their dynamic nature they are often used to evaluate the 
impact of variation and random events, such as equipment failures, resource 
constraints and process delays (Farid 2007; Paz and Puich 2004; Shanklin et 
al. 2001; Stonier et al. 2012; Toumi et al. 2010). Tools of this type include 
Arena® from Rockwell Automation, Inc. (Pittsburgh, PA), Simul8® from 
Simul8 Corporation (Boston, MA), ProModel® from ProModel Corporation 
(Orem, UT) and ExtendSim® from Imagine That, Inc. (San Jose, CA). These 
simulation tools all include a common toolbox of predefined code to carryout 
simple operations within a dynamic environment such as time delays, 
queuing events and mathematical calculation modules. The common toolbox 
of pre-described modules allows a diverse range of systems to be 
represented, making these tools highly versatile. This versatility is reflected in 
their use, with most industries utilising discrete-event simulation tool for their 
modelling needs (Banks 1998; Kelton and Law 2000; Maria 1997).  
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 Discrete-event simulation tools do not contain predefined 
biopharmaceutical unit operations. These have to be constructed within the 
tools, meaning tool construction can be highly labour intensive in contrast to 
the industry targeted simulation tools. However, due to their unique abilities, 
which are not currently available in industry targeted simulation tools, their 
use is increasing. For example, ProModel® has been successfully deployed 
to optimise the planning, scheduling and throughput of a final-stage 
biopharmaceutical manufacturing facility. Haekler et al (2010) highlighted 
how the use of ProModel® had resulted in cost avoidance of $3 million USD 
per year and a revenue increase of over $25 million USD per month (Haekler 
et al. 2010). Simul8® was also successfully utilised by Wyeth (now part of 
Pfizer, Inc., NY) to evaluate utility requirements, which resulted in reallocation 
of $1.2 million USD of expected capital expenditure to other key capital 
projects (simul8.com). ExtendSim® appears to be the most widely utilised 
simulation tool in the industry, with demonstrated case studies looking at 
portfolio selection (Rajapakse et al. 2005; Rajapakse et al. 2006); facility 
capacity optimisation (Paz and Puich 2004); facility fit of legacy facilities 
(Stonier et al. 2012); process synthesis and facility design for existing 
technologies (Lim et al. 2006; Lim et al. 2005; Mustafa et al. 2006); and 
future technologies (Farid et al. 2005; Pollock et al. 2013a; Pollock et al. 
2013b). ExtendSim`s® success can be explained by its high versatility which 
is reflected in the variety of problem domains it has been used to tackle. This 
high versatility comes from the ability to edit the existing code modules, 
referred to as `blocks`, and the ability to create new bespoke blocks (Gosling 
2005; Pollock et al. 2012; Stonier et al. 2012). The other simulation tools like 
ProModel® also have this ability, but any custom coding must be carried out 
in an external package and called upon when required in the simulation tool, 
adding to the tools complexity (Heflin and Harrell 1998). 
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Table 1.9. Summary of functionality and capabilities of common 
biopharmaceutical simulation tools 
 Aspen 
Batch 
Process 
Developer 
SuperPro 
Designer BioSolve ProModel ExtendSim 
Mass Balance ✔ 
 
✔ 
 
✔ 
 
✔ 
 
✔ 
 
Batch ✔ 
 
✔ 
 
✔ 
 
✔ 
 
✔ 
 
Continuous ✔ 
 
✔ 
  
✔ 
 
✔ 
 
Dynamic ✔ 
   
✔ 
 
✔ 
 
Customisable 
   
✔ 
 
✔ 
 
 
 Table 1.9 presents a summary of the most prevalent simulation tools 
used in the biopharmaceutical industry and highlights their functionality and 
capabilities (based on reported use and publications). This is not an 
exhaustive summary, there will be many other simulation tools being used in 
the industry including other discrete-event simulation tools and bespoke 
simulation tools offered by a range of simulation consultancy companies, 
such as Bioproduction Group, Inc. (Bio-G, Berkley, CA). 
 
1.5.2 Risk Modelling 
 The simulation tools described so far are primarily designed to operate in 
a deterministic manner, which means all the simulation events will inevitably 
occur and hence their outputs can be termed as `non-risk`. These non-risk 
outputs would be identical if the same scenario was investigated multiple 
times by the simulation tool. However, biopharmaceutical manufacture is not 
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a non-risk environment. There are a several uncertainties in manufacturing 
processes, such as fermentation titres, step yields, batch failure, production 
times and mass throughput to highlight a few (Banks 1998; Biwer et al. 2005; 
Papavasileiou et al. 2007; Papavasileiou et al. 2009). These uncertainties 
lead to variation in the facility throughput, production costs, capital 
investment requirements and product demands. Incorporating these 
uncertainties (risks) into any analysis requires a subjective assessment of the 
probability distributions of the variables in question. This is achieved by 
assessing historical data or knowledge from industry subject matter experts 
(Farid et al. 2007). Two methods often employed to evaluate these risks are 
`risk adjustment` and `Monte Carlo Simulation`.  
 Risk adjustment is a concept that was first used in mid 1980s by the 
Bankers Trust to assess market risk on capital investments. This was 
achieved by multiplying the capital investments by a risk value (percentage); 
generating the risk-adjusted return on capital (Borge 2002). This technique 
can also be employed on other simulation outputs, but is primarily used on 
economic metrics (Borge 2002).  
 The Monte Carlo method was developed in the 1940s at Los Alamos 
National Laboratory while physicists were trying to establish the diffusional 
properties of neutrons through various materials (how far a neutron on 
average would travel before hitting an atomic nucleus) (Anderson 1986). 
Conventional deterministic simulation was unable to solve this problem, but 
by running the simulation multiple times with random statistical sampling they 
were able to establish a probability distribution of the solution. This heuristic 
approach was given the moniker of the Monte Carlo method (Anderson 
1986). The growth in computational power seen in the 1950s, bought Monte 
Carlo simulation into multiple fields of research and its popularity has 
increased inline with the increase in computational power seen in recent 
decades (Anderson 1986; Nicholas et al. 1953). In addition, a number of 
easy-to-use commercial packages capable of running Monte Carol 
simulations are now readily available such as the Excel® based add-ons 
@Risk® from Palisade Corp. (Ithaca, NY) and Crystal Ball® from Oracle 
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Corp. (Redwood City, CA). These tools have the ability to turn any 
deterministic simulation tool into a stochastic tool capable of running Monte 
Carlo simulations. Biwer et al (2004), among others, demonstrated how 
SuperPro Designer® could be linked to the Crystal Ball® add-in to allow the 
definition of stochastic input variables, the random number generation of the 
specified variables and the resulting output probability distributions (Biwer et 
al. 2005; Papavasileiou et al. 2007; Papavasileiou et al. 2009). The highly 
versatile discrete-event simulation tools discussed earlier also have this 
capability by linking to external add-ons or by utilising their own internal 
Monte Carlo algorithms. For example, ExtendSim® is capable of defining 
probability distributions and generating random numbers with the specified 
distributions for the multiple simulation runs required in a stochastic Monte 
Carlo analysis without external add-ons (Lim et al. 2006; Lim et al. 2005; 
Mustafa et al. 2006; Pollock et al. 2013b; Rajapakse et al. 2005; Stonier et al. 
2013; Stonier et al. 2012). Lim et al demonstrated how this functionality could 
be used to assess the annual throughput and resulting cost of goods 
(Fermentation titre variation and DSP yield) of fed-batch and perfusion cell 
culture processes (Lim et al. 2006; Lim et al. 2005). Stonier et al also used 
this functionality to assess current and future process robustness 
(fermentation titre variation) and the short-term facility fit issues on tech 
transfer to a new facility (fermentation titre, eluate volumes and step yield 
variation) (Stonier et al. 2013; Stonier et al. 2012). These publications 
demonstrate how discrete-event simulation tools specifically ExtendSim® can 
be utilised to evaluate a large number of different scenarios found throughout 
the biopharmaceutical industry. 
 
1.5.3 Multiple Criteria Decision Analysis  
 The simulation tools described so far are capable of generating 
quantitative outputs (annual throughput, COG etc.). However, when 
evaluating alternative manufacturing or portfolio strategies qualitative outputs 
(ease of development, ease of control etc.) are also important to consider. 
Often both quantitative and qualitative outputs, in alternative strategy 
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evaluation can be conflicting leading to situations where it is not apparent 
which strategy is the most preferential. For example in investment strategy 
comparisons, profit may be in conflict with the inherent risk of each strategy.  
 Multi-criteria decision-making (MCDM) is a method of decision-making 
that is capable of reconciling these conflicting attributes (quantitative and/or 
qualitative) when evaluating strategy alternatives against a set of decision 
criteria (Triantaphyllou 2000). Trinataphyllou describes how MCDM can be 
divided into multi-objective decision-making (MODM) and the more common 
multi-attribute decision-making (MADM) (Triantaphyllou 2000). MODM is 
used when the decision space is continuous (undefined alternatives), 
whereas MADM is used in decision problems with discrete decision spaces 
(predefined alternatives). Regardless of the approach used there are three 
steps seen in all MCDM approaches (Triantaphyllou 2000): 
1. Determining the relevant decisional criteria and alternatives. 
2. Assign numerical measures ranking criteria on importance and also to 
the impact of the alternatives on these criteria. 
3. Process the resulting numerical values assigned to each alternative 
and then establish the preferential ranking of the alternatives. 
 There are multiple methods available in MCDM that have been widely 
used in multiple decision spaces in multiple industries (Triantaphyllou 2000). 
The oldest and most widely used method is the weighted sum method (Deb 
2008; Fishburn 1967), followed by the weighted product method (Miller and 
Starr 1960) and the analytical hierarchy process method (Saaty 1980). These 
methods are primarily reported in literature in decision-making scenarios 
concentrating on financial responses, as demonstrated by Steuer and Na 
(2003). However, more recently these techniques have been employed to 
assess a number of scenarios specific to the biopharmaceutical industry. 
Farid et al (2005) demonstrated the use of MCDM methods to combined both 
quantitative and qualitative attributes in order to assess the use of single-use 
technologies in clinical manufacturing facilities. Also, George et al (2008) 
demonstrated how MCDM methods could be used in portfolio management 
and capacity planning. These bodies of work demonstrate how MCDM has 
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the ability to support decision-makers in the biopharmaceutical industry when 
evaluating alternative manufacturing strategies with conflicting quantitative 
and qualitative attributes. 
 
1.5.4 Modelling of Continuous Processes 
 The use of continuous processing in other industries such as the 
petrochemical, chemical, polymer, pharmaceutical, and food industries has 
been previously highlighted. Simulation tools played a key role during the 
period of conversion from batch to continuous manufacturing experienced by 
these industries and is now often the norm in a number of activities including 
facility design, optimisation and scheduling (Farid 2007; Mollan and Lodaya 
2004; Petrides et al. 2002; Toumi et al. 2010). Simulation tools used in these 
industries are designed to capture continuous processes, however, as 
previously discussed most biopharmaceutical processes are operated in a 
batch-to-batch manner. The emergence of continuous processing in the 
biopharmaceutical industry does not mean existing simulation tools from 
other industries can be readily employed. This is due to the nature of 
continuous processing and the continuous unit operations seen in the 
biopharmaceutical industry. 
 A key concept of a continuous process is that continuous, steady-state 
processing extends from the bioreactor to the final purification operation. 
However, this concept is currently not possible in biopharmaceutical 
manufacture due to the lack of suitable technology. For example, continuous 
perfusion bioreactors do generate a continuous stream of harvested cell 
culture fluid (HCCF), but they can only achieve this in a batch operation. 
Firstly, the cell culture has to reach the desired steady-state cell density to 
achieve a constant concentration of HCCF; then it can only produce a 
continuous stream of HCCF for a defined period, before a new cell culture 
batch is required. This semi-continuous mode of operation is also found in 
the search for continuous downstream processing operations, where 
chromatography systems that are described as continuous are capable of 
continual loading but only generate discrete elution pools of product.  
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 Therefore, any simulation tool capable of modelling continuous 
processing in the biopharmaceutical industry must be able to model batch 
(e.g. bind & eluate mode chromatography, viral inactivation), semi-continuous 
(e.g. periodic counter current chromatography, perfusion cell culture) and 
continuous unit operations (e.g. filtration, flowthrough mode chromatography) 
in the same manufacturing process. Toumi et al highlights that 
biopharmaceutical processes are represented more realistically with batch 
process simulators that account for time and event scheduling (Toumi et al. 
2010). However, batch based simulation models tend to be more challenging 
to develop due to their time-dependant behaviour; this will be further 
complicated with semi-continuous and continuous unit operations. This is 
reflected in the fact that the majority of the simulation efforts to date have 
concentrated on a single continuous unit operation, with the majority utilising 
static-spread sheet based simulation tools to establish economic, productivity 
and scheduling information (Bosch et al. 2008; Mahajan et al. 2012). Lim et 
al (2004) demonstrated how discrete-event simulation tools could be adapted 
to model semi-continuous and batch unit operations within the same 
simulation environment. However, to date the publication of any dynamic 
simulation tools capable of capturing multiple continuous/semi-continuous 
unit operations, or even a continuous biopharmaceutical process has not 
been seen.    
 
1.6 Aims & Organisation of Thesis 
The preceding sections of this chapter have provided a description of the 
current-state and future direction of biopharmaceutical development and 
manufacturing, highlighting the impact of monoclonal antibodies as 
therapeutic agents. In addition, an overview of the current position of 
computational design-support tools available to the industry has been 
discussed. However the presented literature review highlighted that at 
present no design-support tool is capable of capturing the economic, 
environmental and operational feasibility of continuous mAb manufacturing.  
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 Consequently, the aim of this thesis is the development of a decision-
support framework that is capable of simulating and optimising continuous 
mAb manufacturing processes in the challenging environment 
biopharmaceutical manufactures currently find themselves. This will facilitate 
more informed decision-making when evaluating continuous and semi-
continuous manufacturing strategies, with respect to their economic, 
environmental and operational feasibility. In order to realise this aim a set of 
objectives was established and these form the basis of each of the 
proceeding chapters. 
 In Chapter 2, a decisional framework is presented to facilitate the 
evaluation of continuous manufacturing alternatives. Initially a description of 
the problem domain that is addressed by the decision-support framework is 
presented. The hierarchal approach adopted throughout the framework is 
then introduced, followed by a detailed explanation of the modelling approach 
taken. Highlighting key process models for both batch and continuous unit 
operations. A multi-attribute decision making technique is also presented to 
allow the reconciliation of both quantitative and qualitative metrics generated 
by the framework. Chapter 2 also describes the materials, equipment and 
analytical techniques used to evaluate a semi-continuous chromatographic 
system prior to implementation into the framework. 
 Chapter 3 presents the use of the decision-support framework in the 
evaluation of fed-batch and perfusion cell culture manufacturing strategies for 
commercial mAb production. The chapter use a combination of deterministic 
and stochastic analysis techniques to verify the historical perception of poor 
productivities and high cell culture failure rates. Before highlighting the 
benefits of the latest perfusion cell culture technologies compared to 
conventional stainless steel fed-batch facilities as well as emerging single-
use fed-batch facilities. The information generated from this analysis is then 
combined with qualitative attributes to determine a ranking of the 
manufacturing alternatives. 
 In Chapter 4 an integrated approach to technology evaluation is 
described that combines experimental evaluation and simulation assessment 
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employing the decision-support framework. A systematic design methodology 
is presented that uses a number of small-scale single-column 
chromatography experiments to determine the key design and operating 
parameters for an optimised semi-continuous chromatography operation. The 
resulting design methodology was validated with semi-continuous 
constituency runs and incorporated into the simulation framework. The 
decision-support framework was then used in combination with a dynamic 
cycling study to evaluate the potential impact of adopting semi-continuous 
chromatography for commercial manufacture. 
 Chapter 5 presents a vision for a number of integrated continuous 
manufacturing strategies, combining the batch and continuous technologies 
evaluated in Chapters 3 and 4. The economic impact and operational 
robustness of these future-manufacturing strategies was then assessed via 
the decision-support framework. Addressing a number of unique scenarios 
throughout the development pipeline for a range of manufacturing scales and 
company sizes. The resulting analysis provides a wide-ranging overview of 
the performance of continuous processing relative to the current batch 
platform for the mAb sector. 
 Chapter 6 presents an assessment of the issues and challenges faced 
when validating a continuous manufacturing process. Looking at the 
guidance provided by regulatory bodies and how these can be interpreted for 
a continuous process. The chapter also provides insight into how 
manufacturers would demonstrate process understanding, robustness and 
reproducibility of a continuous unit operation. 
 In Chapter 7 a summary of the main conclusions of this thesis are 
presented and some future avenues of research to augment this work are 
presented. Finally, papers by the author, published during the course of this 
work are shown in the appendices. 
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2 Materials & Methods  
The preceding chapter highlighted the challenging environment in which 
biopharmaceutical manufactures currently find themselves. To remain 
completive in such an environment companies are looking to reduce R&D 
and manufacturing costs by improving their manufacturing platform 
processes whilst maintaining flexibility and product quality. As a result 
companies are now exploring whether they should choose conventional 
batch technologies or invest in novel continuous technologies, which may 
lead to lower production costs. In this chapter, a decision-support framework 
is presented that is capable of simulating and optimising continuous mAb 
manufacturing processes in this challenging environment, and is therefore 
capable of aiding design-makers when evaluating these alternative 
manufacturing strategies.  
The chapter is organised as follows: Section 2.1.1 provides a description 
of problem domain that is addressed by the decision-support framework. The 
scope and requirement specification of the framework are addressed in 
Sections 2.1.2 and 2.1.3. This is followed by a detail explanation of the 
modelling approach taken in Section 2.1.4. Section 2.1.5 describes the 
multi-attribute decision making technique used to reconcile the quantitative 
and qualitative metrics generated by the framework. A brief description of the 
data collection methods employed is given in Section 2.1.6. Sections 2.2.1, 
2.2.2 and 2.2.3 describe the materials, equipment and analytical techniques 
used to evaluate a semi-continuous chromatographic system prior to 
implementation into the framework. The final section then summaries the 
significant properties of the decision-support framework. 
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2.1 Decision-Support Framework 
 
2.1.1 Domain Description 
 The key features of the biopharmaceutical manufacturing problem 
domain are identified in this section. Biopharmaceuticals such as mAbs are 
produced for a range of demands for either clinical trials or commercial 
product sales. Prior to commercial manufacture, the drug candidate (DC) will 
be manufactured at a number of different manufacturing scales as the DC 
progresses through the development pipeline. These range from multiple 
commercial scale batches in the order of 10 – 100s kilograms of product for 
validation studies and small pre-clinical batches only producing grams of 
product. Throughout the development pipeline manufacturing must adhere to 
strict current Good Manufacturing Practices (cGMP) and comply with the 
unique process validation requirements for biopharmaceutical manufacturing 
facilities. It is of critical importance that these regulations are followed due to 
the influence they have on product quality, safety and regulatory approval. 
 MAbs are primarily produced in batches derived from mammalian cell 
culture fermentation and purified through a series of orthogonal purification 
steps. Each batch is produced in a stirred-tank bioreactor, which can be 
operated in a batch, fed-batch or continuous perfusion mode. The resulting 
cell culture broth is a complex mixture containing low concentrations of the 
target product, cells and cells debris. Further purification is required by a 
number of processing steps to yield the purified target protein. These steps 
include: primary recovery, product capture and polishing. Primary recovery 
often includes centrifugation and depth-filtration to remove cells and large 
debris. The resulting harvest cell culture fluid (HCCF) is typically purified 
further using a number of chromatographic operations. The initial product 
capture is typically carried out using affinity based capture in the form of 
Protein A chromatography. The product is then purified through a further 
sequence of chromatographic operations and filtration operations. In addition 
to these processing operations, the manufacturing process must demonstrate 
viral clearance, with a mandatory inclusion of two dedicated viral clearance 
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operations (viral inactivation & viral retention filtration). Inactivation is 
commonly seen after the initial product capture in the form of a low pH hold 
step. Virus retention filtration is carried out towards the end of the process to 
minimise filter fouling and is often found immediately before a final 
concentration and diafiltration step prior to final bulk formulation. Alternative 
semi-continuous unit operations are increasingly being seen in manufacturing 
including second-generation perfusion fermenters and semi-continuous 
chromatographic operations. These semi-continuous manufacturing 
operations require careful integration into the manufacturing facility due to 
their unique resource and scheduling requirements. 
 Alongside the aforementioned manufacturing operations, there are a 
number of ancillary operations that are not directly involved in the 
manufacture of a product batch. These include the formulation of 
intermediary materials including process buffers, fermentation media and 
cleaning-in-place buffers. Another key ancillary operation is the preparation 
and management of equipment and vessels (product and buffer), namely 
column packing, equipment and vessel cleaning-in-place (CIP) and 
sterilising-in-place (SIP) activities. 
 The biopharmaceutical facility has a number of complex sizing and 
scheduling options that need to be optimised to generate the required 
throughput of material and meet the target product demand. The scaling and 
scheduling of the upstream processes (USP) (fermentation and primary 
recovery) balance the frequency of harvest volumes which is determined by 
reactor number and cell culture duration against the USP equipment sizes 
and running costs. The resulting harvest volumes and frequency dictate the 
size of the vessels and equipment required in the downstream processing 
(DSP) operations. The principle aim of the biopharmaceutical manufacturer is 
to select a size of USP and DSP equipment that meets the DSP slot length 
(time between harvest volumes) at a minimum cost while ensuring that the 
neither the USP nor DSP becomes a bottleneck in the production schedule.  
 Establishing the optimal sizing and scheduling options for a 
biopharmaceutical manufacturing facility is a complex trade-off between 
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processing time and costs. However the complexity of the problem domain 
increases further when the inherent uncertainties found in manufacturing are 
considered. There are a number of uncertainties around key variables that 
lead to significant variation between batches, including cell culture titres and 
chromatography binding capacities. These variations can lead to delays, 
yield losses and even to some batches surpassing regulatory limits of 
product quality and resulting in the complete batch loss. Alongside the 
inherent variability in key manufacturing parameters there is also a high risk 
of equipment and sanitation failure that can also result in product losses or 
complete batch loss. Fermentation is a key example of both variability and 
risk, with variation being seen in cell culture titres and the risk in equipment 
failure or cell culture contamination leading to either product loss or batch 
failure. Accounting for these variations and risk events can assist in the 
design and operation of more robust manufacturing processes and facilities. 
 
2.1.2 Scope of Framework 
 Defining the scope of the framework was a crucial task in the initial 
development of the framework to ensure the analysis did not become too 
complex to handle and remained focused on the complex problem domain 
described. As mentioned earlier the aim of the simulation tool was to capture 
the key costs and operating concerns in biopharmaceutical manufacture and 
use these findings to assess the operational, environmental and 
business/financial implications of multiple manufacturing strategies. More 
explicitly, the scope was defined as follows: 
• To model multi-suite facilities with different process configurations, 
demands and performances for mAb manufacture on a campaign 
basis. 
• To evaluate the performance of alternative manufacturing 
technologies across a range of cell culture titres and scales in terms of 
cost, throughput, environmental impact and risk metrics.’ 
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 The model was also required to capture the unique challenges found with 
the incorporation of continuous manufacturing technologies into the current 
batch process sequences discussed earlier. These included: 
• The ability to capture the resource requirements for both batch and 
continuous manufacturing technologies in a dynamic discrete-event 
environment. 
• The ability to track and record the creation, division and merging of 
product batches into sub-batches, which is an inherent consequence 
of continuous processes. 
• The ability to screen sizing and scheduling strategies for both batch 
and continuous manufacturing strategies to establish the optimal 
equipment and scheduling strategy with respect to cost and time. 
  
The simulation tool should also be able to make a number of key decisions in 
the evaluation of a number of manufacturing alternatives, including: 
• Facility decisions – e.g. the use of stainless steel product and process 
vessel versus disposable bag technologies. 
• Process decisions – e.g. the use of continuous perfusion cell culture 
versus fed-batch cell culture and semi-continuous chromatography 
with conventional batch chromatography. 
• Strategy decisions – e.g. the best pooling strategies of sub-batches in 
hybrid batch and continuous manufacturing strategies. 
  
The following sections of this chapter demonstrate the approach taken to 
create a framework capable of fulfilling the aforementioned scope by 
modelling the economic, operational and environmental aspects of 
biopharmaceutical manufacturing. 
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2.1.3 Requirement Specification & Software Selection 
 The definition of the scope of the framework and the analysis of the 
problem domain meant it was possible to establish a requirements 
specification that describes what the software platform should be able to 
accomplish. The requirements specification of this framework was styled on 
previous work conducted at UCL (Farid et al. 2007; Stonier et al. 2012; 
Stonier et al. 2009). The requirements specification presented in this chapter 
builds on the need to rapidly reconfigure multiple process alternatives in 
multi-suite facilities and manipulate and share the resulting data sets. The 
key addition was to meet all these requirements for both batch and 
continuous unit operations, whilst maintaining the ability to capture 
uncertainty and present the resulting data in an easy to interpret visual 
format. A summary of the requirements specification is shown in Table 2.1, 
with the feature specifically required to capture continuous manufacturing 
technologies are shown in bold. 
 The suitability of commercially available bioprocess simulation packages 
to meet the requirements specification was investigated. These packages 
comprise of mainly spread-sheet based static models that can generate cost 
estimates but that are unable to capture the impact of resource constraints 
and the resulting delays in manufacturing (Farid 2007; Paz and Puich 2004; 
Pollock et al. 2013b; Shanklin et al. 2001; Stonier et al. 2012; Stonier et al. 
2009), a critical feature required for this analysis. Furthermore, they did not 
enable the specific scheduling features of semi-continuous unit operations to 
be modelled, meaning it was not possible to capture the scheduling 
interactions between continuous and batch product streams. On the other 
hand, discrete-event simulation languages were found to offer the flexibility to 
build dynamic models that had all these required capabilities. Hence, a 
stochastic dynamic decision-support tool was built to capture the specific 
scheduling challenges seen in batch and semi-continuous process 
sequences, as well as the impact of resource constraints, process variability 
and failure events.   
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Table 2.1. Requirements specification for the simulation tool 
Requirement Type Specification 
  Representation of declarative and 
procedural knowledge 
Tasks and their characteristics 
Resources and their characteristics 
Material flow and its characteristics 
 Batches, sub-batches and their properties  
 Sequence of sequential and parallel tasks 
 Resource requirements for each task 
 Calculation procedures for mass balances and costing 
 Variables for the calculation procedures 
 Time 
 Hierarchical views of tasks 
 Risk/uncertainty: stochastic variables defined using probability distributions 
 Facility definition 
 Processing Suites 
 Scheduling logic and its consequences 
  
Dynamic simulation Dynamic simulation of sequential and 
parallel task sequences 
 Dynamic allocation of resources to sequential and parallel tasks 
 Dynamic invocation of calculation procedure to compute compositions and costs 
 Dynamic invocation of procedures to compute resource utilisation statistics 
 Monte Carlo simulation 
 Single-threaded, multi-threaded and parallel processing 
  
Flexible development environment Modular 
 Extensible 
 Ability to store large amounts of data 
 Database driven 
  
Note: Features specifically required to capture continuous manufacturing technologies are 
shown in bold, Adapted from Farid et al, 2007.  
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 ExtendSim (ExtendSim v8, Imagine That! Inc., San Jose, CA) was 
selected as the discrete event simulation tool due to its multi-domain 
environment that can dynamically model continuous, discrete-event, discrete-
rate, linear, non-linear and mixed-mode systems. ExtendSim models are 
comprised of a large number of interconnected blocks between which items 
representing the product stream are passed. These blocks contain functions 
that generate simulation events on interaction with items. ExtendSim had a 
number of pre-fabricated blocks representing key discrete-event functions 
(time delays, queues, resource pools, etc.). Due to the common 
programming language ModL (based on C++) found in all the blocks, the 
existing per-fabricated blocks can be customised or specialist custom blocks 
can be coded. This resulting flexibility was a key driver in the selection of 
ExtendSim as the discrete-event simulation due to its ability to meet the key 
specified requirements with the existing block infrastructure and was able to 
meet all the other requirements due to the software’s inherent customisation 
ability.  
 A key requirement in the specification for the simulation tool was the 
ability to specify a wide range of process sequences whilst maintaining the 
ability to manage and access the large datasets created. A distinction 
between input and output tables was seen as vital to the interpretation of the 
scenarios investigated. The internal database present in the ExtendSim 
software is embedded in the ModL programming language that has no 
distinction between input and output tables making management and access 
challenging.  As a result linking ExtendSim to an external database platform 
was seen an efficient way of meeting the requirement specification. The 
external database selected for incorporation in to this framework was the 
MySQL distribution (MySQL AB, Uppsala, Sweden) of structured query 
language (SQL). SQL is an open source specialised programming language 
for managing large data volumes in relational databases by using a logical 
structure for relating data and maintaining organisation.  
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 The SQL data access functionality in ExtendSim is possible but is a slow 
and inefficient way to access the input and output data tables. A more 
efficient method was used which involved linking the MySQL database to the 
internal ExtendSim database and importing all the input data tables on 
initialisation of the simulation and upon completion export the output tables 
back to the MySQL database. This approach allowed the ExtendSim blocks 
to rapidly access the internal database when running discrete-event functions 
significantly improving simulation times. The data communication required 
between ExtendSim and MySQL was achieved through Microsoft Open Data 
Base Connectivity (ODBC). Figure 2.1 demonstrates how the use of a 
middleware such as Microsoft’s ODBC (Microsoft Corporation, Redmond, 
WA, USA) allowed the simulation framework to connect to third party 
applications including database user interfaces such as Microsoft Access 
(Microsoft Corporation, Redmond, WA, USA) and visualisation packages 
such as Origin (OriginLab, Northampton, MA, USA). 
 
2.1.4 Tool Implementation 
2.1.4.1 Modelling Approach  
 The framework utilised a hierarchical approach throughout the 
framework, assigning key activities to a series of levels. This hierarchal 
approach has been used extensively by researchers at UCL to represent the 
phases of drug development (George and Farid 2008a; George and Farid 
2008b; Rajapakse et al. 2005; Rajapakse et al. 2006) and the key 
manufacturing operations found in biopharmaceutical production (Farid et al. 
2007; Stonier et al. 2012; Stonier et al. 2009). The hierarchal structure 
presented in this chapter focuses on the manufacturing operations, where 
different levels of the process and facility are defined.   
 Previous hierarchical structures adopted at UCL have focused on five 
principal hierarchical levels (Campaign, Batch Recipe, Unit Operation, Task, 
Sub-Task) (Stonier et al. 2012). These levels are all linked in a whole-part 
relationship where a parent level can have one or many children, while one 
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child can only have one parent. For example a campaign has one or many 
batches and a batch is part of a single campaign. This modular structure is 
highly extensible by allowing further levels of detail to be added when 
required. High-level activities seen in the campaign level allow a summary of 
the key financial, environmental and operational to be created. With each 
new child level an increasingly accurate value of key operating parameters 
can be found. For example the sub-task level is able to capture exact values 
for buffer usage, improving the overall financial, environmental and 
operational summary. This structure of levels allowed the resulting framework 
to cost, track and record the progress of a batch in a campaign, as it 
progresses through the specified number of unit operations, completing the 
required tasks for each unit operation.  
 In combined continuous and batch manufacturing processes batches are 
often divided into smaller volumes in continuous unit operations that are then 
processed subsequently by batch unit operations, before being recombined 
into larger volumes again. The existing five level approach described is not 
capable of capturing the realities of these continuous unit operations, since 
they lack the ability to track the merging and splitting of batches. The 
introduction of a new level was required that linked the batches (in a 
campaign) to not just the unit operation level but also to a new level 
accounting for possible divisions of that batch (sub-batches). Sub-batches 
are the child group of a batch and come into existence when a parent batch 
is split or when multiple existing sub-batches are merged. This means a 
batch can consist of multiple sub-batches at any one time, which can be 
processed by different unit operations in the same process sequence, thus 
conducting different manufacturing tasks in parallel. The new hierarchal 
structure adopted is shown in Figure 2.2 in the form of a Unified Modelling 
Language (UML) class diagram, which represents the main classes 
implemented into the framework. 
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Figure 2.2. UML class diagram representing the main classes and 
associations in the framework. Each block represents a class (e.g. Suite), 
with attributes (e.g. SuiteID, Description etc.) and procedures (e.g. 
CalcUtilisation). Lines symbolise the associations and number the multiplicity 
between the classes. An unfilled triangle and a solid line represent a 
generalised relationship (e.g. Chromatography is a type of Unit Operation), 
with an unfilled diamond and a solid line as a aggregated relationship 
(e.g.one Process Sequence is made of Unit Operations) and a dashed line 
as an associated class (e.g. FilterSizeDF exists for a particular Unit 
Operation and Filter). 
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 The Unified Modelling Language (UML) (Bennett et al. 2010) is a 
standardised modelling language used to describe object-orientated systems 
and UML class diagrams are a common method to specify the structure of 
databases in an object-orientated manner. Figure 2.2 shows the different 
objects (classes) and how their affiliations interact between packages 
(grouped objects). Each block represents a class, which has a list of 
attributes and operations. The attributes of each class are either input values 
(attributes with no prefix) or output values calculated within the classes 
(attributes with a `O_` prefix). Most of the attributes have a single value 
(attributes with no suffix), however a number of the attributes can have either 
a single value or a distribution of values (attributes with a `_Dist` suffix). Lines 
symbolise the associations (relationships) between classes, where the 
multiplicity of an association is shown as a number on the line (e.g. one 
Vessel has exactly one VesselType, while one VesselType can have one or 
more Vessels associated with it).  A generalisation association (unfilled 
triangle and a solid line) shows the abstraction of a common feature among 
the classes, for example the class UnitOperation and the classes 
representing the different process steps. This relationship type can be 
expressed as Fermentation `IS A` UnitOperation. There are also a number of 
aggregation relationships (unfilled diamond and a solid line) showing whole-
part associations between classes, where one represents a whole and the 
others parts of that whole. These whole-part associations determine the 
hierarchical nature of the framework, where Campaigns are the highest level 
and Sub-Tasks the lowest. Figure 2.2 highlights the seven hierarchal levels 
used in the framework, where the additional levels (versus five levels) occur 
from the incorporation of sub-batch recognition into the framework. In this 
framework the level Batch Recipe is replaced by three new levels (Batch, 
Sub-Batch, Process Sequence) where a Batch is made of one or many Sub-
Batches of which all use only one Process Sequence. 
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2.1.4.2 Database Structure 
 The SQL database structure used in this framework is derived from the 
UML class diagram shown in Figure 2.2. The UML object-oriented class 
diagram was converted by a set of guidelines described by Bennett et al, to a 
relational structured database. The guidelines show how to map the classes 
and multiplicities from the class diagram to data tables in a relational 
database. The classes all have a simple data structure and therefore can be 
directly converted into data tables, where the attributes become fields. The 
class associations are enforced by the use of primary and foreign keys. For 
example the Batch class is transformed into the BatchTable, which has 
primary key of BatchID and a foreign key of CampaignID. The common 
foreign key (CampaignID) forms the aggregated relationship between the 
Batch and Campaign classes and the primary key (BatchID) forms the 
aggregated relationship between the Batch and Subbatch classes shown in 
Figure 2.2. This equates to a single record in the CampaignTable linked to 
multiple records in the BatchTable.  
 The data tables can also be grouped along the lines of the packages of 
classes shown in Figure 2.2. The tables in the Process package contain all 
the information directly relative to the manufacture of a batch. The package 
contains the seven hierarchal layers previously specified. The data in this 
package ranges from the number and properties of the batches at the highest 
level to the buffer and labour requirements of an individual sub-task at the 
lowest level. The variables in the sub-task level are scale-independent, which 
allows multiple simulation jobs with different batch sizes to be run without 
requiring extensive data entry. For example buffer requirement is specified as 
column volumes or filter areas with respect to chromatography or a filtration 
unit operation. The actual buffer volume is calculated during simulation runs 
based on the equipment size used.   
 Information on the infrastructure of the facility is found in the Facility 
package, which contains data on equipment sizes, suite availability, shift 
patterns and consumable resources (filter membranes, chromatography 
resins etc.). The tables in this package can be edited separately to the 
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process package, allowing the impact of different facilities configurations to 
be investigated with minimal data entry. For example the same process can 
be run in an 8-hour shift facility or a 24-hour shift facility.  
 The Simulation package contains all the data required to initiate the 
simulation runs, detailing which variable modifiers to apply on each 
simulation job. These modifiers can be applied to each of the previous 
packages, by changing key variable values or distributions. This is a very 
useful mechanism that allows multiple simulation jobs to be queued in the 
SimulationJob table and trigger the key variables to alter during initialisation 
of the simulation run without requiring manual data entry between simulation 
runs. The resulting simulation jobs are distinguished by a unique identifier 
stored in the SimulationRun table, which allows multiple simulation jobs to be 
easily compared upon completion. This is an important feature that allows 
multiple simulation results to be compared a key requirement in any analysis 
of alternative manufacturing strategies. 
 
2.1.4.3 Discrete-Event Simulation Tool 
 The discrete-event simulation tool in the framework was built in 
ExtendSim (ExtendSim v8, Imagine That! Inc., San Jose, CA), using a 
selection of prefabricated, customised and bespoke blocks using the ModL 
programming language.  These simulation blocks contain functions that 
either carryout simulation events or perform numerical calculations. Appendix 
Table A2.1 highlights the principle types of blocks and their functions in the 
simulation tool. 
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2.1.4.3.1 Model Structure 
 Figure 2.3 shows the core structure of the simulation engine, which is 
formed of three modules: initialisation, router and unit operations. The 
remaining modules that are not part of the core structure are responsible for 
the ancillary operations (e.g. buffer preparing, vessel cleaning etc.) are 
discussed in Section 2.1.4.3.3.  
Figure 2.3. Core structure of the simulation engine. USP, upstream 
processing; DSP, downstream processing; UOp, unit operation. 
 
 The simulation begins by running the initialisation module, with the first 
action being the data import of the relational SQL database via the ODBC 
into the simulation tools internal database. The data import function 
corresponds to the SimulationJob class function GenerateSimInput() shown 
in Figure 2.2 (Simulation package). This function imports a copy of the 
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database and then amends field values using the attributes specified in the 
SimulationJob class. The next step in the module is the USP pre-calculation 
and scheduling block, this block runs the USPSchedule() procedure seen in 
the campaign class (process package). The procedure calculates the number 
of batches that will be required to fulfil the annual demand (kg/year) and also 
select the size and number of the fermentation reactors based upon cell 
culture mode and reactor size limitations to achieve this throughput. The 
procedure then produces a schedule upon which items will enter the seed 
train to generate a product batch. The items representing product streams 
are assigned with a number of unique identifiers (item attributes). These 
include the BatchID, SubbatchID, StepID and stream properties (volume & 
product concentration). The BatchID will remain constant throughout the life 
of the item, constantly linking the item to the batch class. The SubbatchID will 
be altered during the simulation as product streams are split or merged and 
the consequences will be tracked in the sub-batch table derived from the 
sub-batch class. The StepID will alter after every unit operation is completed 
and be updated to the next unit operations StepID based upon the process 
specified in the process sequence table. The last block in the initialisation 
module is the DSP Pre-calculation and Optimisation block, which runs the 
OptimiseDSPschedule() procedure from the campaign class. The procedure 
optimises the DSP by finding the most cost effective DSP sizing that meets 
the slot time constraint (time between harvests). The procedure then predicts 
the buffer demands for all the unit operations and populates a buffer order 
table to make sure buffer is prepared in time for each task. 
 After all the procedures in the initialisation module have been completed 
the item enters the Router module. The Router module contains a series of 
blocks that calculate the mass balance of the given unit operation and then 
assign the item to a particular suite before allocating the required equipment 
and vessels. The UOp Mass Balance block represents the UnitOperation 
class and runs the MassBalance() procedure calculating the resulting 
changes to the product stream (volume & concentration). The block also runs 
the CalcProperties() procedure for all the possible unit operations, calculating 
the key operating parameters for each unit operation. These parameters are 
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either stored on the item as attributes or written to the unit operations 
corresponding data table (e.g. Fermentation table). The next block 
(Infrastructure Allocation) allocates the facility infrastructure for a particular 
unit operation. The location and status of suites, equipment and vessels are 
stored in the database and are called by the Locate() and CalcUtilisation() 
procedures found in the Facility package. If a suite, piece of equipment or 
vessel is unavailable (i.e. assigned to a different location, already in use or 
awaiting CIP) the item is routed to holding, where it waits until the suite, 
equipment or vessel required is available for use. If all the required 
infrastructure is available the item is routed to an Equipment block. Each 
Equipment block corresponds to a record in the Equipment table (Equipment 
class), allowing the equipment type and properties to be readily modified. 
This is possible because each Equipment block is identical and is capable of 
performing all the possible unit operation tasks. This modelling approach 
follows the key software principal of abstraction, which is the process of 
selecting all the common features of multiple procedures and combining 
them into a single procedure. This technique was used to reduce the models 
complexity and simplify development by placing all the unit operation mass 
balances and parameter calculations into a single block in the Router (UOp 
Mass Balance block) and by also combining all the task and sub-task 
procedures into a single block that can be cloned multiple times (Equipment 
block).  
 
2.1.4.3.2 Unit Operation Model Structure 
 The Equipment blocks contain all the necessary functions to simulate all 
the types of unit operations investigated by the simulation. The Equipment 
blocks are hierarchal blocks that include a series of further blocks that 
allocate resources, calculate processing times, manage vessels usage and 
schedule sub-tasks. Figure 2.4 shows the detailed structure of the 
Equipment block, demonstrating the paths taken by the item and the lines of 
communication between key blocks and resource manager blocks. The 
Equipment block contains a new type of block (denoted with `D`) that can 
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delay an item to represent the duration of a task (e.g. filling of a vessel) or the 
delay an item until the next labour shift. These blocks are actually formed of 
two simulation blocks a bespoke passing block, which calculates the delay, 
and an activity block that causes the item delay (see Table A2.1).  
 When the Equipment block first receives an item from the Router, it 
checks if the unit operation uses a process vessel (e.g. UFDF), if it does the 
item is delay representing the filling of this vessel. The next block (Pooling 
Operation) is used in the pooling of sub-batches. The block delays the item 
until sufficient number of sub-batches has been collected, before releasing 
the updated item as a new sub-batch and records its creation in the sub-
batch table. After these initialisation steps the Equipment block starts to cycle 
through the sub-tasks required to complete the unit operation. The Sub-task 
Calculator block runs a number of Sub-task class procedures, including 
CalcBufferVolume() and CalcTaskTime().  
 The buffer volumes and durations for the particular sub-task are recorded 
in the sub-task data table as scale-dependant variables, for example 
chromatography buffer requirements are specified in column volumes (CVs). 
The resulting buffer volumes and durations values calculated in the 
procedures are written in the sub-task data table and as attributes on the 
item. The item then moves to the Shift Manager where the procedures 
EstimateTaskTime() and ManageShift() from the Task class are run. These 
functions calculate the duration of a unit operation task (a group of sub-tasks 
that must be completed together) and manage the labour shift, which results 
in one of the three outcomes specified below: 
1. There is sufficient time in the shift for the task to continue processing. 
 
2. There is insufficient time in the shift to process the task, the item is 
delayed until the start of the next shift. 
 
3. There is insufficient time in the shift to process the task, however the task 
can be completed in over-time and processing can be continued. 
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Figure 2.4. The structure of an Equipment block, where the solid line show 
the items path and the dotted line the lines of communication between blocks 
and resource managers. Blocks that can delay the items are marked with `D`.  
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 The item then either requests a volume of buffer based on the stored 
attribute, or triggers the draining of the previous steps product vessel if 
loading the product stream. The item then requests the required labour to 
complete the sub-task and triggers a delay for the task duration (stored as an 
item attribute) before releasing the labour used. After releasing the labour the 
item is directed to either the Sub-task Router block or the Product Vessel Fill 
block. If the sub-task is a product release sub-task the item moves to the 
Product Vessel Fill block where it records the filling of the current product 
vessel. The item is then released from the Equipment block and returned to 
the router to trigger the next unit operation at this point unless it is not the 
final cycle of a chromatographic operation. The rest of sub-tasks just trigger 
the item to proceed to the Sub-task Router. The Sub-task Router moves the 
item onto the next sub-task and either directs the item back to the Sub-task 
Calculation block or if it is the final sub-task triggers the release of the 
equipment.  
 
2.1.4.3.2.1 Sub-task Routing 
 The majority of the unit operations follow the prescribed iterative sub-task 
progression in a linear fashion, starting at the first sub-task and progressing 
through all the sub-task until they have all been completed. Chromatography 
and some continuous unit operations behave slightly differently, due to the 
use of different types of sub-task routing. Figure 2.5 demonstrates ‘Task 
Cycling’ and shows all the sub-tasks required to complete three cycles in a 
bind and elute chromatography unit operation. The chromatography sub-
tasks are grouped into three tasks; Initialisation, Cycle and Storage. The item 
completes the initialisation task ‘Set-up’ before progressing through all the 
sub-tasks in the ‘Cycle’ task group. The two highlighted sub-tasks show 
interactions with the vessel manager block, with the ‘Load’ sub-task triggering 
a partial draw of material from the previous steps product vessel and the 
‘Bag’ sub-task triggering a partial fill of the current steps product vessel. 
When the ‘Cycle End’ sub-task is reached instead of progressing to the final 
‘Storage’ task, the sub-task count is reset and the item starts the complete 
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‘Cycle’ task again. This continues until the final cycle, with the total number of 
cycles being calculated in the Router block during the MassBalance()  and 
CalcProperties() procedures. The final ‘Load` sub-task triggers the complete 
draining of the previous steps product vessel and the ‘Bag’ step triggers the 
product vessel filling and release of the item. The final task ‘Storage’ is now 
completed and the Equipment block is released afterwards ready for 
reassignment. 
 
 
Figure 2.5. Overview of the sub-tasks used in a bind and elute 
chromatographic unit operation demonstrating the Task Cycling routing 
methodology. Highlighted sub-tasks show vessel manager interactions. 
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 Continuous unit operations behave differently to the previous two sub-
task routing methodologies (linear progression and task cycling). Figure 2.6 
demonstrates the sub-task cycling methodology used in continuous perfusion 
fermentation unit operations. A fermentation unit operation groups all the 
sub-tasks into three task groups: Initialisation, Fermentation and Cleaning. 
The conventional batch fermentation mode progresses through the sub-tasks 
using the linear progression methodology. The ‘Inoculate’ sub-task triggers 
the draining of the previous product vessel (e.g. seed train fermenter) and the 
‘Bag’ sub-task the harvesting of the fermenter and filling of the current 
product (harvest) vessel. In a continuous perfusion fermentation unit 
operation media is exchanged daily resulting in daily material harvests. The 
simulation tool captures this by cycling around a distinct sub-task in a task 
group, unlike chromatography that cycles the whole task group. During a 
continuous perfusion fermentation the initialisation task is completed, 
alongside the ‘Inoculate’ and ‘Ferment’ sub-tasks. After this point the item is 
re-set to run the ‘Ferment’ and ‘Bag’ subtasks every day for the duration of 
the fermentation operation to represent the daily media exchanges and 
harvests. On the last day of the fermentation operation the material is 
harvested and then the item is routed to the ‘CIP’ sub-task allowing the 
equipment block to be released ready for reassignment. These three types of 
sub-task routing, linear progression, task cycling and sub-task cycling allow 
the simulation tool to capture a number of different types of unit operations 
using the same simulation architecture. 
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Figure 2.6. Overview of the sub-tasks used in a continuous perfusion unit 
operation demonstrating the Sub-task Cycling routing methodology. 
Highlighted sub-tasks show vessel manager interactions, where Inoculate 
triggers the draining of the N-1 reactor and Bag triggers the filling of the 
harvest vessel. 
 
2.1.4.3.2.2 Resource Allocation 
 The allocation of resources in the Equipment block is controlled by the 
resource manager blocks. The resource managers receive resource requests 
from the sub-task blocks and attempt to meet this demand without causing a 
process delay due to unavailable resources. The Buffer Manager for example 
communicates with the requested buffer pool represented as a record in the 
Buffer table and checks if there is enough buffer available for the sub-task. If 
there is not enough buffer it triggers an additional buffer preparation request, 
this will be discussed further in Section 2.5.4.3.3.  
 The Labour Manager receives requests and release notifications, which 
signal when labour has completed a task and is available for reassignment. If 
labour is not currently available (e.g. being employed already), the Labour 
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Manager will signal a process delay and only trigger the release of the item 
when sufficient labour is available.   
 The Vessel Manager controls the status and properties of the vessels for 
the unit operations. There are two types of vessels in the model; Process 
vessels and Product vessels. Process vessels are used in conjunction with a 
particular piece of equipment (i.e. permeate vessel used in UFDF 
operations). Product vessels hold the product stream between unit 
operations (i.e. a chromatography elution pool). When a sub-task block 
signals the filling of a vessel, the vessels status in the Vessel data table is 
updated to full and the volume recorded. Upon emptying of a vessel the 
subtask block again signals the vessel manager, which marks the vessel as 
empty and awaiting CIP in the vessel data table. The vessel is then queued 
ready for vessel CIP; this is discussed further in the next section.  
  
2.1.4.3.3 Ancillary Model Operations 
 There are two key ancillary operations; buffer preparation and vessel 
CIP. Both these operations use the same principles of abstraction to reduce 
the complexity of the simulation tool by using a router and equipment block 
structure. The ancillary operations both use the same architecture, with a 
single ‘Manger’ block replacing the Router, which still performs the required 
parameter calculations and assigns infrastructure if required. The Manager 
block then directs the item to an Ancillary Equipment block, which behaves 
exactly the same as the core models Equipment Block, but represents a 
buffer prep or CIP skid instead. 
 Buffer preparation orders are specified in the buffer order table during the 
OptimiseDSPSchedule() procedure run in the DSP Pre-calculation & 
Optimisation block. The buffer order table interacts with a bespoke remote 
generation block type and the executive block (see appendix Table A2.1) to 
generate items at the requested buffer order times. Upon the creation of the 
item (represents a buffer order not a product stream) the Manager block pulls 
the requested BufferID and order volume from the Buffer Order table and 
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assigns the resulting values as item attributes. The item is then assigned a 
buffer preparation (process vessel) and buffer holding vessel (process 
vessel) before being directed to an available Ancillary Equipment Block, 
which represents a buffer prep rig. The item then completes all the buffer 
prep sub-tasks using the linear progression routing methodology. On 
completion of the last sub-task a signal is sent to the Manager block, which 
updates the required buffer resource pool and record in the buffer table 
showing buffer availability. If the Buffer Manager from the core models 
Equipment Block has a buffer shortage it signals the Manager block, which 
generates a new item to fulfil the requested shortfall.  
 Vessel CIP has its own manager block (CIP Manager) which receives 
signals from the Vessel Manager in the core models Equipment Block, when 
a vessel empty and marked for CIP. An item is then generated to represent 
the vessel, it then proceeds to an available Ancillary Equipment Block, which 
represents a CIP rig. Upon completion of all the CIP sub-tasks the CIP 
Manager updates the status of the vessel in the vessel data table to available 
and ready for use. 
 
2.1.4.3.4 Process Models 
 Up to this point only an overview of the procedures used in the simulation 
tool has been given. Attention is now turned towards the process models 
within the procedures used to describe the manufacturing processes. The 
process models used to describe each unit operations are found in the 
MassBalance() and CalcPropeties() procedures called in the UOp Mass 
Balance block. The process models specified in this section are used to 
calculate the product stream properties and as well as key unit operation 
parameters, using a number of design and mass balance equations. The key 
outputs of each process model are summarised in Table 2.2, where the 
common output variables of Output Volume, Output Concentration and 
Processing Time are not shown. 
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Table 2.2. Key outputs from the unit operation process models. 
Unit Operation Key Outputs 
  
Fermentation Total Cell Integral 
 Total Cell Mass 
 Feed Volume 
 Flush Volume 
 Daily Cell Integral 
 Daily Perfusate Volume 
  
Centrifugation Cell Mass Carry Over 
 Dewatering Level 
 Settling Velocity 
  
Depth Filtration Filter Area 
 Flush Buffer Volume 
  
Chromatography Cycle Capacity 
 Number of Cycles 
 Buffer Volumes 
 Number of System & Column Cycles 
  
Viral Inactivation Base Volume 
 Acid Volume 
  
Virus Removal Filtration Filter Area 
 Flush Buffer Volume 
  
Concentration & Diafiltration 
Filter Area 
Diafiltration Buffer Volume 
  
Note: Outputs specifically required for the process models of continuous manufacturing 
technologies are shown in bold. 
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2.1.4.3.4.1 Fermentation 
 
2.1.4.3.4.1.1 Fed-batch Cell Culture 
 In a fed-batch fermentation process, a low density of cells is added to a 
bioreactor containing a nutrient rich environment, which is controlled with 
further additions to promote sufficient cell proliferation. The increasing cell 
densities lead to an increase in product protein concentrations and are 
therefore maximised where possible. Detailed mass-stoichiometry models 
can be used to establish the key relationships between substrates and 
product. However this level of detail was deemed to be unnecessary due to 
the extra level of complexity it would add to the fermentation process models. 
The key outputs from Table 2.2 show how the volumes of the media and 
feed buffer are required but not the chemical composition of these buffers. 
Therefore a cell integral model was used to calculate the final product 
concentration and hence derive the bioreactor volumes required for a 
particular batch throughput (Cacciuttolo 2007). Figure 2.7.a shows the 
relationship between viable cell density (x) and resultant titre (+) for four fed-
batch fermentations. 
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Figure 2.7. Fed-batch fermentation cell culture growth profiles of four 
fermentation runs a) tracking the viable cell density (x) and resultant product 
titre (+), and b) with fitted viable cell density (bold black line) and estimated 
product titres (bold dashed line), with key growth regions highlighted. 
 
b) 
a) 
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 Figure 2.7.b highlights how a fed-batch cell culture growth profile can be 
readily divided into four different growth regions. The titre can found by 
calculating the viable cell integral in each of these regions and then based on 
the cells specific productivity a product concentration can be estimated. 
Region A represents the exponential growth phase and the Integrated Viable 
Cell Density (IVCD) (cell hr ml-1) can be calculated using Equation 2.1. 
 
!"#$!"#$%&'()* = !!! !!!! − !!!!      (2.1) 
 
Where  X0  = Seeding density (cells ml-1) 
   µ = Specific growth rate (hours-1) 
   t0 = 0 hours 
   t1 = 96 hours 
 
 Region B shows the deceleration phase; at this point a cold temperature 
shock is applied to prevent runaway cell proliferation. The viable cell growth 
is no longer exponential due to the cold shock and cell death. Instead a linear 
approximation can be made until the maximum Viable Cell Density (VCD) is 
achieved. 
!"#$!"#"$"%&'()* = !! !! − !! ∗ !!!!!! + !!"#    (2.2) 
 
Where  XMax  = Maximum VCD (cells ml-1) 
   t2 = 144 hours 
 The fermentation then maintains the maximum VCD for 48-hour period 
(Region C – Equation 2.3) before the level of cell death increases and the 
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overall viable cell count declines (Region D – Equation 2.4). At this point it 
becomes a balance between increasing product titre versus high cell death 
and therefore cell-related impurities. This relationship defines the harvest cell 
viability, which is normal expressed as the drop in cell density from the max 
VCD. 
 !"#$!"#"$%&#'( = !!"# ∗ !! − !!       (2.3) 
!"#$!"#$%&" = !! !! − !! ∗ !!"# + !!"# ∗ !"#$%&'    (2.4) 
 
Where     Harvest  = % of maximum VCD that triggers harvest  
   t3 = 192 hours 
   t4 = 264 hours 
 
 The resulting cell integrals can be summed and used to establish the 
expected titre (ConcFerm), using the cells productivity (qp, pg cell-1 day-1). 
 !"#$!"#$ = !"#$!"#$% ∗ !!       (2.5) 
 
 Figure 2.7.b demonstrates how Equations 2.2 – 2.5 can be employed to 
generate the expected VCD curve (bold black line) and resultant titre (bold 
dashed line) and how these predictions compare to the actual fermentation 
data from Figure 2.7.a. Now that the cell culture properties have been 
established the principal output variables can be calculated. The expected 
titre (Equation 2.5) can be used in conjunction with the cell culture harvest 
volume (VolHarvest) to establish the mass of product synthesised (Massout) and 
the resulting volumetric productivity (ProductivityVol) of the bioreactor 
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(Equations 2.6 – 2.9). However, the volume at harvest is not the same as 
the initial volume at the start of fermentation (inoculum and media). The final 
volume incorporates a number of additional feeds. These feeds consist of a 
number of different buffers added from the fourth day onwards (start of region 
B) to promote cell proliferation and later product synthesis. 
 !"#!""# = !"#!"#$#%& ∗ !""#       (2.6) !"#!"#$%&' = !"#!"#$#%& + !"#!""#      (2.7) !"##!"# = !"#$!"#$ ∗ !"#!"#$%&'      (2.8) 
!"#$%&'()('*!"# = !"#$!"#$!!        (2.9) 
 
Where VolFeed = Total volume of feeds added to bioreactor 
  Volinitial  = Volume of fermenter at t0 (inoculum and media) 
  Feed  = % increase in volume produced by feed additions  
  VolHarvest  = Volume of fermenter at t4 (inoculum, media and feeds) 
  
 With all the cell culture parameters now established the principal output 
variables for volume (VolOut), concentration (ConcOut) and mass of cells (MCell) 
can be calculated (Equations 2.10 – 2.13). The volume out of the 
fermentation step is not the same as the harvest volume, due to use of a 
further flush buffer addition step. The flush buffer addition (VolFlush) has two 
aims firstly to rinse the fermentation vessel to maximise product recovery and 
secondly the addition of collating agents (e.g. EDTA) to prevent excessive 
product degradation, as the harvest is further processed. 
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!"#!"#$! = !"#!"#$%&' ∗ !"#$ℎ!"      (2.10) !"#!"# = !"#!"#$%&' ∗ 1− !" + !!"#!"#$!    (2.11) 
!"#$!"# = !"##!"#!"#!"#         (2.12) !!"## = ! !!"#$%&'!"#!"#$%&' ∗ !"##!"## ∗ !"#!"#$%&'     (2.13) 
 
Where FlushFB  = % of harvest volume required to flush fermenter 
  Ev   = % of volume lost to evaporation 
  XHarvest  = Viable cell density at harvest 
  VCDHarvest  = Cell viability at harvest 
  CellMass  = Mass of a single mammalian cell 
 
 
2.1.4.3.4.1.2 Perfusion Cell Culture 
 In a perfusion cell culture process, a low density of cells is added to a 
bioreactor containing a nutrient rich environment, which is controlled with 
continuous media exchanges to promote sufficient cell proliferation. The 
increasing cell densities lead to an increase in product protein 
concentrations, which is maintained to maximise product expression. The 
continuous media exchanges result in a daily volume of harvested material 
enriched in the product protein, which is then purified.  
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Figure 2.8. Continuous perfusion fermentation cell culture growth profile for 
viable cell density (black line), estimated product titre (dashed line) and 
perfusion rate (dotted line), with key growth regions highlighted. The growth 
profiles shown were derived from discussions with Morten Munk, Christoffer 
Bro and Jacob Jensen (CMC biologics, Copenhagen, Denmark) and based 
on valid fermentation data. 
 
 The cell integral methodology described for fed-batch cell culture can 
also be utilised for continuous perfusion cell cultures but with some subtle 
differences. Instead of establishing the total cell integral for the total duration 
of the cell culture, a daily cell integral is used to calculate the product titre for 
that day of production. Region A shown in Figure 2.8 represents the batch 
growth phase where the cells grow exponential using the existing nutrients in 
the media. Perfusion is started after 2 days and the media nutrients are 
refreshed by the addition of new media and removal of spent media. At this 
point a cold shock is applied to the cell culture to prevent uncontrolled cell 
proliferation due to the increase in nutrients, this results in the reduced rate of 
growth seen in region B. The perfusion rate starts at 0.5 vessel volumes per 
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day (vv/day) and increases to 1 vv/day after the initial cell doubling to 
maintain the progression of cell proliferation. Region C highlights the 
deceleration phase where the viable cell growth is no longer exponential due 
to the limitation of nutrients and increase in cell death. At this point (day 9) 
the cells density is sufficient to generate daily harvests with sufficient product 
concentrations to make it worthwhile to purify. The fermentation then 
maintains the maximum cell density in the steady phase represented by 
region D, which will last to the end of the cell culture duration selected. 
 The daily perfusate volumes from the continuous perfusion cell culture 
are only collected after day 8 (first on day 9) during the deceleration phase 
when the product concentration values are required. Therefore the daily cell 
intergral is only required from day 9, this is achieved by establishing the 
viable cell density at the end of the batch (XBatch) and perfusion (XPerfusion) 
growth phases (region A and B) using Equations 2.14 and 2.15. 
 
!!"#$! = !!!!"#$! !!!"#$!!!        (2.14) !!"#$%&'() = !!!!"#$%&'() !!!"#$%&'()!!      (2.15) 
 
Where  X0   = Seeding density (cells/ml) 
   µBatch  = Batch phase specific growth rate (hours-1) 
   µPerfusion = Perfusion phase specific growth rate (hours-1) 
   t0  = 48 hours 
   t1  = 216 hours 
  
 For daily cell integrals required during deceleration phase (region C) and 
steady state (region D) Equations 2.16 - 2.18 are employed. 
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!! = !!!!! + !!"#!         (2.16) 
!"#$!"#$%#&'($%&%# = !! !!!! + !!       (2.17) !"#$!"#$%&!"$"# = !!"#       (2.18) 
 
Where  XMax  = Maximum viable cell density (cells/ml)  
   Xi  = Viable cell density on day i (cells/ml) 
   n   = Number of days culture is deceleration phase 
 For the first media exchange on day 9 Xi-1 equals XPerfusion. The resulting 
daily cell integrals can be used to establish the daily harvest output volume 
(VolOut) and target protein product concentration (ConcOut) of the bioreactor. 
The volumetric productivity (ProductivityVol) of the perfusion bioreactor is 
calculated with Equation 2.9, where ConcFerm is the average concentration of 
product harvested from day 9 to the final day of the culture. 
 !"#$!"#$%&'() = !"#$! ∗ !!       (2.19) !"##!"# = !"#$!"#$%&'() ∗ !"#!"#$#%&     (2.20) !"#!"# = !"#!"!#!$% ∗ !"       (2.21) 
!"#$!"! = !"##!"#!"#!"#         (2.22) 
Where  ConcPerfusion  = Expected daily titre  
   qp   = Cells productivity (pg cell-1 day-1). 
   Volinitial = Volume of fermenter at t0 (inoculum and media) 
   PR   = Perfusion rate (vessel volumes) 
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2.1.4.3.4.2 Centrifugation 
 Centrifugation is used to separate suspended solids from a 
heterogeneous mixture based on their differences in size and density. 
Centrifugal forces are used to increase the settling velocities of heavy 
particulates (cells and cell fragments) to produce a solid based sediment and 
a supernatant depleted in solids. Table 2.2 shows the key output parameters 
generated by the centrifugation process model. Where the settling velocity 
(ug) is used to establish the key operating parameters (sigma efficiency) and 
the dewatering level is used to assess step performance. The remaining 
mass balance equations are shown in the appendix. 
 
!! = !!"#$%!!!"#$"% ∗!"#$%%!∗!!"!       (2.23)  !!"#$%"&' = !!"## − !!"## ∗ !"##$%&'#      (2.24) 
!"#$%"&'() = ! !!"#$%"&' !!"#$%!"#!"#$%"&'! !!"#$%"&' !!"#$%     (2.25) 
 
Where ρ   = Density of the solid or liquid phase 
  CutOff  = Mass Cut Off achieved by the centrifuge 
  η   = Viscosity  
  M  = Mass of key component 
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2.1.4.3.4.3 Chromatography 
2.1.4.3.4.3.1 Batch Chromatography 
 
 Chromatography is a high-resolution technique, which separates 
complex mixtures based on differences in binding specificity, ionic charge 
and hydrophobicity. The simulation tool captures two modes of 
chromatography; bind and elute (B&E) where the product is bound on to the 
resin and eluted by a change in buffer conditions, and flow through (FT) 
where the product passes through the column and contaminates are bound 
instead.  
 
 
Figure 2.9. Protein breakthrough curve for a column operated in bind & elute 
mode, highlighting A) the dynamic binding capacity used in manufacturing 
(90% of 1% breakthrough), B) the point of breakthrough (1% breakthrough), 
C) 10% breakthrough and D) resin saturation. 
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 A typical chromatography column operated in bind and elute mode is 
loaded up to 90% of 1% breakthrough capacity, underutilising the resin’s 
capacity (Figure 2.9). This strategy is used to offer a safety margin to reduce 
product losses in the flow-through during loading caused by product 
concentration variation and variation in dynamic binding capacity (ligand loss, 
fouling, lot-to-lot variation etc…). Figure 2.9 also highlights the actual DBC of 
the resin at the point of breakthrough (B), the point of 10% breakthrough (C) 
and the loading required to fully saturate the resin (D). After point B some of 
the protein starts to breakthrough in the flowthrough, as the resin no longer 
captures it. By point D the breakthrough curve levels off as no more protein is 
retained due to saturation of the resin. This makes calculating DBC more 
complex than just recording the value shown on the x-axis (which is possible 
for point A & B). The DBC can be found at points C and D by calculating the 
integral of the breakthrough curve, where the area beneath the curve is the 
unbound protein and the area above the curve the bound protein. The 
integral of the total bound protein can the used to establish the DBC.  A 
column operated in flowthrough mode is still assigned a protein based DBC, 
even though it is not binding the target protein but contaminants instead. To 
simplify the scale-up and operation of flow-through columns a protein based 
DBC is defined using the same technique shown in Figure 2.9. The figure 
would display the breakthrough of contaminants rather than target protein 
and the protein DBC selected is for a point prior to the breakthrough of the 
contaminants. 
 Equations 2.26 - 2.28 demonstrate how the cycle capacity (CapCycle), 
column volume (ColVolume) and Dynamic Binding Capacity (DBC) can be used 
to determine the number of cycles (NCycles) a column is used during a batch. 
 !"#!"#$% = !"#!"#$%& ∗ !"#      (2.26) 
!!"#$%& = !!"!"#!"#$%        (2.27) !!"#$%& = !"#$#%&(!!"#$%&, 1)      (2.28) 
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 The number of column cycles calculated using Equation 2.27 may not 
be a whole number; but to reflect reality (not possible to process a fraction of 
a cycle) a ceiling function is applied to generate a whole integer value for the 
number of cycles (Equation 2.28). The buffer requirements for each 
chromatography sub-task (i) are specified in column volumes (CV); a scale 
dependant variable. These values are then transformed into buffer volumes 
using Equation 2.29. 
 !"#! = !"#!"#$%& ∗ !"! ∗ !!"#$%&      (2.29) !"#!"#$% = !"#!" + !"#!"#$!       (2.30) 
 
 The final volume out of the chromatography step depends on the mode 
of operation. The final volume for the B&E operated chromatography steps is 
calculated using Equation 2.29, where CVi equals the elution peak volume. 
The defined volume of elution buffer causes the dissociation of the product 
from the resin, which in reality is either a specified volume for collection or a 
volume collected based on UV stop gate (when protein UV signal decreases 
below threshold the elution flowthrough is no longer collected). Equation 
2.30 shows the calculation required for a column operated in FT mode, 
where the flush volume (VolFLush) is found using Equation 2.29. The 
remaining scheduling and mass balance equations are shown in the 
appendix. 
 
 
 
 
114 
 
2.1.4.3.4.3.2  Continuous Chromatography 
 The previous section highlighted how a typical chromatography column 
operated in B&E mode is only loaded up to 90% of 1% breakthrough 
capacity, underutilising the resin’s capacity. This loading regime results in the 
entry (top) of the column being saturated and the exit (bottom) unsaturated 
upon completion of loading, leading to an excess buffer consumption caused 
by washing, elution and cleaning of the unsaturated column portion. An 
approach to increase utilisation would be to divide the column into multiple 
portions and wash and elute the saturated top portion of the column and 
continue loading the unsaturated portion of the column until saturated. This 
principle is applied in semi-continuous chromatography, which allows the 
columns to be loaded to a higher binding capacity, reducing the resin volume 
required and the overall buffer consumption 
 This section describes the updates made to the batch chromatography 
process model to account for the operation of a semi-continuous 
chromatography system. The same mass balance equations are utilised for 
both the batch and PCC chromatography systems. However, there are some 
additional equations due to the extra columns. For example Equation 2.28 
calculates the number of cycles required to process the total product mass 
per batch. For a semi-continuous chromatography step this value equates to 
the total number of cycles completed by all the columns (NColumns), so the 
number of cycles calculated in Equation 2.28 is equal to the number of 
system cycles (NSystem Cycles). The number of cycles an individual column 
(NCycles) is utilised for can be found using Equation 2.31.  
 
!!"#$!" = !!!"#$%&!!"#$%&!!"#$%&'        (2.31) 
 
 The remainder of the batch chromatography equations can be utilised in 
the same manner for the semi-continuous chromatography system. However 
a number of input parameters will be different, most notably the DBC. The 
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higher DBC is realised by loading the column to full saturation represented by 
point D in Figure 2.9. To prevent loss of the protein that breakthroughs form 
the primary column, the load effluent is passed over a secondary column to 
capture any protein. Upon full saturation of the primary column, the 
secondary column becomes the new primary column with respect to loading 
and the previous primary column is washed and eluted. This column 
switching mechanism is explored further in Chapter 4.  
 
Figure 2.10. Schedule of the loading (grey) and non-loading (white) 
processes for the batch, 3-column periodic counter current chromatography 
system and the simulations interpretation of the periodic counter current 
chromatography system. 
 
 Figure 2.10 demonstrates how a semi-continuous system processes a 
number of operations at the same time in different columns, where a grey 
block represents the loading of a column and a white block the non-loading 
operations. The semi-continuous chromatography system represented in 
Figure 2.10 is the GE Healthcare (Uppsala, Sweden) 3-column periodic 
counter current (PCC) system. To avoid major changes to the structure of the 
equipment blocks and follow the software principal of abstraction adopted 
throughout the development of the simulation framework. The semi-
continuous chromatography’s systems resource requirements (buffers & 
labour) were converted into a single column system, which the current 
116 
 
equipment block and sub-task routing rules previously highlighted can be 
applied without alteration. This was achieved by reducing the apparent 
duration of the loading operations, to the loading time remaining after the 
non-loading operations have been completed. Figure 2.10 shows the 
reduced loading time for the simulated semi-continuous chromatography 
system and can be best visualised by overlaying all the columns of the 
system. This methodology made it possible to convert multiple parallel 
operations into a single operations schedule, but still request the right 
amount resources at the correct time. The design and optimisation of a semi-
continuous chromatographic system with respect to switch times, possible 
DBCs and column sizing is explored in Chapter 4.  
 
2.1.4.3.4.4 Viral Inactivation 
 The remaining viral clearance step (Viral Inactivation) often occurs after 
Protein A chromatography, because the elution pool will already be at a low 
pH due the elution buffers composition. The step therefore requires less acid 
to achieve the required inactivation pH. After the inactivation time the product 
streams pH is adjusted ready for the next processing step. The following 
equations demonstrate how the volumes of acid and base required are 
calculated, using the molar ratios (TitrateAcid and TitrateBase) to establish the 
amount of titrant to add. 
 !"#!"#$ = !"#!" ∗ !"#$%#&!"#$      (2.32) !"#!"#$ = !"#!" ∗ !"#$%#&!"#$      (2.33) 
 
 
 
 
117 
 
2.1.4.3.4.5 Membrane Filtration 
 Filtration exploits differences in particle sizes to separate target particles 
from complex mixtures. The simulation tool captures two modes of filtration; 
cross-flow used in concentration and diafiltration operations and dead-end 
filtration used in depth and virus retention filtration.  
2.1.4.3.4.5.1 Depth Filtration 
 Depth Filtration (DF) is often used in primary recovery to remove the fine 
cell particles and reduce key containments still present in the feed stream 
after centrifugation. When a depth filter is run in series with a centrifuge the 
average flow rate across the filter unit should match the centrifuge flow rate 
to remove the requirement for a holding vessel. At the same time the 
resulting filter area are must of sufficient size to prevent contaminant 
breakthrough. Equations 2.34 and 2.35 both calculate a filter area (AreaDF). 
The largest value for the resulting areas is then selected. The resulting area 
is then rounded to the nearest available unit size for a depth filter using the 
ceiling() function (Equation 2.36). The remaining mass and scheduling 
equation are shown in the appendix. 
 
!"#$!" = !!" !!"        (2.34) 
!"#$!" = !"#!" !!"#       (2.35) !"#$!" = !"#$#%& !"#$!" ,!"#$%#&'      (2.36) 
 
Where QIn  = Flowrate into the unit 
   JDF  = Average flux rate  
   Vmax  = Max volumetric challenge before breakthrough 
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2.1.4.3.4.5.2 Viral Retention Filtration 
 Viral Retention Filtration (VRF) is one of the two dedicated viral 
clearance steps required in biopharmaceutical manufacturing. The principle 
aim is to retain all the possible viral bodies in the feed stream and therefore 
generate a permeate stream that contains no viral bodies or viral fragments. 
VRF is also operated in the dead-end filtration mode but the required filter 
area is calculated using Equation 2.37, which actively over-scales the filter 
area (AreaVRF) by a pre-defined safety margin to make sure the filter is never 
over-challenged. 
 
!"#$!"# = !"#!"!!"#$%&'() ∗ !!"#$%&'()!!"# + ! !!!"# ∗ 1+ !"#$%&   (2.37) 
 
Where tVRFTarget = Target processing time for the step 
  Safety  = % Over-scale applied to filter area 
 
 The resulting filter area is then rounded to the nearest available unit size 
using the ceiling function shown in Equation 2.36 and the remaining mass 
balance equation are shown in the appendix. 
 
2.1.4.3.4.5.3 Concentration and Diafiltration 
 Concentration and Diafiltration (UFDF) operates in tangential flow mode, 
where the product stream passes through semi-permeable membrane whilst 
under tangential flow across the membrane. The UFDF operation is divided 
into three distinct phases of operation; Concentration, Diafiltration and Final 
Concentration. The first phase (Concentration) concentrates the feed stream 
to the required product concentration (ConcDF) used during the diafiltration 
phase. The resulting volume (VolDFRetentate) then undergoes diafiltration, 
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where the volume of diafiltration buffer (VolDFBuffer) can be found using 
Equation 2.38 and the number of buffer volumes you intend to exchange 
(DFVolumes). 
 
!"#!"#$%$&%'%$ = !"#!"∗!"#$!"!"#$!"        (2.38) !"#!"#$%%&' = !"#$%&'() ∗ !"#!"#$%$&%'%$    (2.39) 
 
 If the final product concentration (ConcFinal) is higher, a further 
concentration step is employed to establish the final product stream volume 
(VolRetentate). 
 
!"#!"#"$#%#" = !"#!"#$%&'&$∗!"#$!"!"#$!"#$%       (2.40) 
 
 The final process time can be found by summing all the processing times 
calculated in Equations 2.41 - 2.43, with the remaining mass balance 
equations shown in the appendix. 
 
!!"#$%#&'(&)"# = !"#!"!!"#!"#$%$&%'%$!!"#$%#&'&("#∗!"#$!"#"     (2.41) 
!!" = !"#$%&'()∗!"#!"#$%$&%'%$!!"∗!"#$!"#"       (2.42) 
!!"#$% = !"#!"#$%$&%'%$!!"#!"#"$#%#"!!"#$%∗!"#$!"#"       (2.43) 
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2.1.4.3.5 Optimisation Protocols 
 The simulation was operated in two facility sizing modes; Rating mode, 
where the facility size (equipment and vessels) was fixed and Design mode, 
where the simulation tool decided the facility size. During initialisation of the 
simulation tool the item passes through two blocks, the USP Pre-calculation 
and Scheduling block and DSP Pre-calculation and Scheduling block. These 
two blocks contain the facility scaling procedures for the USP and DSP unit 
operations. When the simulation tool was operated in design mode it called 
these procedures to scale the USP and DSP, however these procedures 
were bypassed in rating mode. 
 The USP unit operations were sized during design mode when the 
Campaign class procedure USPSchedule() was called. The procedure runs 
an iteration sequence constructed of the principle USP scaling equations. 
The first equation (Equation 2.44) calculated the batch time (tBatch), the time 
the fermenter is in use, with respect to cell culture time (tCellCultire) and CIP 
downtime (tDowntime). The resulting batch time was then called via Equation 
2.45 to establish the number of batches (NBatches) that can be achieved in the 
prescribed operating window (NDays). The final equation (Equation 2.46) in 
the iteration established the required bioreactor volume (VolFerm) based upon 
the mass demand (MDenand), process yield (YieldProcess) and expected 
bioreactor productivity (ConcFerm) from Equation 2.12 or 2.22. Once all these 
equations were run the iteration was subject to a conditional statement with a 
Boolean condition that dictated if a further iteration was required. Equation 
2.47 highlights this condition, which establishes if the calculated bioreactor 
volume is larger than the maximum constraint set (VolFermMax). If the 
calculated volume was greater than the maximum constraint then the number 
of fermenters was increased by one and the iteration was reinitiated at 
Equation 2.44. 
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!!"#$! = !!"##!$#%$&"!!!"#$%&'(!!"#$%        (2.44) 
!!"#$!!" = !"##$ !!"#$!!"#$! , 1        (2.45) 
!"#!"#$ = !!"#$%& !!"#$!!" !"#$%!"#$%&!!"#$!"#$      (2.46) !"(!"#!"#$ > !"#!"#$%&')!!ℎ!"! !"#$ + 1    (2.47) 
 
 The use of the prescribed iteration sequence allowed the simulation tool 
to establish the required number and scale of bioreactors to meet defined 
mass throughputs under a number of constraints (Max bioreactor volume, 
operating window, bioreactor productivity etc.). The procedure also 
calculated the scale of the seed train bioreactor and predicted when to 
inoculate the first seed bioreactor to make sure a new batch was ready for 
DSP purification every batch interval (tBatch).  The USPSchedule() procedure 
adds great versatility to the simulation tool by allowing a number of different 
demand scenarios to be simulated without constantly needing to manually 
redefine the facility scale between simulations. 
 The DSP unit operations were sized during design mode when the 
Campaign class procedure OptimiseDSPSchedule() was called. The aim of 
the procedure was to establish the optimal process configuration by selecting 
the scales of DSP equipment that resulted in the minimum batch cost but still 
met the DSP slot length (time between harvest volumes). The procedure 
behaves like the router in the simulation engine, but instead of routing items, 
the procedure called the Unit Operation, Task and Sub-task class procedures 
to estimate mass balances, buffer costs and task durations. These functions 
were called within the procedure and not by simulation events and therefore 
only generate parameter values for an unconstrained facility. This mimics the 
approach seen in static spreadsheet based simulation tools and only results 
in an estimation for time and cost, where resources are not constrained. This 
approach was still able to track shift changes but is unable to capture the 
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delay of a key resource, however this was sufficient for comparing multiple 
process configurations in an optimisation procedure. 
 The procedure starts by generating a decision space for all the 
equipment size configurations that can be implemented in the facility. The 
principle equipment size variable investigated was the size of the 
chromatography columns with respect to the columns diameter. The 
remaining DSP unit operations are filtration based and are scaled based on 
upon the ideal filter time constraint (i.e. the filter step must be completed in a 
defined time period). The number of possible configurations options (NOptions) 
was therefore dependent on the number of chromatography steps (NSteps) 
and the number column diameter sizes (NColDias) and can be calculated using 
Equation 2.48. 
 
!!"#$!%& = !!"#$%&'!!"#$%       (2.48) 
 
 Equation 2.48 highlights the potentially high number of process 
configurations that needed to be investigated. For example a process 
sequence with three chromatographic steps and a facility with ten possible 
column sizes resulted in one thousand process configurations. If the 
procedure was used to estimate the time and cost for every process 
configuration for the whole manufacturing campaign (multiple batches), then 
the computational burden would be very high. To address these 
computational time and power concerns, the procedure only tracked a single 
‘Master Sub-batch’. This methodology reduced the computational burden of 
the procedure by running a single sub-batch instead of the potentially high 
number of batch and sub-batches that are present in a complete 
manufacturing campaign. The procedure uses the time and costs from a 
single sub-batch (`Master Sub-batch`) to extrapolate the complete batch cost. 
For example if a chromatography step is required to process multiple sub-
batches the batch cost was increased by the number of sub-batches that 
would be processed. 
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 The cost and time data generated for all the process configurations is 
then stored in an array along with a number of key process parameters 
shown below. 
• DSP equipment scales 
• Number of chromatography cycles 
• Duration of chromatography processes 
• Overall process time 
• Batch cost 
 The process configuration parameters were then used to select the 
optimal process configuration. The primary aim of the procedure was to 
establish the most cost effective process configuration, however it also had to 
meet a number of processing rules. For example the Protein A 
chromatography steps processing time must not surpass the maximum 
harvest cell culture fluid holding time. Once all the selection criteria set by the 
user were applied, a pool of viable process configurations would remain. 
From these viable process configurations the most cost effective option was 
selected and labelled as the optimal process configuration. The procedure 
then used the optimal process configuration to predict the order times and 
volumes for all the buffer requests made during the manufacturing campaign. 
These values were then used to populate the buffer order table, which in 
conjunction with the buffer resource manager block, made sure buffers are 
made in time for each task. 
 
2.1.4.3.6  Cost Models 
 The key finical performance metrics, used to compare alternative 
manufacturing strategies, were the Fixed Capital Investment (FCI) and the 
Cost Of Goods (COG). The simulation tool employed two cost models to 
establish the FCI and COG. This section summarises the two cost models 
used. 
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2.1.4.3.6.1 Fixed Capital Investment 
 The fixed capital investment was approximated using a factorial method, 
which is often attributed to Lang (1948). The Lang factor method for cost 
estimation uses a cost factor (LangFactor) derived from previous construction 
projects, relating the capital outlay used in facility construction to the cost of 
equipment in the facility (Lang 1948). Therefore the fixed capital investment 
(FCI) can be given as a function of total equipment purchase cost 
(CostEquipment) shown in Equation 2.49. Lang Factor values depend on the 
type of facility. For chemical facilities used for liquid or solids processing, 
values in the range of 3-5 are often used (Peters et al. 2006; Sinnott et al. 
2005). For biopharmaceutical facilities much larger values are seen, ranging 
from 3.3-8.1 (Farid 2007; Novais et al. 2001). The high Lang Factors used in 
biopharmaceutical facilities are due to the requirement to maintain higher 
GMP suite contaminant level ratings, which result in increased HPAC/HVAC 
costs. 
 !"# = !!"#$%"&'() ∗ !"#$!"#$%&'()     (2.49) 
 
 To make more accurate facility cost estimates, the cost factors that are 
normally combined to create a Lang Factor value were considered 
individually. Table 2.3 shows a breakdown of these capital investment costs 
incurred in the construction of a conventional (stainless steel dominated) and 
disposables-based facility. The cost factors were then combined into a more 
accurate single Lang factor for a biopharmaceutical facility. 
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Table 2.3. Biopharmaceutical facilities capital investment factors and 
corresponding “Lang” factors 
Factor Description 
Conventional / 
(Conventional 
TEPC)* 
Disposable / 
(Conventional 
TEPC)* 
Disposable / 
(Disposable 
TEPC) 
 
1 
 
 
Equipment (incl. utilities) 
(Total Equipment Purchase 
Cost) 
1 0.2 1 
2 Pipework and installation 0.9 0.3 1.49 
3 Process control 0.37 0.37 1.85 
4 Instrumentation 0.6 0.4 1.98 
5 Electrical power 0.24 0.24 1.2 
6 Building works 1.66 1.33 6.64 
7 Detail engineering 0.77 0.39 1.93 
8 
 
Construction 
and site management 
0.4 0.30 1.5 
9 Commissioning 0.07 0.07 0.35 
10 Validation 1.06 0.53 2.65 
     
 Contingency factor 1.15 1.15 1.15 
     
 “Lang” Factor 8.13 4.73 23.67 
*Adapted from Novais et al 2001 
  
 To use the described factorial costing methodology the total equipment 
purchase cost must be known. The purchase cost of a piece of equipment 
was estimated using the R factor method (six-tenths rule); which relates the 
cost and size of the equipment (Williams 1947). Equation 2.50 highlights this 
exponential scaling relationship, where the unknown equipment cost (Cost1) 
is related to a known cost (Cost2) and the ratio of their sizes (Size1/Size2) to 
the power of a coefficient (C).  
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!"#$! = !"#$! ∗ !"#$!!"#$! !       (2.50) 
 
 Historically an exponential scaling coefficient value of 0.6 was commonly 
used. However, Remer et al (1991) warns against the use of a single scaling 
coefficient for multiple types of equipment, by demonstrating how the scaling 
coefficients for biopharmaceutical equipment range between 0.37 and 1.16 
(Remer and Idrovo 1991). Table A2.2 highlights the equipment dependant 
exponential scaling coefficients, sizes and costs used throughout this work. 
Most equipment types are linearly scalable, however their purchase cost is 
not always. For example, small-scale bioreactors costs are dominated by the 
ancillary components not the vessel, whereas for larger scale bioreactors the 
vessel cost dominates the overall purchase cost. This phenomenon was 
accounted for in the tool, and as such is reflected in Table A2.2, where some 
pieces of equipment have multiple costing models. The required costing 
model was selected based on the equipment size and low and higher 
selection thresholds corresponding to the different costing models. 
 
2.1.4.3.6.2 Cost Of Goods 
 Manufacturing costs or Cost of Goods (COG) typically comprise of 
indirect costs and direct production costs. The indirect costs are a fixed 
overhead which is related to the equipment purchase cost (CostEquipment), 
fixed capital investment (FCI) and project life span (tProject) as shown in 
Equations 2.51 – 2.54. These values were then summed to calculate the 
fixed annual overhead representing the indirect costs.  
 
!"#$"%&'(&)* = !"#!!"#$%&'       (2.51) !"#$%&$"$'& = 0.1 ∗ !"#$!"#$%&'()     (2.52) !"#$%&'!!"#$%&"'( = 0.01 ∗ !"#      (2.53) 
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!"#$%&'!!"# = 0.02 ∗ !"#       (2.54) 
 
 The direct costs are variable costs that are dependent on the amount of 
material manufactured such as raw materials, consumables and labour. 
Labour can be calculated as a fixed overhead or a direct cost related to the 
operational activities in the facility. However, labour in the simulation tool was 
considered to be a direct cost and charged at a rate of $58/hour. A number of 
the consumables in biopharmaceutical manufacture can be re-used multiple 
times for the manufacture of the same molecule. This reduces the overall 
cost of the consumable per batch, because a consumable may be used in 
multiple batches and hence the cost will be split over these multiple batches. 
Equation 2.55 takes into account the number of times a consumable 
(NumUses) has been used and offsets the resulting cost (CostConsumable) 
against the total number of re-uses allowed (NumTotalUses).  
 
!"#$!"#$%&'()* = !"#$!"#$%#&'∗ !"#$%&'()* !"#$!"#$ ∗!"#!"#"!"#!"#$%&'('   (2.55) 
 
 All the consumable costs (membrane filter, chromatographic resins, bags 
etc.) and raw materials (buffers etc.) used in this work are shown in the 
appendix. 
 
2.1.4.3.7 Environmental models 
 The simulation tool’s process models generate water and consumable 
usage allowing the environmental burden of a given manufacturing strategy 
to be assessed. A widely utilised concept called the E factor was adopted. 
The E factor was originally developed by Sheldon for the chemical industry to 
assess the overall environmental impact or greenness of production (Sheldon 
1994; Sheldon 1997; Sheldon 2007). The E factor is defined as the total 
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amount of reagents, water and consumables (MassUsed) used per kilogram of 
product (MassProduct) produced, shown in Equation 2.56. 
 
!!!"#$%& = ! !"##!"#$!"##!"#$%&'       (2.56) 
 
 The environmental impact of a manufacturing strategy was assessed by 
the simulation framework using the E factor method to assign a score of 
greenness. This was achieved by recording the water and consumable usage 
for each manufacturing strategy and then using Table A2.5 to calculate the 
mass of all the water/consumables used. 
 
2.1.4.3.8 Risk Modelling 
 So far the simulation tool assumes that all the simulation events and their 
outputs will inevitably occur and hence can be termed as `non-risk` outputs. 
These non-risk outputs would be identical if the same scenario was 
investigated multiple times by the simulation tool. However, 
biopharmaceutical manufacture is not a non-risk environment. There are a 
number of uncertainties around manufacturing processes, such as 
fermentation titres, step yields, batch failure, production times and mass 
throughput (Banks 1998). The simulation tool captured these uncertainties by 
performing a stochastic analysis using the Monte Carlo simulation technique 
(Nicholas et al. 1953). The technique uses the uncertainties in the input 
variables to determine the resulting probability distribution of the outputs; the 
resulting method tends to follow the pattern shown. 
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1. Define the domain of the input values. 
2. Generate inputs randomly from a probability distribution or probability 
event. 
3. Perform the multiple deterministic simulation iterations on the random 
inputs generated. 
4. Aggregate all the simulation outputs to generate the output probability 
distributions. 
 The uncertainties in the input values were found by either applying a 
probability distribution to the values or a probability event related 
consequence. Input values that were deemed to be variable, were generated 
during each simulation iteration using a triangular distribution. The triangular 
distribution was expressed as three values instead on the single deterministic 
value representing the upper limit, lower limit and mode. The function 
GetTrigValue() called within the simulation engine, generates a random 
number and then converts this into a value within the triangular distribution 
every time a value is required. The other uncertainties are generated by 
probability events and the input values set on the consequence of these 
events. This method was used to capture cell culture contamination and 
equipment failure events, in the manufacturing scenarios. 
 The simulation tool captured two types of probability events, non-
weighted and weighted. A non-weighted probability event would generate a 
random number within a defined range and use the resulting value as a score 
to establish which consequence to enact. For example if an event has a one 
in thousand chance of occurring, a random number between 1-1000 was 
generated and if the value is equal to one the event is deemed to have 
occurred. The event could represent a failure event or yield loss and would 
therefore lead to an input value being altered to represent the occurrence of 
that event. This technique was used to describe media contamination and 
filtration failures. Every filter use or addition to the cell culture reactor would 
trigger the generation of a random number and a potential failure 
consequence. The second type of probability event used the same 
methodology as described but on the occurrence of the event, it would trigger 
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the generation of a further random number. The second random number was 
used to select an input value from a weighted distribution. This technique 
was used to capture the fouling of perfusion cell culture separating devices, 
where the event is likely to occur after enough time has passed for the cells 
to adhere and propagate to block the filter. 
 
2.1.5 Multi-Attribute Decision Making 
 The previous sections demonstrate how the simulation framework is 
capable of generating output values for the economic, environmental and 
operational feasibility of a manufacturing strategy. Using these single 
performance values to compare multiple strategies is insufficient as these 
values are likely to involve conflicting objectives. Furthermore the qualitative 
differences between manufacturing strategies, such as the ease of 
control/operation of the different strategies, are important to consider when 
ranking strategies. Multi-Attribute Decision-Making (MADM) techniques 
provide a framework for comparing qualitative and quantitative performance 
values and generating an overall strategy ranking score. The overall strategy 
score allows the end-user to evaluate the alternative strategies for a range of 
different scenarios, where different performance values may be deemed to 
be more important than others. 
 The simulation framework employed the weighted sum method to 
reconcile the qualitative and quantitative outputs so as to identify the most 
preferred alternative. This allowed the impact of relative importance of the 
outputs to be assessed by assigning different weightings for a number of 
scenarios. The quantitative performance values for the economic and 
environmental feasibility were derived from the simulation tool. The 
qualitative performance values representing the operational feasibility were 
obtained through a survey questionnaire sent to industrial experts with 
experience operating the alternative manufacturing strategies or a risk score 
generated to capture the robustness of the strategy. All attribute values (xij) 
were standardized (Deb 2008; Triantaphyllou 2000) to convert them to a 
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rating value (rij) with a common dimensionless scale between 0 – 100 using 
Equation 2.57.  
 
!!" = !!"!!!! "#$%!!! "#$!!!! "#$% ∗ 100       (2.57) 
 
Where , xi Worst  = the worst value for attribute i for the strategies. 
   xi Best  = the best value for attribute i for the strategies. 
 
 The relative importance of the total weighted economic, environmental, 
operational scores in the decision making process was captured using a set 
of combination ratios (dimensionless weight values) whose sum equals one 
(Deb 2008). The overall aggregate strategy score (Sj) is generated by the 
weighted sum method, using the Equation 2.58. 
 
!! = !!"! "#$#%&"!!!! ! ∗ !! + !!"! "#$%&"'(")*+!!!! ! ∗ !!   
+ !!"! "#$%&'()%*!!!! ! ∗ !!        (2.58) 
 
Where R1, R2 and R3 represent the economic, environmental and operational 
combination ratios respectively. 
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2.1.6 Data Collection 
The data used throughout this body of work was collected from a number 
of sources: industrial experts, historical data, literature and vendors. The 
principle source of data was from the projects industrial sponsor (Sa V Ho, 
Pfizer R&D Global Biologics, MA, USA). Data collection with regards to 
perfusion cell culture technologies involved a series of discussions with a 
number of representatives from Centocor, Genzyme, Merck-Serono, 
Novartis, Bayer and Eli Lilly. More-in depth discussions occurred with 
Richard Francis (Francis Biopharma Consulting), Morten Munk, Christoffer 
Bro and Jacob Jensen (CMC). A further series of discussions concerning 
continuous chromatography were held with Karol Lacki and Roger Nordberg 
(GE Healthcare, Uppsala, Sweden). 
 
2.2 Chromatography Experimental Protocols 
2.2.1 Materials 
2.2.1.1 Chemicals 
 All Chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA & 
Dorset, UK) unless stated. 
 
2.2.1.2 Harvested Cell Culture Material 
The IgG1 mAb used was expressed in Chinese Hamster Ovary (CHO) 
cells and produced at Pfizer Inc., Andover, Massachusetts. Multiple batches 
of material were generated via a 14-day fed-batch fermentation with an 
average harvest viability of 85% and viable cell density of 13 million cells/mL.  
Each batch was harvested by centrifugation followed by depth filtration and 
sterile filtration.  The material was then frozen and then thawed prior to use. 
 
133 
 
2.2.2 Chromatography  
 
Protein A chromatography was used to capture the IgG1 mAb using 
MabSelect (GE Healthcare, Uppsala, Sweden), which is an agarose-based 
Protein A affinity matrix. The Protein A chromatography steps were scaled 
down from the manufacturing operations by maintaining the protein/buffer 
residence time used at process scale, while altering the column heights and 
radii. The buffers used were also the same as those used in the 
manufacturing operations. The columns were equilibrated with five column 
volumes (CV) of 150mM NaCl, 50mM Tris (pH7.5). After loading the 
harvested cell culture fluid (HCCF), the columns were flushed with 2CV of 
equilibration buffer. The subsequent wash step used a 5CV high molarity salt 
wash (1.8M CaCl2, 50mM Tris, pH 7.5) to remove product-related impurities, 
followed by a 5CV low salt wash (10mM NaCl, 10mM Tris, pH7.5) to reduce 
the high salt conditions in the column prior to elution. The columns were then 
eluted using 10mM NaCl, 50mM glycine (pH3), where the peak was collected 
for 2.5CV followed by a 5CV strip using the same buffer, before the column 
was cleaned using 0.5M sodium sulphate, 50mM NaOH. All columns were 
packed and stored in 16% ethanol, 150mM NaCl, 50mM Tris (pH7.5) when 
required. 
 
2.2.2.1 ÄKTA FPLC System 
 Conventional chromatographic runs were performed on a ÄKTA FPLC 
system (GE Healthcare, Uppsala, Sweden) at room temperature. The system 
used a single UV monitor (UV-900) and a fraction collector (Frac-950) to 
monitor and collect flow-through fractions. 
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2.2.2.2 Periodic Counter Current Chromatography System 
 
All semi-continuous chromatographic runs were performed using the periodic 
counter current (PCC) chromatography system, which is a custom modified 
ÄKTA Explorer system from GE Healthcare (Uppsala, Sweden), designed to 
operate with up to four columns (Figure 2.11). The system was equipped with 
five UV monitors (UV-900), three pumps (P-900), multiple eight-port values 
(PV-908) and an analog/digital converter (AD900) to allow the linking of the 
multiple components. Three or four Tricorn columns (GE Healthcare, 1mL, 
bed-height 50mm, 0.5mm I.D) manually packed with MabSelect were used. 
The system was controlled using UNICORN software with a customised 
strategy capable of running both the 3-column and 4-column PCC system. 
 
Figure 2.11. Schematic of 4-column PCC system (copyright GE Healthcare). 
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2.2.3 Analytical Techniques 
2.2.3.1 NanoDrop Concentration Measurements 
 The mAb concentration for purified samples (Protein A elution peaks & 
bulk drug substance (BDS)) was measured using a NanoDrop 2000 (Thermo 
Scientific, Wilmington, DE, USA). Sample volumes of 2µl were measured at 
280nm in triplicate and converted to mAb concentration using an extinction 
coefficient for IgG1 of 1.38. A calibration curve is shown in Figure 2.12 for 
the serial dilution of BDS (53.9 mg/ml, Pfizer Inc., Andover, MA, USA). The 
NanoDrop 2000 was found to be able to measure sample concentrations for 
concentrations between 0.25 – 25 mg/ml, any samples of higher 
concentrations were diluted to lie within the calibration range. 
 
 
Figure 2.12. Calibration curve for the NanoDrop 2000 for the serial dilution of 
bulk drug substance. 
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2.2.3.2 Protein A HPLC 
 Quantification of mAb from purified and non-purified samples (HCCF & 
column flowthrough) was measured using a POROS A20 Protein A analytical 
HPLC column (Applied Biosystems, Forest City, CA, USA). Buffer A (50mM 
Sodium Phosphate, 150mM NaCl, pH7) and Buffer B (0.5% Phosphoric Acid, 
100mM Sodium Phosphate, 400mM NaCl) were operated in a step elution for 
a total run time of 10 minutes per sample. The calibration curve shown in 
Figure 2.13 was performed by using dilutions of BDS (53.9 mg/ml, Pfizer 
Inc., Andover, MA, USA). Protein A HPLC was used for sample 
concentrations between 1- 20 mg/ml, any samples of higher concentrations 
were diluted with Buffer A to lie within the calibration range. 
 
 
Figure 2.13. Calibration curve comparing Protein A HPLC peak area to 
known concentrations of BDS. 
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2.2.3.3 CEX HPLC 
 
CEX-HPLC using a Dionex ProPac WCX-10 (Dionex Corporation, 
Sunnyvale, CA, USA) weak cation exchange column was used to analyse the 
product species profile of the elution pool. Buffer A (25mM Sodium 
Phosphate, pH7.6) and Buffer B (25mM Sodium Phosphate, 500mM NaCl, 
pH7.6) were run at 1 ml/min operated in a gradient elution for a total run time 
of 70 minutes per sample. Figure 2.14 shows an example chromatographic 
profile, were species that elute prior to the designated species were 
considered to be in the acidic region and those that elute after the designated 
species, the basic region. 
 
Figure 2.14. Example chromatographic profile of a cation exchange HPLC 
run for a purified IgG1 sample, denoting the acidic, designated and basic 
species of the sample. 
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2.2.3.4 SEC HPLC 
 
 The aggregate profile of the elution pool was captured using analytical 
SEC HPLC with a TosoHass TSK-GEL (Tosoh Biosciences, King of Prussia, 
PA, USA) HPLC column. Buffer A (10mM Sodium Phosphate, 500mM NaCl, 
pH7.3) was run at 0.2 ml/min for a total run time of 70 minutes per sample. 
Figure 2.15 shows an example chromatographic profile, were species that 
elute prior to the monomeric species were considered to be high molecular 
weight (HMW) species (dimer, trimer etc..) and those that elute after the 
monomeric species to be low molecular weight (LMW) species. 
Figure 2.15. Example chromatographic profile of SEC HPLC run for a 
purified IgG1 sample, denoting the HMW, Monomeric and basic LMW of the 
sample. 
139 
 
2.2.3.5 Batch Uptake  
 A set amount of MabSelect resin was collected from the packed columns, 
then resuspended and washed with equilibration buffer (150mM NaCl, 50mM 
Tris, pH7.5) to remove the storage ethanol solution. The resin was allowed to 
settle by gravity, before being measured and resuspended to make a 50% 
(v/v) resin slurry. 80 µl of slurry was then aliquoted into a 2 ml Eppendorf 
tube. Adsorption was started by adding 2ml of model IgG1 antibody at 
concentration of 2.5 mg/ml (provided by Pfizer Inc., Andover, Massachusetts) 
to the resin sample. The Eppendorf was kept under constant agitation, 
except at fixed times when it was rapidly centrifuged for 10 seconds at 1200 
g, before a 50 µl sample was taken and the sedimented resin particles were 
resuspended and agitation continued. The sample was taken from the 
supernatant and collected for subsequent analysis using the NanoDrop 2000 
to establish mAb concentration at the given time point. 
  
2.2.3.6 Isotherms 
 The MabSelect resin samples were each prepared as previously shown 
in section 2.2.3.5. 50 µl of slurry was aliquoted by Tecan (Tecan Freedom 
EVO 150, Tecan Group Ltd. Mannedorf Switzerland) for accuracy into each 
well in a 96-well 0.45 µm filter plate, (Whatman, GE Healthcare, Uppsala, 
Sweden). Ten different dilutions of model IgG1 antibody feed solution 
(provided by Pfizer Inc., Andover, Massachusetts) were prepared. Adsorption 
was started with the addition of 150 µl of the corresponding feed solution into 
each well and agitated on a Tecan plate shaker at 1200 rpm for 3 hours until 
equilibrium was reached (as calculated by experiments in Section 2.2.3.5). 
At equilibrium the plates were centrifuged for 4 minutes at 1200 g and 
supernatant collected in a receiver plate. A 150 µl wash of equilibrium buffer 
(150mM NaCl, 50mM Tris, pH7.5) was added to remove any remaining 
unbound mAb followed by two 150 µl elution buffer washes (10mM NaCl, 
50mM glycine, pH3) to elute all the bound protein. The filter plates were 
centrifuged for 4 minutes at 1200 g and the supernatant collected in a 
receiver plate after every wash addition. The receiver plate samples were 
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then analysed using the NanoDrop 2000 to establish mAb concentration for 
each wash in every well.  
 The resulting adsorption equilibriums were described by the Langmuir 
adsorption isotherm shown in Equation 2.59 (Langmuir 1916). With q being 
the concentration of mAb in the stationary phase when at equilibrium, qmax 
the maximum equilibrium binding capacity, Kd the equilibrium dissociation 
constant and C the concentration of mAb in the mobile phase. To establish 
the Kd and qmax of each resin the data collected from the isotherm 
experiments was linearised using Langmuir regression (Langmuir 1918), 
where the reciprocal of slope is equal to the maximum equilibrium binding 
capacity (qMax) and the y-intercept equal to the reciprocal of Kd.qMax 
(Equation 2.60). 
 ! = !!"#∗!!!!!          (2.59) 
!! = !!!"# + !!!∗!!"#       (2.60) 
 
 
2.2.3.7 Scanning Electron Microscope 
 Resin sample preparation for scanning electron microscope (SEM) 
imaging consisted of sample drying followed by the application of a gold-
palladium coating to avoid the charge effect. A thin layer of resin sample was 
pipetted onto a pre-coated glass slide and excess liquid was careful 
adsorbed using filter paper without contacting the resin sample, before being 
left for 30 minutes for the remaining liquid to evaporate. The dried resin 
sample was then mounted in a copper block and transferred to a high-
resolution ion beam coater (Gatan model 681, Oxford, UK). The Argon ion 
beam coater was operated at 6 mA at an acceleration voltage of 10 keV and 
was used to ion sputter the resin sample with a 2-3 nm gold-palladium 
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surface coating at an angle of 45°. The coated resin surfaces were 
subsequently imaged with a JEOL JSM-7410F field emission scanning 
election microscope (JEOL Ltd., Tokyo, Japan) at 1 keV accelerating voltage. 
 
2.3 Conclusions 
 This chapter has presented the development of a decision support 
framework to assist decision-making in the evaluation of alternative 
manufacturing strategies employing semi-continuous unit operations. The 
framework was built to tackle the complex problem domain found in 
biopharmaceutical manufacturing. This was achieved through the utilisation 
of deterministic discrete-event simulation, MADM and Monte Carlo simulation 
techniques. Hence, the framework is capable of describing a large number of 
scenarios within the industry, highlighting the key economic, environmental 
and operational metrics of the facilities, processes and technologies 
investigated under uncertainty. 
This was made possible by the hierarchal nature of the framework, 
which simulated the manufacturing scenarios on a number of levels of detail 
ranging from high-level process performance metrics to low-level ancillary 
task estimates. This approach made the resource-demand profiles for tasks 
more realistic, allowing the constraining nature of facility resources to be 
modelled more accurately in both deterministic and stochastic simulations. 
The hierarchal approach adopted also aided the development of semi-
continuous unit operation process models with the addition of a sixth 
hierarchal layer (sub-batches) making it possible to track the merging and 
splitting of batches. The framework is therefore capable of capturing a 
number of individual semi-continuous unit operations (Chapter 3; Perfusion 
cell culture, Chapter 4; Semi-continuous chromatography) and also a 
manufacturing strategy linking multiple semi-continuous unit operations 
(Chapter 5; Integrated continuous processing).  
Prior to the integration of the semi-continuous unit operations into the 
simulation framework a detailed understanding of the technologies 
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performance and resource requirements were required. This was achieved 
by consulting industrial experts, vendors, historical data, literature, and by 
hands on technological evaluations. The chromatography experimental 
protocols presented in this chapter were employed in the evaluation of a 
semi-continuous chromatographic system, which will become evident in 
Chapter 4. 
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3 Fed-batch & Perfusion Culture  
3.1 Introduction 
 Perfusion culture manufacturing strategies for cell-culture-derived 
biopharmaceuticals offer the potential of greater daily productivities and 
hence smaller facility footprints than batch and fed-batch culture 
manufacturing strategies. However, their use has been hampered historically 
by perceived greater logistical and validation complexity as well as higher 
likelihoods of technical failures. More recent perfusion culture systems aim to 
overcome some of these obstacles and this has seen their use increase, with 
the promise of more cost-effective processing, higher productivities, lower 
failure rates and improved environmental performance. For example, 
Janssen Biotech has implemented a newer perfusion technology, alternating 
tangential flow (ATF) perfusion (Refine Technology, Edison, NJ) for the 
production of its more recent mAbs, such as Simponi® (Centocor 2006). This 
combined with the introduction of single-use technologies for cell culture 
operations have triggered renewed interest in the potential of bioprocesses 
based on perfusion culture systems. It is also important to consider less 
tangible operational factors such as the ease of development and flexibility 
as well as the environmental burden of these strategies. Previous work 
evaluating batch and continuous cell culture technologies has either focused 
on the impact on the cell culture stages rather than the whole process, or on 
a particular scenario in terms of titre and scale of operation, or not accounted 
for failure and uncertainties.  
 Hence this chapter describes how the simulation framework was used to 
evaluate fed-batch strategies and both a first generation perfusion system 
(spin-filter) and second generation perfusion system (ATF) whilst considering 
the impact of single-use bioreactors. Whilst assessing the impact on 
downstream processing, equipment sizing and process economics across a 
range of scales and titres under uncertainty. The chapter is organised as 
follows: Section 3.2 describes the case study and assumptions used in this 
assessment. This followed by the deterministic analysis in Section 3.3.1, 
which address the impact of scale and titre on the economic performance of 
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the cell culture technologies. Section 3.3.2, build on the deterministic 
analysis using the stochastic Monte Carlo technique to understand the 
impact of failure and its consequences on the robustness of the alternative 
manufacturing strategies. The chapter then takes into account the qualitative 
concerns associated with the adoption of perfusion technologies and 
combines these findings with the calculated economic and environmental 
performance metrics in Section 3.3.3. The final section then summarises the 
principle conclusions of the preceding sections of the chapter. 
 
3.2 Methods 
3.2.1 Fermentation  
 The deterministic and stochastic analysis shown in this chapter were 
achieved using the simulation framework defined in Chapter 2. The 
fermentation process models shown in Section 2.1.4.3.4.1 detail the growth 
profiles and mass balance equations for both fed-batch (FB) and perfusion 
based cell cultures. The same cell integral modelling approach was utilised 
for both the spin-filter perfusion (SPIN) and alternating tangential flow (ATF) 
perfusion systems. Figure 3.1 shows the projected growth profiles of the 
SPIN and ATF system and the four different growth regions expected. The 
growth profiles shown were derived from discussions with Morten Munk, 
Christoffer Bro and Jacob Jensen (CMC biologics, Copenhagen, Denmark) 
and based on valid fermentation data. 
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Figure 3.1. Perfusion fermentation cell culture growth profiles for a) spin-filter 
perfusion cell culture and b) alternating tangential flow perfusion cell culture, 
where viable cell density (black line), estimated product titre (dashed line) 
and perfusion rate (dotted line) are highlighted alongside the key growth 
regions. 
a) 
b) 
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 Region A shown in Figure 3.1 represents the batch growth phase where 
the cells grow exponential using the existing nutrients in the media. Perfusion 
is started after 2 days and the media nutrients are refreshed by the addition 
of new media and removal of spent media. At this point a cold shock is 
applied to the fermenter to prevent uncontrolled cell proliferation due to the 
increase in nutrients, this results in the reduced rate of growth seen in region 
B. The perfusion rate starts at 0.5 vessel volumes per day (vv/day) and 
increases to 1 vv/day after the initial cell doubling to maintain the progression 
of cell proliferation. The ATF system is able to achieve higher cell densities 
than the SPIN, and therefore requires a further increase in perfusion rate 
from 1 vv/day to 1.5 vv.day, to support the nutritional demands of the 
additional cells. Region C highlights the deceleration phase where the viable 
cell growth is no longer exponential due to the limitation of nutrients and 
increase in cell death. At this point (day 9) the cells density is sufficient to 
generate daily harvests with sufficient product concentrations to make it 
worthwhile to purify. The fermentation then maintains the maximum cell 
density in the steady phase represented by region D, which will last to the 
end of the cell culture duration selected. Table 3.1 demonstrates how the cell 
integral model was applied highlighting cell integrals and the corresponding 
production concentrations (taking into account the dilution caused by the 
higher perfusion rate in the ATF system). The key operational parameters for 
the three-cell culture technologies (FB, SPIN and ATF) explored in this 
chapter are further summarised in Table 3.2. 
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Table 3.1. Cell integral and product concentration calculations for the fed-
batch, spin-filter and ATF processes 
STEP-SPECIFIC DATA 
Variable FB SPIN ATF 
Culture duration 12 60 60 
Perfusion rate - 1 1.5 
Max VCD  
(million cells/ml) 10 15 50 
Integrated VCD 
(million cells/ml/day) 
Region A  =  6.5 
Region B  =  20 
Region C  =  22 
Region D  =  26 
Total         =  75 
Day 9      =  5.4 
Day 10    =  7.5 
Day 11    =  10.5 
Day 12    =  13.5 
Day 13+  =  15 
Day 9      =  11.5 
Day 10    =  19.6 
Day 11    =  31.8 
Day 12    =  43.9 
Day 13+  =  50 
Cell line productivity 
(pg/cell/day) 27 27 27 
Product 
concentration  
(g/L) 
  
 
 
 
Day 12  =  2.02 
Day 9      =  0.14 
Day 10    =  0.20 
Day 11    =  0.28 
Day 12    =  0.36 
Day 13+  =  0.41 
Day 9      =  0.21 
Day 10    =  0.35 
Day 11    =  0.57 
Day 12    =  0.79 
Day 13+  =  0.90 
    
Note: Assumptions for key inputs in this table are discussed in Sections 3.2.3 & 3.2.4. 
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3.2.2 Multi-attribute Decision-Making  
 The weighted sum method shown in Chapter 2 was used to reconcile 
economic, environmental and operational outputs so as to identify the most 
preferred alternative for scenarios with different weightings assigned to each 
of these categories. Table 3.2 lists all the attributes considered in the MADM 
analysis. The values of the attributes under economic and environmental 
feasibility were derived from the simulation tool. The attributes were ranked in 
order of importance, where a higher ranking indicates an attribute of greater 
significance. For example, the COG/g was deemed to be slightly more 
important than initial capital investment required to construct a new facility. 
The attributes representing the environmental feasibility were ranked equally 
because the environmental impact of water and consumable usage was 
deemed to be equally disadvantageous to the environment. The operational 
feasibility scores and weightings were obtained through a survey 
questionnaire (shown in appendix) sent to industrial experts with experience 
operating both fed-batch and perfusion culture. The participants were asked 
to rank the cell culture technologies against each of these qualitative 
attributes: ease of control/operation, ease of validation (time/effort), ease of 
development (time/effort), operational flexibility and batch-to-batch variability. 
Table 3.2. Attribute grouping and ranking                                                               
Economic and environmental scores (low = best, high = worst), operational scores (3 = best, 9 = worst) 
 
Attribute Field Attribute Name Rank FB SPIN ATF 
Economic 
feasibility 
Cost of goods per gram 2 39 45 31 
Initial capital expenditure 1 88 68 48 
      
Environmental 
feasibility 
Water E-factor rating 1 6300 9900 6500 
Consumable E-factor rating 1 0.2 23.9 19.1 
      
Operational 
feasibility 
Batch-to-batch variability 5 5 9 6 
Ease of control/operation 4 3 9 6 
 Operational flexibility 3 3 9 8 
 Ease of development 2 3 9 7 
 Ease of validation 1 3 9 8 
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3.2.3 Case Study 
 
 The simulation framework was used to compare commercial mAb 
facilities using three cell culture systems: fed-batch (FB) culture, spin-filter 
perfusion (SPIN) and alternating tangential flow (ATF) perfusion. The case 
study explored the trade-offs between the higher productivities, and hence 
smaller upstream and downstream capacities, versus the higher cell culture 
failure rates caused by filter fouling and contaminations with perfusion 
systems relative to FB systems. Commercial manufacture of highly 
successful mAbs can require annual demands of 1000 kg/year (Kelley 2007; 
Rodrigues et al. 2010). An analysis of drug substance demand for 15 mAb 
and Fc-fusion products by Kelley (2009) demonstrated that annual kg output 
ranged from 1200 kg/yr to less than 100 kg/yr, with a median annual kg 
output of 200 kg/yr. This case study therefore compared each of the cell 
culture technologies over a range of scales of production from 100 – 1000 
kg/yr so as to explore the rankings over the entire design space. Cell culture 
titre will also have a large effect on the results of any process comparison 
(Farid 2009a). In the past mAb titres reached only mg/L values, but now the 
norm is 2-3 g/L, with processes in development with reported titres of 5 g/L 
and higher (Kelley 2009). Titres of 10 g/L or higher could become the norm in 
the next 5-10 years. To capture the industry’s current and future titre 
capabilities the case study investigated the following titre values: 2, 5 and 10 
g/L.  The key metrics used to evaluate the merits and limitations of the three 
strategies were: COG/g, capital investment, E factor and operational 
feasibility. 
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3.2.4 Assumptions 
 Figure 3.2 illustrates the process flowsheets for the production of mAbs 
using the three cell culture technologies, FB, SPIN and ATF. Each cell 
culture operation fed into a single purification train regardless of the number 
of cell culture reactors. When multiple reactors were required to achieve the 
desired annual demand, two different scheduling approaches were used. The 
FB process staggered any additional reactors, and altered the scale of the 
purification train according to the revised times between harvests. In contrast 
the SPIN and ATF operations operated the additional reactors in parallel, 
where the resultant daily perfusate harvests were pooled into a single daily 
harvest prior to Protein A capture. This combining of different reactor 
harvests was made possible by inoculating each reactor from the same seed 
reactor. Figure 3.2 also highlights the differences between the primary 
recovery operations in each flowsheet where the FB process requires the 
most steps for cell removal and liquor concentration in contrast to the ATF 
process that does not require any given its external hollow fibre filter. The 
purification train was based on a generic mAb purification platform using 
three orthogonal chromatographic steps with intermediate filtration and viral 
clearance steps (Farid 2006; Kelley 2007; Liu et al. 2010). The perfusion 
culture purification train also includes a pooling operation, where the daily 
Protein A chromatography eluates were pooled into a larger volume, before 
being released for further purification. Although it is possible to locate the 
pooling operation pre-Protein A and post cation-exchange chromatography, 
the current commercial manufacturing norm is post-Protein A pooling due to 
the benefits of operating a smaller highly utilised Protein A column 
(Wojciechowski et al. 2007).  
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Figure 3.2. Case study process sequences and suite configuration for (a) the 
fed-batch (FB), (b) the spin-filter (SPIN) and (c) the alternating tangential flow 
(ATF) process. CC = cell culture, Cent = centrifugation, DepF = depth 
filtration, UF = ultrafiltration, ProA = Protein A chromatography, VI = virus 
inactivation, Pool = daily perfusate volume pooling, CEX = cation exchange 
chromatography, UFDF = ultrafiltration/diafiltration, AEX = anion exchange 
chromatography, VRF = virus retention filtration. 
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 Table 3.3 lists a number of key assumptions that differ between the 
processes, including the overall process yield, which is lowest for the FB 
process due to the extra centrifugation and depth filtration operations. The 
FB culture step ran for 12 days in contrast to the SPIN and ATF cultures, 
which ran for 60 days. A typical maximum cell density for FB cultures of 10 
million cells/mL, was assumed. The SPIN culture can generate cell densities 
of 20 million cells/mL but to maintain the longer culture duration in this case 
study, a cell density of 15 million cells/mL was selected to prevent premature 
cell culture termination due to filter fouling. The ATF system is able to reach 
cell densities of 100+ million cells/mL (Carstens et al. 2009) according to the 
vendor (Refine Technology, Edison, NJ), however to maintain a stable 
product quality and feasible perfusion rate a more conservative cell density of 
50 million cells/mL was used (personal communication with Christoffer Bro 
and Jacob Jensen of CMC Biologics, Copenhagen, DK). The differences in 
maximum cell densities result in very different volumetric productivities, with 
the SPIN and ATF processes offering 2 and 6.6 fold increases in productivity 
respectively. The cell culture technologies also differ in terms of scalability; 
FB reactors can reach 20,000 L, whereas SPIN systems peak at 2000L and 
the ATF system at 1500L due to the limitations in the maximum perfusion 
rates currently achieved. The smaller reactor volumes employed by the 
perfusion systems potentially allow the use of single use bioreactor (SUB) 
technology. Due to the use of an internal cell separation device in the spin-
filter perfusion system, it is not able to use SUBs. In contrast, the ATF system 
can successfully employ SUBs in all scenarios due to its use of an external 
cell separation device. The fed-batch system is capable of employing SUBs 
for reactor volumes below 2000L. For the standard fed-batch base case, the 
use of SUBs was restricted to the seed train where appropriate and stainless 
steel bioreactors were used for the final production stage as is common 
industry practice at present for commercial production. In addition, the impact 
of using SUBs for production bioreactors operated in fed-batch mode was 
also explored by using new concept facility designs involving multiple smaller 
SUBs operated in a staggered fashion. 
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Table 3.3. Key assumptions for the fed-batch, spin-filter and ATF processes  
STEP-SPECIFIC DATA 
Variable FB SPIN ATF 
Input    
Cell culture time (days) 12 60 60 
Max VCD (million cells/ml) 10 15 50 
Max bioreactor volume (L) 20,000 2000 1500 
Max perfusion rate (vv/day) – 
 
 
1 1.5 
Calculated    
Process yield 65% 68% 69% 
Annual # batches 22 5 5 
Max product concentration (g/L) 2 – 10 20% FB 45% FB 
Volumetric productivity (mg/L/day) 169 - 847 2.15 x FB 7.16 x FB 
Annual bioreactor capacity required 1 x FB 1/9 x FB 1/29 x FB 
Installed bioreactor capacity 1 x FB 1/2 x FB 1/6 x FB 
Grams of product per litre of media 1.2 – 6.3 19% FB 44% FB 
    GENERAL COST DATA 
Equipment Investment Cost ($) Consumable Cost ($) 
Single use bioreactor1   
200 L 88,000 4200 
500 L 98,000 5460 
1000 L 110,000 8260 
2000 L 175,000 9800 
Perfusion Device2   
Spinfilter 35,000 N/A 
ATF 4 System 30,000 714 
ATF 6 System 90,000 3,570 
ATF 8 System 130,000 7,140 
ATF 10 System 180,000 16,300 
Key Material Costs   
Protein A resin cost ($/L) 8000 
Cell culture media3 ($/L) 3.15 
Fed-batch feed additions ($/L) 13.1 
Labour Cost ($/hour) 58 
 
1 - Investment cost includes: disposable bioreactor support vessel, agitator motor, gas & fluid pumps, Consumable 
cost includes: bioreactor bag. 
2 - Investment cost includes: filter unit, controller & auxiliary media pump, Consumable cost includes: filter. 
3 - Cell culture media used for initial media fill in fed-batch cell culture and daily perfusion media exchanges. 
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3.2.4.1 Monte Carlo Assumptions 
 Table 3.3 summarises the probability distributions assigned to the key 
uncertainties along with the consequences of each failure event used when 
performing the stochastic cost analysis with Monte Carlo simulations. The 
probability of cell culture contamination was calculated for each strategy 
assuming that each addition to the reactor had a 1 in 1000 chance of causing 
contamination. The FB strategy had a total of ten reactor additions (initial 
media fill and nine feeds) and therefore had a 1% probability of batch 
contamination. In contrast the perfusion strategies had approximately sixty 
additions due to the daily media exchanges and therefore had ~6% 
probability of contamination. The risk of equipment failure due to filter fouling 
in the perfusion strategies was also considered. The SPIN strategy had a 
higher probability of filter failure compared to the ATF strategy due to the use 
of an internal filter that actually relies on a degree of surface cell growth to 
prevent excessive cell carryover into the perfusate. The probability of filter 
fouling increases with duration of the perfusion cell culture (Deo et al. 1996; 
Vallez-Chetreanu et al. 2007). The probability of filter failure is shown as a 
percentage in Table 3.3 but when the tool selects a filter failure scenario, the 
occurrence of the failure is weighted to occur at the latter stages of the cell 
culture duration. Batch-to-batch titre fluctuations in cell culture were also 
captured as they can have a significant impact on the mass of antibody 
generated impacting the purification operations and hence annual kg output 
and COG/g. Typical titre fluctuations at commercial scale are ± 20%. This 
was implemented by applying a triangular distribution to the cell line 
productivity for each batch with the minimum and maximum values being ± 
20% of the most likely base value. A further common uncertainty is failure of 
in-process filtration (IPF) operations associated with every product tank/bag 
fill or draining protocol. The majority of IPF failures occur due to the blocking 
of the sterile filters, hence the probability of IPF failure is significantly higher 
after viral inactivation due to the increased probability of aggregate formation 
due to the low pH holding conditions. 
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Table 3.4. Monte Carlo assumptions 
Process event p(Failure) Consequence 
Fed-batch culture contamination   1 % Batch loss 
Spin-filter culture contamination   6 % Batch loss & discard two pooled perfusate volumes 
Spin-filter filter failure   4 % Batch loss & no pooled volumes are discarded 
ATF culture contamination   6 % Batch loss & discard two pooled perfusate volumes 
ATF filter failure   2 % Replace filter & discard next 24 hours of perfusate 
In process filtration failure; 
General   5 % 4 hour delay & 2% yield loss 
In process filtration failure;  
Post viral inactivation 20 % 4 hour delay & 2% yield loss 
 
 Table 3.4 also highlights the consequences of a failure event, which vary 
depending on the cell culture strategy. For the FB scenario a contamination 
resulted in the loss of the whole batch. However for the perfusion strategies 
material harvested prior to the contamination event could be processed apart 
from the two latest pooled perfusate volumes that were discarded. The 
perfusion strategies are also prone to filter failure which would also halt the 
cell culture upon a failure event. The use of an external filter by the ATF 
strategy meant the filter could be replaced and the cell culture resumed, after 
discarding the subsequent day’s perfusate volume due to high levels of HCP. 
The SPIN strategy employs an internal filter which cannot be replaced mid-
culture resulting in the halting of the cell culture, but allows all prior harvested 
material to be processed. When a failure event occurred, the discrete-event 
simulator triggered the start of the subsequent planned batch so as to 
prevent idle time and poor facility utilisation, with a time lag of approximately 
2 weeks for the production reactor inoculum to be generated. This had little 
effect on the fed-batch scenario since the batch interval was also 
approximately 2 weeks, meaning the next planned batch would be available 
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prior to any replacement batch. In contrast for the perfusion systems with 
long culture durations, the rescheduling could potentially allow a replacement 
batch to be processed depending on the timing of the failure event. In the 
event of an IPF failure event, the process was delayed by four hours and 2% 
of the product material was lost. Advice from industrial experts was solicited 
to sanity check the validity of these risks and the resulting consequences on 
production. 
 
3.3 Results and Discussion 
 The tool was used to assess how the cost-effectiveness of the fed-batch 
and perfusion strategies changes across a range of titres and scales of 
production. This was initially carried out deterministically and then expanded 
to account for the impact of equipment failures and uncertainties in 
performance. The economic outputs were then considered alongside 
operational and environmental metrics using a multi-attribute decision-
making technique. 
 
3.3.1 Deterministic Cost Comparison 
3.3.1.1 COG/g Comparison Across Scales 
 Figure 3.3 shows the COG/g for the FB, SPIN and ATF strategies for the 
5g/L scenario across a range of scales of production (100kg/yr, 500kg/yr, 
1000kg/yr). The analysis suggests that although the SPIN strategy offers 
similar COG/g values to the FB strategy at the smallest production scale of 
100kg/yr, it becomes less economically attractive at the higher production 
scales. In contrast the ATF strategy is seen to offer cost advantages across 
all production scales of ~20% in the 5g/L scenario. 
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Figure 3.3. A comparison of the cost of goods per gram on a category basis 
for labour costs (black), direct material costs (light grey), and indirect costs 
(dark grey) between the fed-batch process (FB), the spin-filter process 
(SPIN) and the alternating tangential flow process (ATF) over a range of 
scales of production for an equivalent fed-batch titre of 5 g/L, where the 
percentage difference is relative to the fed-batch process. The embedded 
table highlights the materials cost per gram for the production strategies.  
The optimal sizing strategy for each process is indicated in the boxes above 
each bar highlighting the number and scale of bioreactor(s) (solid box) and 
the column diameter for the Protein A chromatography step (dashed box) 
across a range of scales of production. 
 
 A closer examination of the COG/g breakdowns highlighted in Figure 3.3 
reveals how changes in the relative importance of different cost categories 
influence the cost-benefit rankings. The trade-off between the lower indirect 
costs and higher material costs with the SPIN strategy relative to the FB 
strategy is dependent on the production scale. At the smallest production 
scale, changes in material costs can be seen to have much less influence 
due to the dominance of the investment-driven indirect costs, as has been 
echoed in other reports (Farid 2009b; Farid et al. 2007). Across all production 
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scales, the material costs per gram decrease at a slower rate than the other 
leading cost contributors as illustrated in the embedded table in Figure 3.3 
and the SPIN strategy exhibits a ~1.8-fold increase in material costs (16 – 21 
$/g) relative to the FB strategy. This difference in material costs becomes 
increasingly more significant at the higher production scales as material costs 
represent a much higher proportion of the COG/g, contributing to the reduced 
competitiveness of the SPIN strategy. In contrast, the ATF strategy is able to 
compete across all scales since its superior cell density and hence volumetric 
productivity coupled with a smaller highly utilised purification train results in 
significantly larger savings in indirect costs (~40%) combined with only a 
~1.2-fold increase in material costs. This translates into overall savings 
irrespective of the dominance of either indirect or material costs at either 
extremes of the production scales.  
 The tool was also used to identify the material cost drivers for each 
strategy. Figure 3.4 presents a detailed percentage breakdown of the 
COG/g, for all three strategies in the scenario at 5g/L and a 500kg/y 
production scale, on a category basis with particular emphasis on the key 
material costs. The higher material cost contributions in the perfusion 
systems can be attributed primarily to the higher usage of culture media, 
product-holding bags, and SUB liners (for ATF systems). It is interesting to 
note that although the dominant material cost shifts from chromatography 
resins (36% material costs) in the FB strategy to culture media (31% material 
costs) in the SPIN strategy, this shift in dominance is not seen in the ATF 
strategy. This is in spite of the fact that increases do occur in other cost 
categories. This can be attributed to the more productive ATF systems 
utilising comparably less media than the SPIN strategy; hence the increase in 
media cost is not substantial enough to outweigh the high costs associated 
with the chromatographic resins. 
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Figure 3.4. A comparison of cost of goods per gram with a detailed 
breakdown of material costs on a category basis for (a) the fed-batch 
process, (b) the spin-filter process, (c) the alternating tangential flow process 
and (d) the concept fed-batch SUB process, for a 500 kg/yr scale of 
production and an equivalent fed-batch titre of 5 g/L. The COG/g values for 
each process are also indicated in $/g. 
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 The impact of new concept facility designs based on multiple staggered 
single-use bioreactors operated in FB mode was also investigated. A new 
concept SUB facility (FB-SUB) with a 500 kg/yr scale of production and a 
5g/L titre would require four 1500L staggered SUBs with a harvest frequency 
of 3 days, compared to a single 5600L stainless steel bioreactor with a 
harvest frequency of 12 days. Capital investment estimates (Total Equipment 
Purchase Cost (TEPC) x Lang factor) required the derivation of a suitable 
Lang Factor (23.67) for the SUB-based cell culture suites so as not 
underestimate their infrastructure costs (see Table 2.3). Despite a shift in the 
COG breakdowns to a more evenly spread distribution across indirect, 
material and labour costs (Figure 3.4d), no significant difference was seen in 
the magnitude of COG values between the FB and FB-SUB strategies. 
Consequently, FB strategies with multiple SUBs are still unable to compete 
with the ATF COG savings. 
 
3.3.1.2 Key Economic Metrics Across Scales and Titres 
 The impact of both scale of production (100kg/yr, 500kg/yr, 1000kg/yr) 
and titre (2g/L, 5g/L, 10g/L) on the competiveness of the three strategies was 
investigated. The contour plot in Figure 3.5a shows the results for the SPIN 
strategy relative to the FB strategy when expressed as percentage change.  
The corresponding number and scale of the reactors employed is shown in 
Table A3.5. The figure highlights that the SPIN strategy is only able to 
compete with the FB strategy at either the low production scales (100kg/yr), 
irrespective of titre or at the high titres of 10g/L across all the scales (with a 
±10% difference). Both these sets of conditions place low demands on 
bioreactor capacity where the savings on investment-related indirect costs 
dominate. Hence the benefits of installing a single bioreactor train that is 
typically half the size of the FB strategy is balanced against the higher 
material costs. In contrast, as the scale of production (kg/yr) increases, 
coupled with decreases in titres, the SPIN strategy becomes increasingly 
unattractive. This effect is particularly pronounced at the lowest titre (2g/L) 
and the highest scale of production (1000kg/yr), where the SPIN strategy’s 
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COG/g reaches double that of the FB strategy. This can be attributed to the 
need for a high number (8) of SPIN reactors to cope with the large-scale of 
production, given their scale limitations combined with the larger bioreactor 
capacities required at lower titres. This negates any potential advantages 
offered by having lower total installed bioreactor capacities with the SPIN 
strategy relative to the FB strategy. Instead the results generated by the tool 
indicate that the difference in capital investment and the related indirect costs 
(x1.4) as well as labour costs (x3) between the SPIN and FB strategies 
become exaggerated. These increases coupled with the higher material 
costs in perfusion strategies illustrate how the SPIN strategy loses its 
competitive advantage under high bioreactor capacity demands that result in 
scale-out to multiple bioreactors. 
 
 
Figure 3.5. Contour plot showing the impact of scale of production and titre 
on the percentage difference in COG/g relative to the fed-batch process for 
(a) the spin-filter perfusion process and (b) the alternating tangential flow 
(ATF) perfusion process. The processes are resized for each combination of 
scales of production and titres. 
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 In contrast the impact of increasing titre across the different scales of 
production does not significantly affect the cost-effectiveness of the ATF 
strategy (Figure 3.5b) in the same manner as the SPIN strategy. The 
superior cell density of the ATF strategy relative to the FB strategy (5 fold 
higher), leads to significantly smaller bioreactor volumes compared to the 
SPIN strategy and prevents the rapid increase in bioreactor number and 
COG/g values seen. This translates into an installed reactor capacity that is 
approximately 6 times smaller than the FB strategy in comparison to the 
SPIN strategy’s ability to only offer half the installed reactor capacity of the 
FB strategy. The installed bioreactor capacities are derived from the annual 
bioreactor capacities divided by the number of batches. Given that the 
perfusion strategies only operated five batches annually compared to twenty-
two for the FB strategy, the ATF strategy offers a 29-fold decrease in annual 
reactor capacity compared to only a 9-fold decrease with the SPIN strategy. 
The superior productivity of the ATF strategy coupled with a small highly 
utilised purification train, allows the ATF strategy to offer capital investment 
savings of ~40% and COG/g savings of ~20% across all titres and scales of 
production compared to the FB strategy. These results assumed a 5-fold 
difference in maximum viable cell density between the ATF and FB systems. 
The tool was also used to investigate the relationship between the ATF 
systems maximum cell density and both the scale of production and titre 
(Figure 3.6).   The tool predicted that even if the ATF cell density dropped 
such that only a 3 fold difference in cell densities was achieved (Figure 
3.6b), it would still offer COG/g savings compared to the FB strategy across 
the different combinations of production scales and titre, except for the worst 
case combination of low titres (2g/L) and high production scale (1000kg/yr). 
When the ATF system only has a 2 fold difference in cell density it is only 
able to offer a saving for low production scales (100kg/yr) and high titre 
(10g/L) scenarios (Figure 3.6a), due to the reduced reactor productivity 
resulting in a higher number of reactors (7) being required, mirroring the 
trend exhibited by the spin-filter system in low titre (2g/L) scenarios.  
163 
 
Figure 3.6. Contour plot showing the impact of the ATF system’s viable cell 
density at different scales of production and titres on the percentage 
difference in COG/g relative to the fed-batch process for (a) 20 million 
cells/mL, (b) 30 million cells/mL, (c) 40 million cells/mL, and (d) 50 million 
cells/mL. The fed-batch system was assumed to achieve a maximum viable 
cell density of 10 million cells/mL. The processes are resized for each 
combination of scale of production and titre.  
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3.3.2 Stochastic Cost Comparison 
 The initial deterministic cost comparison highlighted the overall economic 
advantages offered by operating the ATF strategy. The study was extended 
to include the perceived risks associated with perfusion based strategies, 
namely cell culture failure attributed to either contamination or equipment 
failure due to filter fouling over the long culture durations. The Monte Carlo 
simulation technique was used to characterise the variability in the kg output 
and COG/g values caused by fluctuations in failure rates and titre. The 
following discussion highlights the key findings from this analysis and 
assesses the robustness of the FB and perfusion strategies. 
 
3.3.2.1 Expected Scenario Outputs 
Figure 3.7 shows the expected kg output and COG/g values for the FB, 
SPIN and ATF strategies under uncertainty at a 500 kg/yr scale of production 
and a titre of 5g/L.  Figure 3.7a depicts the expected annual output achieved 
by each cell culture strategy, showing every kg output value recorded (thin 
lines), the frequency that the values occur (and the expected annual output) 
(horizontal dashes), alongside the frequency that the values occur 
(histogram). The FB strategy is the most robust strategy as indicated by the 
narrower spread of the frequency values (410 – 490 kg/yr). The frequency of 
annual output values for the FB scenario has a distinct shape which was 
found to relate directly to the number of batch failures in any given year of 
production. This is highlighted in Figure 3.7c where the biggest bar 
represents no batch failures and the subsequently smaller bars represent the 
occurrence of one and more batch failures per year. The robustness of the 
FB strategy can be attributed to the low probability of cell culture failure (1%) 
and the high number of batches (22 batches/yr) lessening the effect of titre 
variation on annual kg output. In contrast the perfusion strategies are not as 
robust as the FB strategy due to their higher probability of failure and fewer 
number of batches per annum (5 batches/yr) amplifying the effect of titre 
variation on the annual kg output achieved. The shape of the frequency plots 
depicting annual kg output is not as defined as the FB strategy either, due to 
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the variability in the timing of a failure event dictating how much material has 
been processed from the failed batch. The perfusion strategies both have 
occurrences of kg outputs over 500kg/yr due to scenarios when all the titres 
achieved that year are above average and there were no cell culture failures. 
The ATF strategy achieves high kg outputs more readily due to only 6 in 100 
cell cultures runs failing compared to 1 in 10 failures for the SPIN strategy. 
This results in the ATF strategy having a higher expected annual kg output of 
488kg/yr compared to the SPIN strategy value of 470kg/yr and the FB 
strategy value of 472 kg/yr, even though the SPIN strategy often fails to 
achieve kg output values above 400kg/yr. The t-Statistic value for the ATF 
strategy versus the FB strategy indicates that there is a statistically 
significance difference. 
Figure 3.7b shows the expected values for the COG/g, where the 
COG/g frequency plots are a reflection of the annual kg output frequency 
plots, given that a higher output results in better facility utilisation and hence 
a reduced COG/g value. The only exception to this rule occurs when the ATF 
strategy achieves an annual output over 500kg/yr, which is a higher output 
than the facility design, resulting in a higher COG/g than expected due to the 
extra costs required to process the extra material, resulting in a frequency 
plot more aligned with the FB strategy. The ATF strategy further 
demonstrates its economic superiority by maintaining a ~20% reduction in 
COG/g with an expected value of 32 $/g compared to the FB strategy’s 
expected COG/g value of 41 $/g. The ATF strategy is also able to maintain 
this COG/g advantage over the FB strategy even in its worst-case scenario 
involving multiple failure events. Overall the expected stochastic COG/g 
values are ~5% higher than the deterministic values and maintain the 
economic ranking shown in the deterministic cost comparison. However the 
stochastic analysis gives a clear indication of the robustness of the 
manufacturing strategy employed unavailable through deterministic analysis. 
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Figure 3.7. Frequency distribution plots depicting the expected process 
outputs under manufacturing uncertainty for (a) the expected annual kilogram 
output, (b) the expected cost of goods per gram, and (c) the number of fed-
batch culture failures, for a 500 kg/year scale of production and equivalent 
fed-batch titre of 5 g/L. 
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3.3.3 Multi-attribute Decision Making 
 This section extends the analysis beyond economic metrics to include 
the environmental and operational benefits of each strategy. 
 
3.3.3.1 Environmental Impact Analysis 
 The tool was also used to capture the water and consumable usage of 
the strategies to assess the environmental impact of the FB and perfusion 
strategies across a range of titres and scales of production. E factor values 
were derived for the usage of process water (cell culture media & process 
buffers), non-process water (CIP buffers & rinse water) and consumables 
(bags, membranes & resins). Typical FB manufacturing strategies consume 
water (process and non-process) from 3000 to over 7000 kg water per kg 
product. The cell culture steps consume between 20-25% of the total, with 
the chromatographic operations often surpassing 50% of the total (Ho et al. 
2011).  
 As expected the perfusion strategies have a much higher process water 
E factor value in comparison to the FB strategy, where the higher process 
water E factors can be directly related to the volumetric productivity of the 
perfusion strategies and their resulting media usage. The perfusion 
strategies` extra burden on CIP caused by the highly utilised primary 
clarification operations and purification train for the high number of pooled 
perfusate volumes, results in the SPIN strategy consuming double the non-
process water relative to the FB strategy. In contrast the ATF strategy has a 
~30% lower non-process water E factor value relative to the FB strategy, due 
to the ability of the strategy to utilise single-use bioreactor (S.U.B) technology 
and the removal of a dedicated primary clarification operation.  The 
consumable E factor values are highly dependent on the amount of single 
use technologies employed by the strategies. This effect is particularly 
pronounced at the smallest scale of production (100kg/yr), where all the 
manufacturing strategies can successfully employ single-use technologies, 
resulting in higher consumable E factor scores and lower non-process water 
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E factor scores. The smaller purification train in the perfusion strategies is 
ideally suited to such technologies across all the scales of production, 
leading to the high consumable E factor scores seen in Table 3.5. 
 
Table 3.5. E-Factor scores for water and consumable consumption 
  E-Factor scores (kg/kg product)  
 FB SPIN ATF 
Process water 4300 – 5050 4950 – 9800 4700 – 5300 
Non-process water 1150 – 4950 2600 – 12,500* 1400 – 6300 
Consumables 0.2 – 16.1 7 – 48.8 4.6 – 37.4 
 
*High spin-filter perfusion strategy water E-Factor scores are a consequence of a high number of 
reactors employed 
 
 
3.3.3.2 Qualitative Operational Benefits 
 Qualitative attributes related to the operational feasibility of the strategies 
were derived from survey responses from industrial experts with both FB and 
perfusion experience (shown in appendix). In terms of attribute weights, the 
responses highlighted that the batch-to-batch variability and ease of 
control/operation were considered more important than the other attributes. 
In terms of rating each strategy against these attributes, Table 3.2 indicates 
that the FB and ATF strategies scored evenly with regard to batch-to-batch 
variability due to the ability to successfully control the cell culture conditions 
for the strategies. The FB strategy was the clear favourite with regard to ease 
of control/operation due to the added complexity associated with the 
perfusion strategies’ cell retention devices and daily feeding operations. 
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3.3.3.3 Overall Aggregate Strategy Scores 
 The results of reconciling the trade-offs between economic, 
environmental and operational outputs using a single multi-attribute score are 
reviewed in this section. The key output was the overall aggregate strategy 
score over a range of combination ratios to reflect the impact of the relative 
importance of the economic, environmental and operational scores on the 
ranking of the manufacturing strategies. Figure 3.8 depicts the sensitivity of 
the overall aggregate strategy scores to the economic attribute combination 
ratios for the FB, spin-filter and ATF strategies at a 500 kg/yr scale of 
production and a titre of 5g/L. For the scenario shown in Figure 3.8a the 
operational attribute combination ratio was fixed at 0.1 and the environmental 
attribute combination ratio varied with the economic attribute combination 
ratio such that the sum of all the combination ratios always remained equal to 
one. Figure 3.8a illustrates that when the environmental and economic 
scores are equally weighted (R1 = R2 = 0.45), the ATF strategy has the 
highest aggregate score and therefore would be the preferred manufacturing 
strategy. If the environmental benefits are considered to be approximately 1.5 
times as important as the financial benefits (R1 = 0.35, R2 = 0.55) the FB 
and ATF strategies are equally attractive and outperform the SPIN strategy. 
The FB strategy only comes out as the superior strategy over the ATF and 
SPIN strategies when the environmental benefits are considered over twice 
as important as the financial savings. Interestingly, Figure 3.8b shows that 
when the environmental attribute combination ratio is fixed at 0.1 and the 
operational and economic scores are equally weighted (R1 = R3 = 0.45), the 
FB and ATF are equally ranked. Figure 3.8b illustrates that when the 
economic benefits are considered more important the ATF strategy is the 
preferred manufacturing strategy, however if the operational benefits are 
more important the fed-batch strategy becomes the favoured manufacturing 
strategy. Appendix Figures A3.1 and A3.2 demonstrate how these 
relationships were maintained across all the annual kg outputs investigated. 
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Figure 3.8. Sensitivity plots showing the effect of the economic attribute 
combination ratio (R1) on the overall aggregate scores when (a) the 
operational attribute combination ratio is constant and (b) the environmental 
attribute combination ratio is constant. For the fed-batch (solid line), spin-filter 
(dashed line), and ATF (dotted line) processes, for 500 kg/year scale of 
production and equivalent titre of 5 g/L. 
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3.4 Conclusions 
 This chapter presents the utilisation of the simulation framework to assist 
in cost-effective bioprocess design in the presence of uncertainty and 
multiple conflicting outputs relating to economic, environmental and 
operational feasibility. The tool was configured to cope with the continuous 
nature of perfusion cultures, the consequences of failures as well as the use 
of single-use bioreactors and bags when the scale was appropriate.  The tool 
was used to provide an in-depth analysis of the potential of mAb facilities 
based on fed-batch processes compared to 1st (spin-filter) and 2nd (ATF) 
generation perfusion systems across a range of titres and scales of operation 
so as to represent different possible scenarios of relevance to industry. The 
analysis highlighted the underlying cost drivers for each process and 
identified the robustness of each process along with the root causes for the 
differences. The derivation of environmental indices not only provided useful 
benchmarks of E factors for fed-batch and perfusion processes but also 
enabled the economic, environmental and operational outputs to be 
assessed simultaneously. This was achieved using a multi-attribute decision-
making technique that provided a more holistic approach to managing 
conflicting outputs. The tool’s predictions that the spin-filter perfusion strategy 
struggles to compete on economic, environmental, operational and 
robustness fronts at most titres and scales provides insight into its limited use 
in industrial processes.  In contrast, the ATF perfusion strategy is predicted to 
offer economic benefits that outweigh its lower robustness, even when it 
achieves cell densities that are only 3 fold higher than fed-batch strategies for 
typical titre and demand levels.  However, the analysis highlighted that if 
environmental or operational feasibility (e.g. ease of operation and validation) 
are considered more important than process economics savings then the fed-
batch strategy is found to be preferred. The simulation framework therefore 
acts as a valuable test bed for assessing the potential of novel strategies to 
cope with future titres and scales of operation. 
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4 Batch & Semi-Continuous Chromatography 
4.1 Introduction 
  The manufacture of mAbs is typically achieved using a series of product 
specific chromatographic resins. During clinical development manufacture 
these resins are often used for just a few cycles, particularly if the drug 
candidate (DC) is unsuccessful, the resin will then be discarded before 
reaching its full potential cycle lifetime. The impact of poor resin utilisation is 
a particular concern in mAb development due to the use of costly protein A 
capture resins. Improving utilisation of these expensive resins can have a 
significant effect on the manufacturing costs by reducing the cost burden 
associated with failed DCs. Semi-continuous chromatography has been 
shown by Mahajan et al (2012) to be an effective way to increase resin 
utilisation. This concept is similar to the simulated moving bed concept 
commonly used in the chemical and pharmaceutical industries, but to date 
this concept is not widely used in mAb purification. 
 This chapter explores the potential of semi-continuous chromatography 
to reduce clinical and commercial mAb manufacturing costs. An integrated 
approach to the technology evaluation is described that encompasses 
experimental evaluation and simulation assessment employing the 
decisional-support framework. The chapter is organised as follows: Section 
4.2 provides a description of the semi-continuous technology evaluated in 
this chapter, alongside a systematic design methodology to determine the 
key design and operating parameters for an optimised semi-continuous 
chromatography operation. In Section 4.3 the resulting design methodology 
was validated with semi-continuous constituency runs (Section 4.3.1) and 
incorporated into the decision-support framework to assess the performance 
and economic feasibility of the technology (Section 4.3.3). The framework 
was then used in combination with a dynamic cycling study (Section 4.3.4) to 
evaluate the potential impact of adopting semi-continuous chromatography 
for commercial manufacture. The final section then summarises the principle 
conclusions of the preceding sections of the chapter. 
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4.2 Methods 
 The materials and protocols used for the chromatography experiments 
are outlined in Chapter 2. 
 
4.2.1 Three and Four Column Periodic Counter Current Chromatography 
 The periodic counter current chromatography system was operated in 
both the 3-column and 4-column mode using either three or four 1ml 
columns, respectively. Figure 4.1 details the process description for the PCC 
system when operated in the 4-column mode. In an effort to utilise the full 
resin capacity, the harvested cell culture fluid (HCCF) was loaded onto 
column 1 until the column reached 100% breakthrough (BT) capacity, with 
the flow-through (FT) HCCF passing to column 2 (Figure 4.1a).  When 100% 
BT was achieved in column 1 the HCCF loading was switched to column 2; 
meanwhile the flush from column 1 was passed to column 3 to retain any 
unbound protein (Figure 4.1b). Upon completion of the column 1 flush step, 
column 1 underwent two dedicated wash steps before elution of the target 
protein, whilst the FT of column 2 was directed to column 3 (Figure 4.1c). 
The system’s next switch point occurred when 100% BT was reached in 
column 2, resulting in column 3 entering the HCCF loading position, column 2 
undergoing a flush operation with column 4 in the FT position and column 1 
conducting a strip step (Figure 4.1d). In the 3-column mode the switch only 
occurred after column 1 had been equilibrated and was ready to switch to the 
FT position to capture the flushed protein from column 2. In the 4-column 
system column 2 then entered the wash and elution position whilst column 1 
was regenerated and equilibrated for further HCCF loading. Meanwhile 
column 4 switched to the FT position from column 3 (Figure 4.1d). The 
system continued to switch and load as described until all HCCF was loaded 
at which point the system ramped down with the columns in the final load and 
FT position being eluted and cleaned in tandem. The PCC system was 
therefore operated such that loading of the HCCF stream was continuous, 
while the collection of the purified product was discrete and periodic. 
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Figure 4.1. 4C-PCC process description (a) column 1 HCCF loading, (b) 
column 1 flush and column 2 loading, (c) column 2 loading and column 1 
wash & elution, (d) column 2 flush, column 3 loading and column 1 strip, (e) 
column 3 loading, column 2 wash & elution and column 1 regeneration & 
equilibration. 
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4.2.2 Switch Time and Optimisation Calculation 
 The system switch time is the time taken to achieve 100% BT during 
HCCF loading in the load column and switch HCCF loading to the next 
column. When operating the PCC system the switch time must be the limiting 
time versus the non-loading steps to allow continuous loading of HCCF. The 
ideal PCC system would therefore have a switch time which is equal or 
marginally longer than the non-loading steps, allowing the maximum 
utilisation and productivity for the given purification process to be reached. 
When determining the switch time, the total time required for all the non-
loading steps must be known (flush, wash 1 & 2, elution, strip, regeneration 
and equilibration). The 3-column system has only one column in the non-
loading position at any one time and therefore the switch time will have to be 
greater than all the non-loading steps. In contrast, the 4-column system has 
two columns in the non-loading position allowing it split the non-loading steps 
between the columns, effectively halving the minimum possible switching 
time. 
 The switch time is dictated by two properties, the HCCF protein 
concentration and the loading flowrate. To set the switch time to the desired 
time interval based upon the duration of the non-loading steps either of these 
two properties can be altered. Concentrating or diluting the HCCF prior to the 
PCC loading was considered undesirable and could have required the 
addition of an extra processing step and potentially affect product or feed 
stream quality. The system was therefore optimised by adjusting the loading 
flowrate and as a result the protein’s residence time in the column, thus 
causing the BT profile to change. Small-scale single-column (1mL) 
experiments were performed to generate the BT curves at different flowrates.  
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Figure 4.2. The effect of residence time on (a) the protein breakthrough (BT) 
profile from a 2.77 mg/ml load concentration with a residence time of 14.3 
minutes (21 cm/hr) (Blue), 6.5 minutes (45 cm/hr) (Green), 5 minutes (60 
cm/hr) (Red), 3 minutes (100 cm/hr) (Purple) and (b) the relationship 
between the amount of unbound protein in the flowthrough (FT) of the 
column being loaded to 100% BT (x) and  the maximum protein challenge the 
FT column can capture (protein challenge at 1% BT) (+), resulting in either 
protein loss or retention. 
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 These curves were used to determine the maximum residence time and 
hence flowrate allowed so as to avoid product loss. Changes in residence 
times mean different protein loads would be required to achieve 100% BT in 
the loading column (Figure 4.2a) and as a result the unbound protein 
passing onto the second column in the FT position would vary (Figure 4.2b). 
Figure 4.2a highlights these changes in the BT profile indicating that as the 
residence time decreases (linear velocity increases), a higher load challenge 
is required to reach 100% BT (Hahn et al. 2005). These BT-derived plots 
allowed two key characteristics to be established: a) the maximum allowed 
protein challenge (mg protein applied / ml resin) that could be applied to the 
column before material was present in the FT, represented by the protein 
challenge at 1% BT, b) the actual amount of unbound protein in the FT at 
100% BT (the actual FT protein challenge) determined by integrating the 
area under the BT curves (mg unbound protein/ml resin). Figure 4.2b 
highlights how these two values (the maximum allowed protein challenge and 
the actual FT protein challenge) interacted with respect to residence time 
resulting in two intersecting lines. This relationship highlighted the critical 
residence time (6 minutes) below which the amount of unbound material in 
the FT of the column being loaded to 100% BT would be too high for the 
column in FT position to capture (surpassing the maximum allowed protein 
challenge) and would therefore result in material losses. Therefore in an 
effort to find the optimal switch time by altering the loading flowrate, careful 
consideration was paid to potential losses of unbound material. 
 Figure 4.3 details the systematic design approach developed to establish 
the optimal system parameters and switch time intervals that avoid product 
loss. The flowchart logic and underlying equations derived from Figure 4.2b 
were entered into the UNICORN method when running experiments and 
used in the simulation model to predict the performance of the PCC system 
in either 3-column or 4-column mode. 
 It may be possible to use real time absorbance measurement of antibody 
breakthrough as real time indicator of switch time.  However the absorbance 
of small amounts of antibody breakthrough through the resin was small 
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compared to the absorbance of impurities flowing through the column, 
making this approach less robust in this case. It is possible that with more 
sensitive analytics and/or a higher ratio of product to impurities this approach 
would be successful.   
 
Figure 4.3. Flow-sheet detailing a systematic design approach to optimise 
the performance of a 3-column or 4-column periodic counter-current 
chromatographic process, with example input and output variables for a 
completed verification run. 
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4.2.3 Wash Step Optimisation 
 The wash step optimisation study was performed on an ÄKTA FPLC 
using a 1mL column (0.5mm I.D., 5cm height) and the purification buffers 
specified in Chapter 2. The high salt wash buffer’s molarity was reduced 
over a number of cycles to reduce wash step yield losses where the column 
was loaded with HCCF to 100% BT. The product quality of the resulting 
elution pools was analysed using the methods outlined in Chapter 2. 
 
4.2.4 Resin Reuse Study 
 Resin reuse studies are typically performed using small-scale columns 
(ml column volumes) which is resource expensive, laborious and restricts the 
variables studied (Łącki 2012). This is in contrast to high throughput 
miniaturised methods regularly employed for screening of chromatography 
conditions. Hence, careful consideration was applied to the resin cycling 
studies shown in this paper to determine the useful lifetime of the protein A 
affinity resin under two different loading conditions, balancing resource 
constraints with experimental output. Both cycling studies were operated on 
the ÄKTA FPLC and used the process buffers specified in Chapter 2. The 
first study was conducted by the Purification Process Development group at 
Pfizer Inc., Andover, Massachusetts and was designed to replicate the 
standard batch process with a 40mg/ml protein load challenge per cycle, 
loaded at 230cm/hr giving a residence time of 6.5 minutes, for 200 cycles. 
The dynamic binding capacity at 10% BT was established every 50 cycles. 
The study employed a 24ml column with a 1.1cm I.D. and a column height of 
25cm. The second study was designed to capture the conditions found when 
operating the PCC system, with the resin challenged to 100% BT resulting in 
a final protein load challenge per cycle of ~110mg/ml. The dynamic binding 
capacity was recorded every 5 cycles at both 10% and 100% BT. A 3ml 
column was used with a 0.5cm I.D. and 15cm bed height, and was loaded at 
46cm/hr with a residence time of 6.5 minutes, for 100 cycles. 
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4.2.5 Decisional Tool 
 The economic analysis shown in this chapter was achieved using the 
simulation framework defined in Chapter 2. The chromatography process 
models shown in Section 2.1.4.3.4.3 detail the scheduling and mass balance 
equations for batch chromatography and semi-continuous chromatography 
(PCC). The same mass balance equations are utilised for both the batch and 
PCC chromatography systems. However Figure 4.1 demonstrates how the 
PCC system processes a number of operations at the same time in different 
columns. The scheduling of these different operations is shown in Figure 4.4, 
where the loading of a column is represented by a grey block and the non-
loading operations by a white block. To avoid major changes to the structure 
of the tool and follow the software principal of abstraction adopted throughout 
the development of the simulation framework. The semi-continuous 
chromatography’s systems resource requirements (buffers & labour) were 
converted into a single column system. The tool was then able to predict the 
resource requirements of the semi-continuous system without significant 
adaption. This was achieved by reducing the apparent duration of the loading 
operations, to the loading time remaining after the non-loading operations 
have been completed. This can be best visualised by overlaying all the 
columns of the PCC system (Figure 4.4). The methodology made it possible 
to convert multiple parallel operations into a single operations schedule, but 
still request the right amount resources at the correct time. This methodology 
was also successfully applied to the 4-column PCC system.  
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Figure 4.4. Schedule of the loading (grey) and non-loading (white) processes 
for the batch, 3-column periodic counter current chromatography system and 
the simulations interpretation of the periodic counter current chromatography 
system. 
 
4.2.6 Case Study & Assumptions 
 The simulation tool was used to compare the cost-effectiveness of the 3-
column and 4-column PCC system to the standard batch process throughout 
the development pipeline, exploring the trade-offs between reduced column 
and buffer volumes versus the higher number of column cycles. 
 Table 4.1 illustrates the clinical trials estimates used throughout this case 
study to calculate the amount of mAb required for each phase of the clinical 
trials throughout the development pipeline. The case study uses the quick 
win, fail fast development paradigm (Paul et al. 2010), where the material 
required for Phase I & II is generated in a single batch for the Proof-of-
Concept (PoC) development phase.  Assuming the average body weight of a 
US male to be 86kg (Ogden et al. 2004), a single 4kg batch of mAb was 
required for PoC development also accounting for non-clinical uses. This 
amount increases to 40kg of mAb for the phase III clinical trials and is 
produced by four 10kg batches at the Commercial batch scale allowing 
parallel process validation studies. The 10kg Commercial batch size is based 
on the median market demand of the top 15 mAb (200kg) (Kelley 2009) and 
the ability to process 20 batches per year. The cell culture titre also increases 
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with clinical phase, where due to continued process development the titre 
was assumed to increase 2-fold from the PoC batch to the Phase III & 
Commercial batches. The case study looks at two titre scenarios capturing 
the current and future mAb titres in the development pipeline. The scenario 
produced a 2.5g/L titre for the minimally developed PoC batch before 
increasing to a final titre of 5g/L. 
 
Table 4.1. Case Study Assumptions 
  
 The manufacturing process used in the case study was based on a 
generic two-column mAb process (Kelley 2007; Kelley et al. 2008). The key 
differences between the PCC based process and standard batch process lie 
Clinical Trial Estimates 
Variable  Value  
Dosage (mg/kg body weight)  7  
Number of doses per patient per year  26  
Individuals in Phase I clinical trials (single dose)  40  
Individuals in Phase II clinical trials (6 month dose)  200  
Individuals in Phase III clinical trials (year dose)  2000  
    
Process Parameters 
Maximum Binding Capacity (g/L) 65 
Bed Height  (m)           – Standard Batch Process  0.25 
                                    – PCC process 0.1 
Shift Duration (hours)  – Standard Batch Process 12 
                                    – PCC process  24 
Maximum Media Hold Time (hours) 72 
  
Cost Parameters 
Protein A Resin Cost ($/L) 8000 
AEX Resin Cost ($/L) 1500 
Virus Removal Filtration Membrane ($/m2) 3250 
Labour Cost ($/hour) 58 
Chromatography Process Skid (15-600L/hr) ($) 226,000 
PCC Process Skid (15-600L/hr) ($) 1,080,000 
Chromatography Column (Dia = 0.2m) ($) 132,000 
Chromatography Column (Dia = 2m) ($) 218,000 
183 
 
in the operation of the capture chromatography step (protein A) and are 
highlighted in Table 4.1. The standard batch process employs a single 
column utilising multiple cycles which are loaded with HCCF up to 90% of 1% 
BT (safety factor accounting for capacity losses with resin reuse), resulting in 
a maximum protein challenge of 40g/L. The resulting protein A cycles occur 
over three 12 hour shifts due to a constraint on the maximum HCCF holding 
time of 72 hours. The PCC systems employ multiple columns (3 or 4) for 
multiple cycles which are loaded to 100% BT resulting in a dynamic binding 
capacity of 65g/L. The continuous nature of the PCC system means that it 
has to be operated in a 24-hour shift to truly harness the benefits of the 
system, but it is still constrained by the maximum HCCF hold time of 72 
hours. The case study assumes that both systems are able to offer 
comparable product quality and yield, as this was proven through 
experimental validation (see Table 4.2). However, any change in product 
pool concentration and volume was accounted for by altering the scaling of 
the downstream purification operations where necessary. 
 
4.3 Results and Discussion 
4.3.1 Verification of Optimisation Strategy for Semi-Continuous 
Chromatography 
 The verification study comprised a number runs for a range of loading 
residence times (3 - 14.3 minutes) and HCCF titres (0.9 - 5.3 g/L) for both the 
3-column and 4-column PCC system. The performance of the system was 
measured in terms of UV profile, product quality and step yield. The system 
design approach from Figure 4.3 was utilised to predict the switch time, as 
well as ramp-up and ramp-down times. The sample input and output variable 
values indicated in Figure 4.3 provided the basis for the 3-column PCC 
verification runs shown in Figure 4.5a.  
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Figure 4.5. UV profiles for the 3-column PCC verification runs (column 1; 
red, column 2; green & column 3; blue). (a) A 3-column PCC run loaded with 
2g/L HCCF at 0.15 ml/min with a residence time of 6.5 minutes, including 
system ramp-down. (b) A detailed plot of a 3-column PCC run loaded with 
0.9 mg/ml HCCF at 0.33 ml/min with a residence time of 3 minutes, detailing 
column 1 (red) in the FT position with column 3 in the loading position (blue), 
before switching to the loading position. Point A highlights when column 1 
enters the FT position, capturing any unbound protein from column 3. The 
increase in UV signal at point B highlights the loss of unbound protein, before 
column 1 switches to the load position at point C. Column 1 loading ends at 
point D and the non-loading steps start. 
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 The system was loaded with HCCF at 2g/L and a residence time of 6.5 
minutes, resulting in 3 system cycles (10 column cycles including system 
ramp-down) to process ~650mg of mAb. The UV profiles in Figure 4.5a and 
the other verification runs demonstrated no secondary BT of unbound protein 
from the column in the FT position, due to successful implementation of the 
design approach. To evaluate the accuracy of the small-scale single-column 
data (Figure 4.2) and design approach (Figure 4.3), an example run was 
conducted where the residence time was set to be below 5.5 minutes. Based 
on Figure 4.2b a loss of material was projected, this was seen as BT in the 
FT column and resulted in a 10% lower yield than projected. Figure 4.5b 
demonstrates the results of this validation run where the residence time was 
set to 3 minutes and loaded with HCCF titre of 0.95g/L. Figure 4.5b shows 
an expanded scale chromatogram highlighting column 1 (red UV profile) 
throughout a single cycle. Point A highlights when column 1 enters the FT 
position and records an increase in UV signal as material starts to pass 
through column 1 from the loading of column 3 (blue UV profile). The UV 
signal for column 1 then plateaus signifying the maximum signal for impurity-
related BT. After point B the signal should remain linear (as seen in Figure 
4.5a), however the UV signal increases highlighting that the target protein is 
passing through column 1 unbound in the FT and being lost. Column 1 is 
then switched into the loading position at point C and achieves column 
saturation at point D where it has completed loading and moves to the wash 
position. 
 At high column loadings the potential exists for strongly binding antibody 
variants to displace weaker binding antibody variants.  This would result in 
different product quality in the eluate pools from the continuous system 
compared to the batch system.  Product quality of the eluate pool volumes 
was assessed by CEX-HPLC and SEC-HPLC evaluating acidic/basic species 
and high molecular weight species content (HMW), respectively. Table 4.2 
shows that the product-related impurity profile in the eluent pools from the 
verification runs was consistent regardless of the loading residence time and 
was found to be comparable to the eluate pool data generated from the same 
batch of HCCF but processed in the conventional batch conditions (40mg/ml 
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protein challenge).  Recent publications (Mahajan et al. 2012; Warikoo et al. 
2012) corroborate these findings for product quality. 
 
Table 4.2. Protein Pool Product Quality 
 
 The step yield for the PCC verification runs was approximately 10% 
lower than expected when compared to the standard batch process (80 – 
90%). The difference in step yield was investigated by conducting a full 
system mass balance for each verification run. This illustrated that the 
reduction in step yield was not caused by losses in unbound protein in the 
FT, verifying the findings from the UV profiles (Figure 4.5a). The reduced 
step yield was attributed to the higher losses in the dedicated salt wash step, 
where higher levels of bound protein were found to be washed off the column 
with the product-related impurities in the PCC system compared to the 
standard batch process. As a result, the impact of the wash step conditions 
performance was investigated further. 
 
 
  
 % Species of Protein Pool 
CEX-HPLC Acidic Designated Basic 
Standard 18.4 ± 2.5 74.8 ± 2.7 6.9 ± 0.3 
3C-PCC 18.3 ± 0.6 75.8 ± 1.5 5.9 ± 1.0 
Wash 18.0 ± 0.6 76.2 ± 0.9 5.7 ± 0.3 
Cycle 19.3 ± 0.8 75.0 ± 1.2 5.7 ± 0.9 
    
SEC-HPLC HMW Designated LMW 
Standard 1.0 ± 0.1 96.9 ± 0.1 2.1 ± 0.0 
3C-PCC 0.4 ± 0.1 98.0 ± 0.1 1.6 ± 0.2 
Wash 0.6 ± 0.1 98.1 ± 0.2 1.3 ± 0.1 
Cycle 0.7 ± 0.2 97.6 ± 0.3 1.7 ± 0.2 
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4.3.2 Wash Step Evaluation 
 The increasing loss of bound protein in the high salt wash step has been 
seen in historical runs of the standard batch process with increasing resin 
cycle count. The impact of reducing the wash step molarity on the losses in 
bound protein was investigated due to its prior success for the standard 
batch process and its ease of implementation with no requirement to alter the 
UNICORN method. The standard batch process only uses approximately 2/3 
of the available protein A ligand due to the reduced challenge load (40 
mg/ml) to prevent FT losses. As the resin cycle count increases protein A 
ligand is lost, eventually leading to a point where the batch process is using 
100% of the available protein A ligand to capture all the protein challenge, 
mirroring the state seen in the PCC system. At this time higher losses of 
bound protein are seen in the high salt wash step. To counter this loss of 
bound protein the molarity of the salt wash is reduced in line with cycle 
number, reducing bound protein loss and maintaining product related 
impurity clearance. An alternative method would be to pass the high salt 
wash FT over a column in FT position similar to the flush step, potentially 
retaining any lost protein. This approach has a number possible concerns 
with respect to product quality (recapturing target protein and product-related 
impurities) and the potential impact of the high salt wash on subsequent 
HCCF loading (precipitation and non-binding) without a new equilibration 
step on the FT column, which would increase the total buffer volume and 
wash time. If the wash step had no impact on subsequent HCCF loading the 
recapturing of material in the FT of the wash step would be more favourable. 
 The results of reducing the wash step molarity in a column loaded to 
100% BT to mimic PCC operation is shown in Figure 4.6 and Table 4.2. The 
evaluation found that the salt molarity had to be reduced by ~ 70% to reach a 
similar step yield seen in the standard batch process. Table 4.2 highlights 
how the reduction in wash step molarity had no adverse effect on product 
quality, offering the same product-related impurity clearance as the standard 
batch process. The lower salt wash was not believed to impact the removal 
of DNA, viruses, and host cell proteins but was not measured in this case. 
The experimental studies therefore demonstrated that the PCC system could 
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achieve similar yields and product quality to the standard batch process. 
These findings were then used in the process economic study to assess the 
economic feasibility of using the PCC system to generate clinical and 
Commercial material. 
 
 
Figure 4.6. The impact of salt molarity of the high salt wash step on 
percentage loss of bound protein for a 100% breakthrough challenged 
column, for a minimally (3 cycles) cycled protein A resin. 
 
4.3.3 Economic Impact of Semi-Continuous Chromatography 
 The simulation tool was used to assess the cost-effectiveness of the 3-
column and 4-column PCC system versus the standard batch process for a 
range of titre and manufacturing scenarios. The system’s cost-effectiveness 
was assessed by calculating the direct costs (labour, buffers, 
chromatographic resin, filter membranes etc.) at the given scale of 
production. Figure 4.7 shows the direct cost per gram for the 3-column, 4-
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column and standard batch process for a range of production scales in the 
clinical development pipeline (4kg, 40kg, 200kg). The analysis suggests that 
although the PCC systems offers reduced manufacturing costs for the 
generation of early phase Proof-of-Concept (PoC) material, the advantage 
becomes less significant later in the development pipeline (Phase III and 
Validation batches) eventually offering similar manufacturing costs during 
Commercial manufacture.  
 A detailed examination of the direct manufacturing costs highlighted in 
Figure 4.7 reveals how the decreased competitiveness of the PCC system 
with production scale can be attributed to the decreasing contribution of the 
protein A resin cost to the total cost, as illustrated in the embedded table. 
Table A4.1 shows the ensuing equipment number and sizes for the 
scenarios shown in Figure 4.7. This is demonstrated in the standard batch 
process which employs a single 31.4L column (five cycles) to process the 
singular 4kg PoC batch at a resin cost of $250k (USD 2011) per batch which 
accounts for 58% of the total direct costs for the batch. The PCC system is 
able to reduce the total direct costs per gram by reducing the volume of resin 
required by utilising the whole resin capacity. The model predicted that the 3-
column PCC system would require three 4.9L columns for 17 column cycles 
(5.7 system cycles). This resulted in a ~50% reduction in total resin cost to 
$118k, resulting in a 31% reduction in batch manufacturing direct costs. The 
level of cost savings was less than anticipated due to an 8% increase in the 
labour cost caused by the switch from shift-based manufacturing to the 24-
hour manufacturing regime required to operate the PCC system 
continuously. The 4-column configuration is able to offer a slightly higher 
level of saving by employing yet smaller columns (4 x 3.1L) and using them 
more frequently (6.5 system cycles, 26 column cycles) leading to a 34% 
reduction in batch manufacturing direct costs.  
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Figure 4.7. A comparison of direct cost per gram highlighting the protein A 
cost (black) to the other direct costs (grey) between the standard batch 
process (STD) and the 3-column (3C-PCC) and 4-column periodic counter-
current chromatographic (4C-PCC) process over a range of scales of 
production for the low titre scenario, where the percentage difference is 
relative to the standard batch process. The embedded table highlights the 
percentage contribution of the protein A resin towards the total direct costs. 
The optimal sizing strategy for each process is indicated in the boxes above 
each bar highlighting the number and scale of columns (solid box) and the 
number of system cycles (dashed box) across a range of scales of 
production. 
 
 The savings offered by the PCC system are reduced significantly as the 
scale of production increases from the generation of PoC material (1 x 4kg 
batch) to the generation of Phase III clinical material (4 x 10kg batches) and 
Commercial material (20 x 10kg batches per annum). This effect is due to the 
fact that the protein A resin is only used for a few cycles in the PoC batch 
and Phase III batches. Due to the requirement to keep the resins product-
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specific, it cannot be reused for another drug candidate, resulting in a higher 
cost burden because the resin may be discarded before reaching its full 
potential cycle lifetime. For example the protein A cost ($250k) accounts for 
over half the direct costs at the PoC scale for the standard batch process. 
However for a 10 kg batch the resin costs $390k (49.1L column, 7 cycles) 
and this cost is split between the multiple batches and therefore reduces the 
overall cost contribution to 34% and 10% for the Phase III (4 batches) and 
Commercial (20 batches) material respectively. The PCC systems maintain 
the same level of column volume reduction with the increase in scale, but as 
shown by the embedded table in Figure 4.7 they fail to offer the same level 
of savings as the protein A cost becomes less significant as other process 
costs dominate the manufacturing cost. For cases where it is possible to use 
the same lot of protein A for both PoC and Phase III batches; the protein A 
cost contributions for late-phase batches would be even lower. 
 The ability of the PCC system to reduce the column volume, also impacts 
the volume of chromatographic buffer required. The standard batch process 
uses 5,500 litres of buffer for the protein A step per PoC batch, which is 
approximately a quarter of the buffer volume used for the generation of the 
batch. The 3-column and 4-column system reduce the protein A buffer 
volume by ~39% and ~49% respectively resulting in an overall process buffer 
reduction of ~12% and ~15%. These savings have minimal impact at PoC 
scale of manufacturing resulting in direct cost savings <1%. This relationship 
was also found during the generation of the 10kg batches for Phase III and 
Commercial material, where again direct cost savings were insignificant. 
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4.3.4 Impact of Resin Reuse 
 Figure 4.7 highlighted the high number of cycles employed by the 3-
column and 4-column PCC system allowing them to reduce the overall 
column volume. The high cycle count combined with the higher protein 
challenges could potentially affect product quality and will lead to a reduction 
in binding capacity. The loss of binding capacity will require the PCC system 
to run more column cycles to purify all the HCCF. This will conceivably 
increase the protein pool volume outside process design volumes and also 
the step processing time over the validated media hold-time (72 hours). 
 
4.3.4.1 Resin Reuse Study 
 The impact of cycle count on binding capacity and product quality was 
investigated via two cycling studies with MabSelect resin, replicating the 
conditions found inside the standard batch process and the PCC system. 
Figure 4.8a shows the effect of cycle count on dynamic binding capacity at 
10% BT for the standard batch process and 100% BT for the PCC system 
which utilises the whole resin capacity every cycle. A binding capacity loss of 
~20% and ~40% was observed over 100 cycles in the standard and 100% 
BT studies. The process buffers used throughout both studies were kept 
constant and therefore the increased rate of capacity loss seen in the 100% 
BT study was attributed to the increased volumes of HCCF (x2.2) that the 
resin was exposed to per cycle. The loss in capacity affects each process 
differently due to their mode of operation. The standard batch process only 
uses 2/3 of the resin’s capacity and therefore any loss in capacity has no 
effect on the maximum allowed protein challenge until the resin use reaches 
100 cycles. Figure 4.8b demonstrates that as the cycle count passes 100 
cycles a small percentage of the material loaded was found in the flow-
through. In contrast the PCC system is designed to utilise the whole resin 
capacity making it highly susceptible to any change in binding capacity. Due 
to the high impact of resin capacity loss on the PCC system, the mechanism 
for this increased rate of loss was investigated further. 
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Figure 4.8. The effect of cycle number on (a) binding capacity for standard 
batch process (40 mg/ml of protein load challenge per cycle)(black circles) 
and 100% break-through study (~110 mg/ml of protein load challenge per 
cycle)(crosses), (b) the percentage of the challenge load in the flow-through 
for the standard batch process. 
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 Table 4.2 shows that throughout the 100% BT study the product quality 
was found to be constant with respect to specification of the product. 
However it was noted that the pH of the elution pool decreased (from 4.2 to 
3.6) with increasing cycle number (Figure 4.9). This was caused by an 
increase in the volume of elution buffer applied to the column prior to peak 
collection (pre-peak volume). The increase in pre-peak volume from 1 CV to 
1.2 CV resulted in a larger volume of pH 3 elution buffer passing through the 
column prior to peak collection, thus a smaller proportion of the pH 7.5 wash 
buffer carried through to the elution pool. This phenomenon strongly 
suggests that the mass transfer properties of the column were changing with 
increasing cycle number and that this affect was due to the loss of surface 
binding sites caused by fouling and/or ligand loss. I.e. due to unavailability of 
surface biding sites it took the mAb longer to diffuse from inside resin bed to 
the mobile phase and hence lead to increased pre-peak volumes. 
Figure 4.9. Elution peak pH for 100% breakthrough cycle study versus cycle 
number. 
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Figure 4.10. Breakthrough profiles on MabSelect resin in the 100% BT cycle 
study for resin used for 20 cycles (red), 40 cycles (green), 60 cycles (yellow), 
80 cycles (light blue) and 100 cycles (purple). The increase in A280 for the 
breakthrough at cycle 60 (yellow) was caused by an air bubble in the UV 
monitor. 
 
 The breakthrough profile of mAb (Figure 4.10) was monitored during the 
loading phase of the cycle study, and was found to occur earlier with 
increasing cycle number due to the loss of binding sites corresponding to the 
decrease in capacity seen in Figure 4.8. It was also noted that the columns 
mass transfer properties changed with increasing cycle number as shown in 
Figure 4.9 by the increasing sharpness of the breakthrough profiles.  
 The leading edge of a breakthrough curve is dominated by the mass 
transfer of the mAb in the fluid film, whereas the tailing edge is dominated by 
diffusion of the mAb into the matrix pores (Helfferich and Carr 1993; Siu et al. 
2006). Therefore if excessive surface fouling is present the breakthrough 
curve is likely to exhibit tailing, where the tailing edge of the breakthrough 
becomes very shallow and takes longer to reach full resin saturation. Figure 
196 
 
4.10 shows that the breakthrough profiles exhibit no signs of tailing and 
therefore strongly suggest that fouling is not having a significant impact on 
the mass transfer properties of the resin. However fouling may still be 
present in the form of pore occlusion, where smaller resin pores are blocked 
preventing access to binding sites. The increasing sharpness of the 
breakthrough curves demonstrates an improved mass transfer rate into the 
bead. It can be assumed that for a large molecule such as a mAb, pore 
diffusion will be the most relevant mass transfer resistance and since pore 
diffusivity depends on the square of the adsorbents diameter (Hahn et al. 
2003). An improvement in mass transfer properties can be attributed to either 
a reduction in steric hindrance (loss of ligand and widening of pores) or a 
reduction in particle diameter (loss of resin structural integrity).  
 
4.3.4.1.1 Resin Characterisation 
 The analysis of the loading breakthrough profiles and increasing elution 
pool pH during the cycle study suggest that the loss in capacity and changes 
in mass transfer properties could be due to loss of binding sites, particularly 
surface ligands. There are a number of mechanisms for the loss of binding 
sites seen, including pore inclusion, protease digestion and proteolysis of the 
ligand. To establish which of the described mechanism is principally 
responsible for the observed effects, the column was unpacked and the resin 
was further analysed using the techniques described in Chapter 2. The 
cycled resin sample was compared to new resin (conditioned with 3 cycles of 
HCCF and elution) and NaOH cycled resin (100 cycles of CIP buffer only). 
 Figure 4.11 shows the batch uptake profiles for the three resins, where 
the cycled resin sample (dotted line) binds the least mAb and the new resin 
sample (solid line) the most. Upon saturation the cycled resin binds ~40% 
less mAb and the NaOH cycled resin ~10% less mAb compared to the new 
resin sample (See Tables A4.2, A4.3, and A4.4). The batch uptake study 
also demonstrates that the changes in mass transfer properties seen are 
negated in the highly agitated environment used in the batch experiment. 
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Where all the resin samples reach ~50% saturation in 12 minutes,~90% 
saturation within an hour and equilibrium after 2 hours.  
 
Figure 4.11. Batch uptake curves of 2.6 mg/ml mAb by new (Solid line), 
cycled (dotted line) and NaOH cycled (dashed line) MabSelect resin samples 
during batch experiments. (Feed to resin volume ratio 45:1). 
 
 Isotherm experiments were then run for all the resin samples to 
determine the maximum capacity and the dissociation constant. The resulting 
adsorption equilibrium were described by the Langmuir adsorption isotherm 
shown in Chapter 2 (Equation 2.59) (Langmuir 1916). To establish the 
equilibrium dissociation constant (Kd) and the maximum equilibrium binding 
capacity (qmax) for each resin the data collected from the isotherm 
experiments was linearised using Langmuir regression (Langmuir 1918). The 
reciprocal of slope is equal to qMax and the y-intercept equal to the reciprocal 
of Kd.qMax (Chapter 2 - Equation 2.60). Figure 4.12 shows the adsorption 
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isotherms for the resin samples, where the experimental data is fitted using 
the Langmuir isotherm. The linearised plots and experimental data points 
used for each resin sample are shown in the appendix.  
 
Figure 4.12. Adsorption isotherms for the new (solid line), cycled (dotted line) 
and NaOH cycled (dashed line) resin samples. The experimental data points 
were fitted with the Langmuir isotherm. 
 
 Table 4.3 highlights the calculated maximum equilibrium binding capacity 
and equilibrium dissociation constant for the resin samples. The equilibrium 
dissociation constant increases over 4-fold, these changes can be attributed 
to the reduction in ligand binding sites and therefore a reduction in ligand 
protein complexes causing the increase in the dissociation constant seen. 
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Table 4.3. Equilibrium Constants for the Resin Samples 
Resin Sample qMax (mg/ml) Kd (mg/ml) 
   
New 67.7 ± 0.9 0.036 ± 0.002 
NaOH Cycled 59.7 ± 0.4 0.042 ± 0.012 
Cycled 45.0 ± 0.7 0.140 ± 0.014 
   
 
 The capacity losses seen in both the batch uptake and isotherm 
experiments are comparable to the column experiments and therefore 
demonstrate that the loss in binding capacity is likely to be caused by 
irreversible binding site loss (based on the current CIP regime). The previous 
experiments (batch and isotherm) did not give a clear answer to the cause of 
the changes seen in mass transfer properties. Therefore scanning electron 
microscopy (SEM) was used as described in Chapter 2 to assess the 
differences in resin structure between samples. Figure 4.13 shows the SEM 
images for the resin samples at x250 magnification allowing individual resin 
particles to be assessed and at x40,000 magnification, to evaluate any 
changes in resin particle surface pore structure.  
 The new resin sample has flawless spherical resin particles (A1) and a 
clear distinction between large and small surface pore structures (B1). The 
NaOH cycled resin sample shows disfigurement of the spherical resin 
particles (A2). This disfigurement was attributed to etching of the resin 
particles agarose linked scaffold by the caustic CIP solution (0.5M sodium 
sulphate, 50mM NaOH). The etching process appears to have only damaged 
the outer layers of the resin particle but not the pore structure, with larger and 
small pores still visible (B2). The cycled resin (C1) shows the same signs of 
surface etching shown by the NaOH cycled resin (B1) along with a higher 
degree of resin particle fragmentation. The cycled resin also shows a distinct 
change in the surface pore structure (C2), where the smaller pores appear to 
have broadened and a number of these larger pores are blocked with 
unknown foulant particles. 
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Figure 4.13. Scanning electron microscopy images of the new (1), NaOH 
cycled (2) and cycled (3) resin samples at (A) x250 and (B) x40,000. 
 
 The column and resin characterisation experiments demonstrate that the 
loss in binding capacity and resulting changes in the column mass transfer 
properties are caused by multiple mechanisms. The binding capacity loss is 
principally driven by protease digestion of the ligand and potentially a degree 
of surface pore occlusion, blocking viable binding sites. However a quarter of 
the capacity loss seen in the 100% BT cycle study can be attributed to the 
A1 
A2 
A3 
B1 
B2 
B3 
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NaOH cleaning, which leads to proteolysis and denaturation of the ligand as 
well. The mass transfer affects seen are likely to be caused by the etching of 
the resin particles and the loss of ligands due to the ensuing reduction in 
particle diameter and predicted reduction in steric hindrance caused by fewer 
ligands and widened surface pores (etching). 
 Recent publications (Mahajan et al. 2012; Warikoo et al. 2012) have 
demonstrated lower levels of binding capacity loss over multiple cycles when 
using another protein A resin from the MabSelect family, MabSelect SuRe 
(GE Healthcare, Uppsala, Sweden), which is alkali-stabilised and thus offers 
greater sodium hydroxide and protease resistance. They also did not fully 
utilise the whole resin capacity by only loading to 70% BT and therefore the 
resin was less susceptible to binding capacity loss from increased HCCF 
volumes.  
 
4.3.4.2 Variable Binding Capacity Study 
 Figure 4.14 demonstrates the influence of the loss in binding capacity on 
the 3-column PPC system for the generation of Commercial material (10kg 
batches). The decrease in binding capacity causes the system to operate an 
increasing number of cycles per batch to process all the HCCF. The increase 
in system cycles leads to a rise in the step processing time, which exceeds 
the maximum media hold time on the 11th batch (Figure 4.14a) resulting in 
an inability to process the complete batch within the desired timeframe. The 
increase in cycles results in a concomitant rise in the protein pool volume due 
to a higher number of eluate pools. Figure 4.14b demonstrates that if the 
product vessel for the step is fixed on the predicted pool volume not 
accounting for increasing cycle number, material will be discarded after 6 
batches due to insufficient tank volume. This effect is even more pronounced 
for the 4-column PCC system due to its higher cycle count per batch, which 
results in it violating the maximum media hold time in the 9th batch and the 
tank volume in the 6th batch. The standard batch process also exceeds the 
maximum media hold time, but not until the 18th batch when an extra cycle is 
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required to counter the loss of material in the flow-through due to decreasing 
binding capacity post 100 cycles. 
 The 3-coulmn and 4-column PCC system have demonstrated the ability 
to offer manufacturing cost savings in early clinical phase material 
generation. The high number of molecules entering early clinical phase trials 
for every successful product launch implies that the PCC technology is likely 
to make a significant impact on clinical manufacturing costs. However Figure 
4.14 demonstrates the limitations of using the PCC system for lengthy 
Commercial manufacturing campaigns. In addition, the lack of familiarity with 
the PCC technology could make the technology unfavourable for technology 
transfer to new facilities or contract manufacturing organisations. A possible 
scenario for adoption of the PCC technology is to use the system throughout 
clinical development and on the successful launch of a product, switch to the 
standard batch process for ease of operation and tech transfer. This type of 
post-launch process change is likely to be classed as a major change by the 
regulatory bodies and will therefore require detailed validation and 
equivalence studies which can take between 12-18 months to complete 
(Hassan 2009; Wojciechowski et al. 2007). 
 To address these findings and to investigate the feasibility of such a 
scenario the simulation tool was reconfigured to design and optimise a 
manufacturing process that for the given time period (18 months) would 
remain in specification (HCCF hold time & process scale limits) allowing the 
process change and the resulting validation efforts to be completed. 
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Figure 4.14. The effect of batch number for the Commercial scale of 
manufacture utilising the 3C-PCC system for (a) dynamic binding capacity 
(solid line) and resulting harvest hold time (dashed line) with respect to the 
maximum allowable harvest hold time (dotted line). (b) The product pool 
volume (dashed line) and resulting bulk drug substance yield (solid line) 
when constrained by the maximum vessel volume (dotted line).   
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 The approach was initially applied to the standard batch process to 
address the impact of the redesign and establish a base case design. The 
redesigned standard process required a 1.4-fold increase in column volume 
(1 x 70.7L) operated for fewer cycles (5). This would allow the process to 
cope with the addition of the extra cycle (6) needed post 100 cycles to 
prevent product loss in the flow-through. In contrast the PCC systems 
required a 2-fold increase in total column volume to create a robust enough 
process capable of remaining within the specified design limits for the 
duration of production. The PCC systems were found to still offer comparable 
Commercial manufacturing costs, due to the diminished impact of resin costs 
at this scale of production. 
 
4.3.5 Retrofitting Costs 
 The PCC system has demonstrated its ability to offer savings in direct 
costs throughout the clinical development pipeline to Commercial 
manufacture. To realise these savings a PCC system and columns must be 
purchased and installed in the facility. This retrofitting process is unlikely to 
have any adverse effects on the existing facility, where the PCC system’s 
ability to reduce buffer volumes by operating smaller column volumes, will 
actually reduce the utilities burden in the facility. The potential increase in 
footprint caused by the PCC skid is unlikely to be sufficient to cause 
operating issues. 
 The current PoC scale of production is achieved using a standard batch 
chromatography skid (15-600L/hr) capable of supporting a 31.4L column, 
with the skid and column costing ~$280k. The corresponding PCC system 
and column cost approximately four times that of the standard batch process, 
costing ~$1,150k regardless if it is operated in the 3-coulmn or 4-column 
mode. The investment cost required for the PCC system designed for the 
PoC scale of production, could be balanced with the savings realised in the 
direct costs (~$150k per batch) after eight PoC batches (8 drug candidates). 
With the increase in production scale to the PIII & Commercial manufacture 
(10kg batch) the standard batch process employs a larger skid scale (45-
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1800L/hr) to support the larger column volume requirements, resulting in an 
increase in equipment cost ($380k). The equivalent PCC system can still 
utilise the same specification skid as in the PoC scale of production with 
larger columns, meaning it is only three times more expensive for the 10kg 
batch scale of production. The reduced savings in direct costs highlighted at 
the larger scale of production shown in Figure 4.7, mean the investment cost 
would take longer to be recouped, requiring thirty-nine PIII batches (~10 drug 
candidates). However in producing 10 Phase III drug candidates, a higher 
number of candidates must have entered the PoC scale of production due 
attrition rates in clinical trials. Taking this lifecycle perspective highlighted that 
the direct cost savings obtained by 9 PoC batches (9 DC’s) would be 
sufficient to pay back the cost of the larger scale PCC system for late-stage 
manufacture. 
 
4.4 Conclusions 
 This chapter evaluates the feasibility of whole bioprocesses that utilise 
semi-continuous chromatography (3C-PCC or 4C-PCC) for product capture 
across a product’s lifecycle from PoC to Commercial manufacture. The 
approach adopted linked small-scale single-column experimental studies with 
a process economics simulation. The experimental work was key to 
determining the critical design parameters for the PCC system through the 
derivation of mass balance, scale-up and scheduling equations. The 
integrated techno-economic evaluation predicts that semi-continuous 
chromatography has the ability to offer manufacturing cost savings in early 
clinical phase material generation which can be significant due to the high 
attrition rates. The analysis also demonstrated the obstacles to using such a 
technology at Commercial scale and the importance in the selection of the 
protein A resin employed. The framework was then employed to determine 
the semi-continuous system specification required to operate with similar 
costs to the standard batch process while a process change application is 
pursued. 
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In addition to the techno-economic evaluation presented in this 
chapter, a further dimension concerns the development and validation effort 
required when implementing alternative technologies such as the PCC 
system. Development time may not be greatly increased with the PCC 
system since early purification development can often include experiments to 
determine aspects such as the wash step conditions and loading flowrate; 
the latter can be easily adapted for PCC switch time determination. Resin 
cycling studies for either the standard batch or PCC system would typically 
occur during late phase process characterisation studies. However it is 
recognized that the potential benefits of a new or alternative technology need 
to be balanced against factors such as technology readiness for large-scale 
manufacture and regulatory concerns. The regulatory impact of new 
continuous technologies will be discussed further in Chapter 6. 
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5 Integrated Continuous Processing 
5.1 Introduction 
 The next generation of mAbs are under increasing pressure from both 
public and private healthcare providers to offer cost effective treatments and 
contend with the intensified competition from rival manufacturers. The 
success of these new mAb therapeutics will be highly dependent on their 
economic performance (Mitchell 2005). As a result production cost, capacity 
utilisation and the ability to rapidly accommodate fluctuating market 
conditions are becoming critical success indicators (Farid 2009a; Kamarck 
2006; Pellek and Arnum 2008). This is increasing the pressure on biotech 
companies to produce more economically sustainable therapies and hence 
adopt more cost-effective manufacturing strategies such as continuous 
processing.  
 This chapter presents a vision for a number of integrated continuous 
manufacturing processes and utilises the decision-support framework to 
assess performance of these future manufacturing strategies, incorporating 
the findings from Chapter 3 & 4. The chapter is organised as follows: 
Section 5.2 provides an overview of the continuous mAb manufacturing 
strategy. Section 5.3.1 highlights the impact of development phase on 
manufacturing costs, followed the impact of company size on facility 
utilisation and resulting costs in Section 5.3.2. In Section 5.3.3 a detailed 
cost of goods comparison between the batch and continuous manufacturing 
strategies for all scenarios is investigated. Section 5.3.4 builds on this 
analysis to include a number of further continuous manufacturing strategies 
to establish the optimal combination of batch and continuous unit operations. 
The chapter then takes into account the operational concerns associated with 
the adoption of continuous technologies and combines these findings with 
the calculated economic and environmental performance metrics in Section 
5.3.5. The final section then summarises the principle conclusions of the 
wide-ranging overview from preceding sections of the chapter, summarising 
the performance of continuous processing in the mAb sector. 
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5.2 Methods 
5.2.1 Visualising an Integrated Continuous Process 
 A key concept of an integrated continuous process is that continuous, 
steady-state processing extends from the bioreactor to the final purification 
operation. However this concept is currently not possible in 
biopharmaceutical manufacture due to the lack of suitable technology and 
strict regulatory requirements. Continuous perfusion bioreactors for example 
do generate a continuous stream of harvested cell culture fluid (HCCF), but 
they can only achieve this in a batch operation. Firstly the cell culture has to 
reach the desired steady-state cell density to achieve a constant 
concentration of HCCF and then can only produce a continuous stream of 
HCCF for a defined period, before a new cell culture batch is required. This 
semi-continuous mode of operation is also found in the search for continuous 
downstream processing operations where chromatography systems that are 
described as continuous are capable of continual loading but only generate 
discrete elution pools of product. The challenge is further complicated by the 
stringent quality and regulatory requirements that dominate 
biopharmaceutical manufacture. The ability of the manufacturing process to 
demonstrate viral clearance is critical, with a mandatory inclusion of two 
dedicated viral clearance operations (viral inactivation & viral retention 
filtration). Both of these operations are currently achieved in a batch 
operation, for example in a viral inactivation step the product stream is held 
at a low pH for a defined period of time, before processing continues. A 
further regulatory complication is batch traceability, a key area of debate 
surrounding continuous processing, with the principal concern being “how do 
you define a batch?”. 
 These factors highlight how continuous processing is not currently 
possible in biopharmaceutical manufacture. However the use of semi-
continuous unit operations can lead to a semi-continuous manufacturing 
process, potentially capturing some of the economic advantages seen in 
continuous processing. The upstream can be operated in a semi-continuous 
manner by using perfusion culture, which is fed and bled at a constant rate to 
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generate a constant stream of HCCF when steady-state cell density is 
achieved. The downstream is more complicated due to the number of 
orthogonal purification operations. The initial capture of the product from 
HCCF can be achieved in a continuous manner, using semi-continuous 
chromatography. The resulting process stream is now being created in 
discrete elution volumes, which can either be pooled into larger volumes or 
processed individually before moving to the subsequent purification steps. 
These sub-batches can be processed in the conventional batch manner for 
the remaining purification steps or can be processed in a continuous manner.  
 Figure 5.1a shows the downstream scheduling for a typical process 
sequence operated in batch mode, where each step is completed before the 
product stream is passed to the next. Figure 5.1b shows an adapted process 
sequence where HCCF is continually loaded onto a semi-continuous 
chromatography step and the resulting elution volumes are pooled into larger 
volumes before proceeding in a batch manner similar to Figure 5.1a for the 
remaining purification steps. Figure 5.1c demonstrates a flow-sheet where 
the individual discrete elution volumes from the semi-continuous 
chromatography step are individually passed onto the subsequent anion-
exchange (AEX) chromatography step and the flowthrough is continually 
passed through the virus retention filtration (VRF) step. Therefore the product 
stream flows through the AEX chromatography column and straight into the 
VRF step in a continuous manner. The VRF unit would be sized by 
calculating the filter area capable of matching the volumetric flowrate from 
the AEX chromatography step whilst maintaining the same transmembrane 
flux (20 LMH) seen in the batch orientated processes (Figure 5.1a & b). Both 
process flowsheets operating the semi-continuous chromatography capture 
step collect all the viral secure sub-batches (post VRF) into one final batch 
prior to the final ultrafiltration/diafiltration (UFDF) step. This pooling approach 
solved the regulatory requirement for batch traceability, by defining the batch 
as all the material created in a single fermentation run. This approach also 
reduces the quality burden by reducing the number of batch releases for a 
given manufacturing strategy. 
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Figure 5.1. Downstream process scheduling for a) the base case process 
sequence, b) the continuous to batch process sequence and c) the 
continuous process sequence. Protein A chromatography; VI, viral 
inactivation; AEX, anion exchange chromatography; VRF, viral retention 
filtration; UFDF, ultrafiltration/diafiltration. 
 
 Table 5.1 demonstrates how this concept results in five different 
manufacturing strategies, where the capture step is defined as the mode of 
Protein A chromatography used and the polishing steps (AEX & VRF) are 
defined by how the resulting purification steps are operated. The base case 
strategy employs a fed-batch reactor generating a single discrete batch, 
which is purified in a batch manner (Figure 5.1a). Similarly the fed-batch, 
continuous capture and batch polishing (FB-CB) strategy also employs a fed-
batch reactor, but the ensuing batch is purified using semi-continuous 
chromatography in a 72 hour window with the polishing steps operated in the 
batch manner (Figure 5.1b). In contrast the ATF perfusion, continuous 
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capture and batch polishing (ATF-CB) strategy employs an alternating 
tangential flow (ATF) perfusion reactor to generate a constant stream of 
HCCF which is captured directly onto the semi-continuous chromatography 
step for the duration of the perfusion run, prior to batch operated polishing 
steps. The remaining strategies (FB-CC; Fed-batch, continuous capture, 
continuous polishing, and ATF-CC; ATF perfusion, continuous capture, 
continuous polishing) both employ a continuous capture step which 
generates discrete sub-batches which are then processed in a continuous 
manner in the polishing purification steps as shown in Figure 5.1c. 
 
Table 5.1. Mode of operation for key stages of the alternate strategies  
Manufacturing Strategies USP Capture Polishing 
    
Base case Fed-batch Batch Batch 
FB-CB Fed-batch Continuous Batch 
ATF-CB ATF perfusion Continuous Batch 
FB-CC Fed-batch Continuous Continuous 
ATF-CC ATF perfusion Continuous Continuous 
    
 
 
5.2.2 Decisional Tool 
 The deterministic analysis shown in this chapter was achieved using the 
decision-support framework defined in Chapter 2. The version of the 
framework used throughout this chapter includes the process model updates 
for perfusion cell culture demonstrated in Chapter 3 and semi-continuous 
chromatography from Chapter 4. The continuous unit operations exhibited in 
the previous chapters allowed the framework to capture a single continuous 
unit operation within a batch dominated manufacturing process. This section 
details the unique adaptions made to the decision-support framework to 
account for the passing of continuous product streams between unit 
operations.  
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Figure 5.2. Continuous flow between two unit operations in a discrete event 
environment. UOp, Unit Operation. 
 
 The decision-support framework employs a discrete event simulation 
tool, which by its nature captures events in discrete time intervals and is 
therefore not capable of representing a product stream as a rate 
(volume/mass per time). This was not an issue previously (Chapters 3 & 4) 
as the use of a single continuous unit operation meant the product stream 
was passed between unit operations in a batch manner. For example each 
perfusion volume was discretised into the volume collected per day before 
being passed to a batch chromatographic process. To avoid major changes 
to the structure of the simulation tool and follow the software principle of 
abstraction adopted throughout the development of the decision-support 
framework a similar approach was utilised for continuous product streams. 
Figure 5.2 demonstrates how this was achieved within the framework`s 
existing architecture. Any continuous unit operations product stream was 
discretised into distinct batch volumes, which were placed into a surge vessel 
(the unit operations product vessel). The next unit operation (continuous or 
batch) would then take the required product stream volume from the vessel 
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when available. If this next step were another continuous unit operation it 
would also request material in a discretised fashion. This approach allows the 
discrete event simulation tool to represent a continuous product stream and 
therefore capture resource requests at the correct time. For example the FB-
CC and ATF-CC strategies utilise this feature when representing continuous 
polishing, with the AEX chromatography and VRF being operated in a 
continuous manner. 
 
5.2.3 Multi-Attribute Decision-Making  
 The weighted sum method shown in Chapter 2 was used to reconcile 
economic, environmental, and operational outputs so as to identify the most 
preferred alternative manufacturing strategy for a range of company scales 
with different weightings assigned to each of these categories. Table 5.2 lists 
all the attributes considered in the MADM analysis. The values of the 
attributes under economic and environmental feasibility were derived from 
the simulation tool. The attributes were ranked in order of importance, where 
a ranking of one indicates an attribute of greater significance.  For example in 
the large-sized company the cost per launch is more important than the 
commercial COG/g and the initial capital investment required in facility 
construction. In contrast the small-sized company ranks the initial capital 
expenditure the highest, highlighting the differing finical philosophies found 
with company size. A large-sized company’s main aim is to reduce the cash 
outlay for a new drug and produce this material as cost effectively as 
possible. In contrast, the small-sized company will have fewer resources to 
invest (facilities & drug development) and will therefore want to minimise 
these costs before looking to alternative funding sources upon product 
launch (licencing, partnerships, mergers and acquisitions). The attributes 
representing the environmental feasibility were ranked equally because the 
environmental impact of water and consumable usage was deemed to be 
equally disadvantageous to the environment. The operational feasibility was 
represented by a risk score, which assesses the manufacturing strategies 
perceived robustness (likeness of batch failure). 
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Table 5.2. Attribute grouping and ranking for each company scale 
Attribute field Attribute name Large Medium Small 
     
Economic 
feasibility 
Cost per Launch 1 1 2 
Commercial COG/g 2 2 3 
Capital expenditure 3 2 1 
     
Environmental 
feasibility 
Water E factor  1 1 1 
Consumable E factor  1 1 1 
     
Operational 
feasibility Batch risk 1 1 1 
     
Note: Rank of 1 refers to most important attribute and 3 to the lowest. 
 
5.2.4 Case Study Assumptions 
 The decision-support framework was used to compare the cost-
effectiveness of the five alternative manufacturing strategies throughout the 
development pipeline for a range of company sizes, exploring the trade-offs 
between reduced equipment scales versus increased manufacturing risk. 
Table 5.3 illustrates the clinical trials estimates used throughout this case 
study to calculate the amount of mAb required for each phase of the 
development pipeline. The earliest development phase captured in this case 
study is the Pre-Clinical phase where material is required for non-primate 
animal model studies. Assuming the average non-primate (Macca Mulatta) 
body weight is ~8kg (Leigh 1996) and the study includes 110 non-primates 
(25% control group) (Chapman et al. 2009), a single 0.5kg batch of mAb is 
required for the Pre-Clinical development studies. The case study then uses 
the quick win, fail fast clinical development paradigm (Paul et al. 2010), 
where the material required for Phase I & II is generated in a single batch for 
the Proof-of-Concept (PoC) development phase.  The average body weight 
of a US male was presumed to be 86kg (Ogden et al. 2004) and  therefore a 
single 4kg batch of mAb would be required for PoC development also 
accounting for non-clinical uses. This amount increases to 40kg of mAb for 
the phase III clinical trials and is produced by four 10kg batches at the 
Commercial batch scale allowing parallel process validation studies. The 
10kg Commercial batch size is based on the median market demand of the 
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top 15 mAb (200kg) (Kelley 2009) and the ability to process 20 batches per 
year. The cell culture titre also increases with clinical phase, where due to 
continued process development the titre was assumed to increase 2-fold 
from the PoC batch to the Phase III & Commercial batches. The scenario 
produced a 2.5g/L titre for the minimally developed Pre-Clinical and PoC 
batch before increasing to a final titre of 5g/L.  
 The base case manufacturing strategy used in the case study was based 
on a generic two-column mAb process (Kelley 2007; Kelley et al. 2008). The 
principal differences between the batch and semi-continuous unit operations 
are highlighted in Table 5.3. The key difference between the cell culture 
technologies is the length of culture, where a fed-batch fermentation lasts 12 
days allowing 20 batches to be processed a year from a single reactor. In 
contrast perfusion cell cultures can be run for much longer, however in this 
case study a culture duration of 28 days was selected, making an annual 
throughput of 10 batches possible. Longer cell culture durations would limit 
the reactor throughput and result in a need for more reactors leading to high 
facility costs to achieve the same batch throughput as a fed-batch reactor. 
The semi-continuous PCC system utilises three smaller columns compared 
to the batch system, these are loaded to 100% saturation increasing the 
binding capacity from 40 to 65 grams of mAb per litre of resin. To achieve the 
higher productivity the PCC system must be operated continuously requiring 
a 24-hour manufacturing shift. 
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Table 5.3. Key assumptions for alternate manufacturing strategies 
Clinical Trial Estimates 
Variable Values 
    Non-human primate dosage (mg/kg body weight)  700  
Non-human primate in Pre-Clinical trial  100  
Patient dosage (mg/kg body weight)  7  
Number of doses per patient per year  26  
Individuals in Phase I clinical trials (single dose)  40  
Individuals in Phase II clinical trials (6 month dose)  200  
Individuals in Phase III clinical trials (year dose)  2000  
    
USP Process Parameters 
    Fed-batch ATF 
Cell culture time (days) 12 28 
Harvest volumes 1 20 
Max VCD (million cells/mL) 10 50 
Max bioreactor volume (L) 20,000 1,500 
Annual number of batches 20 10 
   
DSP Process Parameters 
    Batch PCC 
Binding capacity (g/L) 40 65 
Bed height  (m) 0.25 0.1 
Number of columns      1 3 
Shift duration (hours)  12 24 
  
Cost Parameters 
  QCQA batch release costs ($/batch) 35,000 
Media cost ($/L) 3.1 
Protein A resin cost ($/L) 8000 
AEX resin cost ($/L) 1500 
Virus retention filtration membrane ($/m2) 3250 
Labour cost ($/hour) 58 
Chromatography process skid (15-600L/hr) ($) 226,000 
PCC process skid (15-600L/hr) ($) 1,080,000 
Chromatography column (Dia = 0.2m) ($) 132,000 
Chromatography column (Dia = 2m) ($) 218,000 
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Table 5.4. Number of drug candidates per company scale scenario 
Company Size Pre-Clinical PoC Phase III Commercial 
Large 20 14 4 2 
Medium 10 7 2 1 
Small 5 3 1  1* 
*One successful launch every two years. 
  
 Table 5.4 highlights the major differences between different sized 
companies with respect to the number of drug candidates (DC) at any given 
stage of the drug development pipeline. A large company has been defined 
as a company that aims to launch two new products per year. To achieve this 
level of success 20 new DC`s must enter Pre-Clinical trials, due to the high 
attrition rates seen in clinical development. The medium-sized company aims 
to launch one product a year and therefore requires 10 DC`s entering Pre-
Clinical trials per year. A small-sized company that aims to launch a new 
product every 2 years requires only 5 DC`s in Pre-Clinical trials per year. 
 
 
5.3 Results and Discussion 
 The decision-support framework was used to assess the cost-
effectiveness of five manufacturing strategies with different combinations of 
batch and continuous operations for cell culture, capture and polishing steps 
throughout the drug development pipeline. This was initially carried out by 
determining the direct (labour, media, buffers, chromatographic resin, filter 
membranes, QCQA batch release costs etc.) and indirect (depreciation and 
facility-dependent overheads) costs. These were used to establish the cost of 
goods per gram across combinations of different development phases (Pre-
Clinical through to Commercial production) and company sizes (small, 
medium and large). Each development phase required different 
manufacturing scales, batch numbers and material re-use strategies, and 
each company size resulted in different numbers of drug candidates at each 
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development phase. The economic outputs were then considered alongside 
operational and environmental metrics using a multi-attribute decision-
making technique for all the company sizes investigated. 
 
5.3.1 Impact of Development Phase on Cost Drivers 
 Figure 5.3 shows the individual cost components per product per phase 
as well as per gram for the base case batch scenario for each manufacturing 
scales in the development pipeline (0.5kg, 4kg, 40kg, and 200kg) for a 
medium-sized company. Figure 5.3a highlights that as expected the costs of 
chemicals (media, buffer) and single-use components (e.g. filters, bags) 
increase per product across the development phases in proportion to the kg 
and batch output. Hence the cost per gram for chemicals and single-use 
components remain relatively constant in Figure 5.3b as is typical for 
variable costs. The resin costs also increase as the manufacturing scale 
increases across the development phases but in contrast to the other cost 
categories, the resin cost decreases at the Commercial scale of production. 
The requirement to keep the resins product-specific, results in a high cost 
burden per batch in early development phases, because the resin is often 
discarded before reaching its full potential cycle lifetime. The early 
manufacturing scales (Pre-Clinical and PoC) only use the resin to purify a 
single batch of material and therefore the resin purchase cost accounts for 
over 80% of the material costs per batch. The later manufacturing scales 
(Phase III and Commercial) use the resin to purify multiple batches of 
material and therefore reduce the cost impact of the expensive resin as 
reflected in Figure 5.3b. The resin accounts for approximately 67% of the 
Phase III material costs and 29% of the Commercial material costs. Both 
manufacturing scales utilises the same sized columns but only the 
Commercial scale uses the resin until its full lifetime and therefore the resin 
cost is spread over multiple batches and reduces the related resin costs 
shown. 
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Figure 5.3. Direct cost of goods category breakdown across the different 
manufacturing scales required for each development phase for the base case 
scenario a) direct cost per product per phase and b) direct cost per gram. 
Categories: labour costs (grey dashed line), QCQA batch release costs (grey 
solid line), chromatographic resin costs (black solid line), fermentation media 
(black dotted line) and single use components and buffers (black dashed 
line).  
a 
b 
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 The labour and QCQA costs are scale-independent and rise in proportion 
to the increase in number of batches required per product across the 
development phases rather than the kg output (Figure 5.3a). As a result, 
their cost per gram values decrease with kg output (Figure 5.3b). Finally the 
indirect costs increase across the development phases in proportion to the 
increase in batch size and hence facility size. Figure 5.4 demonstrates as 
expected that the indirect cost per gram becomes less significant in the late 
clinical and Commercial phases since the costs are spread over more 
batches. 
 
 
 
Figure 5.4. Direct (black dashed line) and indirect (black line) cost of goods 
per gram across the different manufacturing scales required for each 
development phase for the base case scenario.  
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5.3.2 Impact of Company Size on Indirect Costs  
 Table 5.3 highlighted the difference in drug candidate throughput for 
each company size throughout the development pipeline. The difference in 
drug candidate throughput will affect the utilisation of the manufacturing 
suites and in turn impact the resulting manufacturing costs. Table 5.5 
highlights the effect of company size on key indirect costs for the base case 
scenario at the PoC scale of manufacture. The capital expenditure required 
to construct the facility to generate a 4kg PoC batch is the same for all the 
company sizes, however the resulting batch suite cost and indirect cost per 
gram is dependent on the batch throughput. The large-sized company has 
the highest batch throughput with 14 drug candidates being processed a year 
resulting in an utilisation rate of 70% and a batch suite cost of $292k. In 
contrast the small-sized company has a batch throughput of 3 drug 
candidates resulting in a batch suite cost ($1,364k) that is 4.5-fold higher 
relative to the large-sized company. 
 
Table 5.5. Effect of company size on indirect cost per gram for the base case 
scenario at the PoC (4kg) manufacturing scale  
Company 
Size 
Capital Expenditure 
(million $) 
Batch Suite Cost 
($/batch) 
Indirect/g 
($/g) 
Large 37.6 292,300 71 
Medium 37.6 584,600 141 
Small 37.6 1,364,000 330 
 
 
5.3.3 Batch versus Continuous COG/g Comparison 
 Figure 5.5 shows the COG/g breakdowns for the base case batch 
strategy and fully continuous strategy (ATF-CC) for the medium-sized 
company. The analysis highlights that the Pre-Clinical batch costs are 
dominated by indirect costs for the base case and direct costs for the 
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continuous strategy. The larger equipment sizes seen in batch processing 
lead to a higher batch suite cost of $255K per batch vs. $120K per batch for 
the smaller highly utilised continuous equipment. However the continuous 
operation requires significant labour resources to support the continuous 
manufacturing operations and therefore this increases the overall direct 
costs. 
 The base case is still dominated by indirect costs in the later 
manufacturing scales in the development pipeline (PoC, Phase III and 
Commercial). For example, the Phase III COG/g is dominated (70% of 
COG/g) by the batch suite cost (indirect costs), due to the costs only being 
spread over four batches in a commercial GMP facility. The continuous 
strategy sees a shift from the direct to indirect costs dominating COG/g for 
the later manufacturing scales. However the labour costs still account for a 
third of the COG/g. Traditionally the direct costs are expected to dominate 
with an increase in kg output, however due to the relatively low kg output in 
this scenario (200kg) the indirect costs continue to dominate COG/g. The 
indirect COG/g does decrease in significance with increasing company size 
with direct costs starting to dominate as kg putout increases (large company 
– 2x200kg products). 
 The smaller batch sizes seen earlier in the development pipeline have 
higher direct manufacturing costs per gram because some of the costs are 
scale independent. For example the QCQA batch release costs ($35,000) 
are constant between a Pre-Clinical and Commercial batch, but due to the 
difference in kg output (0.5kg to 200kg) the batch strategies Pre-Clinical 
QCQA cost per gram is $73/g compared to $3.4/g for the Commercial 
manufacturing scale. The same trend is seen in the batch strategy`s labour 
costs which accounts for nearly half the Pre-Clinical direct manufacturing 
costs at $128/g compared to the Commercial manufacturing scale with labour 
costs of $6/g. The overall percentage of direct costs increases for the 
Commercial manufacturing of the batch strategy, even with the real decrease 
in direct costs per gram. This is due to the significant drop seen in batch suite 
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costs, from the Phase III ($600K per batch) to Commercial ($240K per batch) 
manufacturing scale.  
  
 
Figure 5.5. A comparison of the direct costs per gram for the base case  (B) 
and continuous (C) strategy on a category basis for material costs (black), 
labour costs (light grey), QCQA batch release costs (dark grey) and indirect 
costs (white), between the different manufacturing scales for the base case 
scenario. The embedded table highlights the percentage cost contribution for 
the key direct cost categories.  
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 For the medium-sized company, the tool outputs predict that the 
integrated continuous ATF-CC strategy offers cost savings for Pre-Clinical 
and Clinical production, but becomes less economically attractive at the 
Commercial scale. This is due to the requirement for a second manufacturing 
production line, resulting in the duplication of equipment (USP and DSP). The 
higher utilisation rate of the GMP facility at this manufacturing scale is 
expected to lead to a significant reduction in indirect costs (as shown by the 
batch strategy). However, the extra equipment required for the additional 
production line means the reduction is not fully realised and with the 
significant labour requirements seen in the continuous strategy, the strategy 
is no longer able to offer an economically attractive COG/g as the batch 
scenario. 
 
5.3.4 Key Economic Metrics Across Company Size and Manufacturing 
Scale 
 The impact of both manufacturing scale (Pre-Clinical, PoC, Phase III, 
Commercial) and company size (small, medium, large) on the competiveness 
of the five alternative manufacturing strategies was investigated. The contour 
plots in Figure 5.6 (a, b, c) show the percentage difference in cost of goods 
per gram relative to the base case strategy and Table A5.1 details the 
equipment number and scales employed. 
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Figure 5.6. Contour plots showing the impact of manufacturing scale and 
manufacturing strategies on the percentage difference in cost of goods per 
gram relative to the base case scenario for a) the large-sized company, b) 
the medium-sized company and c) the small-sized company. (Pre-Clinical, 1 
x 0.5kg; PoC, 1 x 4kg; Phase III, 4 x 10kg; Commercial, 20 x 10kg). 
a 
b 
c 
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 Figure 5.6 highlights that the ATF perfusion-based manufacturing 
strategies are not able to compete with the fed-batch strategies at the 
Commercial scale of manufacture regardless of company size. The 
difference is most pronounced for the large-sized company, where the high 
drug candidate throughput in the development pipeline, results in the need to 
manufacture two commercialised products in a year. The ATF perfusion 
strategies are only able to generate 10 batches per year per production line 
and therefore require 4 parallel perfusion reactors with dedicated purification 
trains to meet the 40 batch annual demand. The resulting facilities are 
approximately twice as expensive as the corresponding fed-batch based 
facilities, which employ two staggered reactors utilising a single larger 
purification train. This effect is also seen for the medium and small-sized 
companies where two production lines are required to manufacture 20 
batches of a single successfully commercialised product. The resulting 
Commercial facilities are comparable in cost to the fed-batch based facilities 
and offer the same level of capital expenditure saving (~25%) versus the 
base case due the use of a smaller purification train offered by the 
continuous capture step. Figure 5.7a highlights that the inability of the ATF 
perfusion strategies to utilise a single production line for Commercial 
manufacture, results in the fed-batch based strategy FB-CB being the most 
economically attractive Commercial manufacturing strategy for all company 
sizes. 
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Figure 5.7. Contour plots showing the impact of manufacturing scale and 
manufacturing strategies on a) the most economically attractive 
manufacturing strategies for each scenario and b) the resulting cost per 
launch for all company sizes relative to the base case manufacturing 
strategy. (Pre-Clinical, 1 x 0.5kg; PoC, 1 x 4kg; Phase III, 4 x 10kg; 
Commercial, 20 x 10kg). 
 
 Figure 5.8 presents a detailed breakdown of the COG/g for all the 
alternative manufacturing strategies in a medium-sized company at the 
Phase III manufacturing scale. The figure highlights how the base case and 
alternative fed-batch based manufacturing strategies COG/g are dominated 
by indirect costs, due to the larger fermentation and purification capabilities 
required compared to the smaller highly utilised ATF perfusion-based 
strategies. The higher utilisation of the smaller process sequences seen in 
the ATF perfusion-based strategies is off-set by the ~2.5-fold increase in 
a 
b 
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labour demand required to operate the continuous capture step for the 
duration of the perfusion cell culture. The high labour demand and multiple 
production lines seen in the ATF perfusion-based strategies explains the 
inability of the strategies to offer a competitive alternative to the base case for 
Pre-Clinical manufacture in a large-sized company. 
 Figure 5.7a highlights that the FB-CB manufacturing strategy is the most 
consistent strategy, offering COG/g saving at all manufacturing and company 
scales relative to the base case. This is possible due to the continuous 
capture step which reduces the volume of expensive Protein A resin required 
and generates a more concentrated elution pool allowing a smaller 
purification train to be employed, reducing both direct and indirect batch 
costs. However the FB-CB does not offer the highest level of savings. This 
feat is achieved by the ATF-CB manufacturing strategy, which offers superior 
COG/g savings during clinical manufacture because it is able to reduce the 
size of the purification train even further by the continuous generation of 
small volumes of HCCF. This has a significant impact on the dominant 
material costs by replacing the resin cost with media cost, due to the 10-fold 
reduction in column volume and the 4-fold increase in fermentation media 
use. The FB-CC and ATF-CC also reduce the scale of the purification train 
they employ, however the continuous polishing steps result in the sub-
optimal scaling of the virus retention filtration operation. The batch-operated 
polishing strategies operate the virus retention filtration step for a complete 
10-hour shift to process the larger pooled batch (multiple eluate pools). The 
continuous-operated polishing strategies process each sub-batch (eluate 
pool) individually. However, the smaller process volumes do not translate into 
significantly lower virus filter areas in this case since the step duration is also 
shortened (to 2-3 hours) due to the coupling of the AEX and VRF steps. This 
combined with the multiple sub-batches processed per batch leads to a 3-fold 
increase in VRF filter costs per year. As a result, the optimal polishing 
strategy switches from continuous to batch at larger scales since the cost of 
the single-use virus filters required for each sub-batch in the continuous 
process becomes more expensive than a single larger virus filter in the batch 
process.  
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Figure 5.8. A comparison of cost of goods per gram with a detailed 
breakdown of material costs on a category basis for a) the base case, b) FB-
CB, c) ATF-CB, d) FB-CC, e) ATF-CC scenario for a Phase III clinical batch 
in a medium-sized company. 
a 
b 
c
d 
e 
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 The cost per launch of a successful drug candidate (DC) was a key 
economic metric used to compare the alternative manufacturing strategies 
encompassing the total risk-adjusted clinical development manufacturing 
cost. The cost per launch captures the costs of all the unsuccessful DCs 
incurred alongside the development of a successfully commercialised DC 
(10x Pre-Clinical DCs, 7x PoC DCs and 2x Phase III DCs). Figure 5.7b 
shows the percentage difference in the cost per launch of a successful drug 
candidate for all the alterative manufacturing strategies for all the company 
scales. The figure highlights how the FB-CB strategy offers the biggest cost 
saving (-22%) for a large-sized company. In contrast the ATF-CB strategy 
offers an even bigger cost saving for the small (-40%) and medium-sized (-
48%) companies, because only a single manufacturing line is required 
throughout. This allows a much smaller facility to be used compared to the 
FB-CB strategy and as the company size decreases the cost contribution for 
the indirect costs increase, allowing the ATF-CB strategy to half the cost for 
launch (small-sized company). 
 
5.3.5 Multi-Attribute Decision-Making 
 This section extends the analysis beyond economic metrics to include 
the environmental and operational benefits of each strategy. 
 
5.3.5.1 Environmental Impact Analysis 
 The tool was also used to capture the water and consumable usage of 
the alternative manufacturing strategies to assess the environmental impact 
of the strategies across a range of manufacturing and company scales. E 
factor values were derived for the usage of water (cell culture media, process 
buffers, CIP buffers and rinse water) and consumables (bags, membranes 
and resins) within the manufacturing process. Typical mAb manufacturing 
strategies (base case) consume water from 3,000 to over 7,000 kg water per 
kilogram product. The cell culture steps consume between 20% and 25% of 
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the total, with the chromatographic operations often surpassing 50% of the 
total (Ho et al. 2011). 
 
Table 5.6. E factor scores for alternate manufacturing strategies 
Manufacturing Strategies Water (kg/kg product) 
Consumable 
(kg/kg product) 
Base case 3900–7250 6–73 
FB-CB 3000–6400 8–61 
ATF-CB 2150–5500 6–35 
FB-CC 2750–7450 13–48 
ATF-CC 2300–5550 8–25 
 
 As expected all the alternative manufacturing strategies have a lower 
water E-Factor value in comparison to the base case strategy, where the 
difference in water usage can be directly related to the use of the continuous 
capture step and the resulting lower buffer requirement. Table 5.6 
demonstrates how the ATF perfusion-based manufacturing strategies have 
an even lower water E factor value than the fed-batch based strategies. A 
typical ATF-perfusion process without a continuous capture step has been 
shown to have higher process water usage compared to a Fed-batch process 
due to the high media usage. The removal of the dedicated primary 
clarification step and the use of the single use bioreactors (SUB) by the ATF 
perfusion process reduces the non-process water usage by ~30% (Pollock et 
al. 2013b). These trends when combined with a continuous capture step 
allow the ATF perfusion-based strategies to reduce their total water usage by 
25-45%. In contrast the manufacturing strategies utilising continuous capture 
and polishing (FB-CC, ATF-CC) have higher water E-Factor values 
compared to the continuous capture and batch polishing manufacturing 
strategies (FB-CB, ATF-CB). The increase in E-Factor value is due to the 
higher number of sub-batches processed every batch, causing an increase in 
CIP buffers and rinse water used in cleaning between sub-batches. 
232 
 
 The consumable E-Factor values are highly dependent on the amount of 
single use technologies and resin volume employed by the strategies. Table 
5.6 highlights how all the manufacturing strategies have a lower consumable 
E-Factor that the base case due to the use of the continuous capture step 
reducing the resin volumes used. The ATF perfusion-based strategies have a 
lower E-factor value than the fed-batch based strategies even though they 
employ SUBs because this increase in consumable waste is countered by 
the 10-fold reduction in resin volume seen. 
 
5.3.5.2 Operational Risk Analysis 
 A risk score was assigned to each manufacturing strategy to assess the 
operational feasibility with respect to strategy robustness (likeliness of batch 
failure). The risk score is a ranking value used to compare the alternate 
strategies and does not capture a true value for batch failure risk. Table 5.7 
shows the risk score for both the upstream and downstream sections of the 
manufacturing strategies. The upstream risk score was calculated by 
assuming that each addition to the bioreactor had a 1 in 1,000 chance of 
causing contamination (Pollock et al. 2013b). The Fed-batch based 
strategies have a total of ten reactor additions (initial media fill and nine 
feeds) and therefore have a 1% risk score. In contrast the perfusion 
strategies had approximately twenty eight additions due to the daily media 
exchanges and therefore have a risk score of 2.8%. A similar approach was 
also used for the downstream risk score, where for every virus retention 
filtration (VRF) operation there was a 1 in a 1,000 chance of a filter or quality 
control failure. The same logic was applied to chromatographic operations 
where every cycle there was a 1 in 1,000 chance of a failure event of which 
10% of these would lead to a batch failure. Table 5.7 demonstrates how the 
ATF perfusion-based strategies have a higher risk score for both the 
upstream and downstream due to the high number of media exchanges and 
cycles in the continuous chromatography capture step. The continuous 
capture and polishing based strategies also have high risk scores due to the 
numerous VRF operations, resulting in the ATF-CC strategy having the 
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highest risk score of all the strategies due to high number of processing 
operations per batch. 
 
Table 5.7. Batch risk for alternate manufacturing strategies 
Manufacturing Strategies USP DSP Risk Score 
Base case 1% 0.2% 1.2% 
FB-CB 1% 0.3% 1.3% 
ATF-CB 2.8% 2.3% 5.1% 
FB-CC 1% 1% 2% 
ATF-CC 2.8% 4.6% 7.4% 
 
 
5.3.5.3 Overall Aggregate Strategy Scores 
 The results of reconciling the trade-offs between economic, 
environmental and operational outputs using a single multi-attribute score are 
reviewed in this section. The key output was the overall aggregate strategy 
score over a range of combination ratios to reflect the impact of the relative 
importance of the economic, environmental and operational scores on the 
ranking of the manufacturing strategies. Figure 5.9 depicts the sensitivity of 
the overall aggregate strategy scores to the economic attribute combination 
ratios for the alternative manufacturing strategies for a range of company 
scales (large, medium and small). For the scenario shown in Figure 5.9, the 
environmental attribute combination ratio was fixed at 0.1 and the operational 
attribute combination ratio varied with the economic attribute combination 
ratio such that the sum of all the combination ratios always remained equal to 
one. Figure 5.9a illustrates that for a large-sized company the FB-CB is 
always the preferred manufacturing strategy regardless how important the 
economic or operational feasibility is ranked. The ATF perfusion-based 
manufacturing strategies fail to achieve a high aggregate score due to their 
high risk scores and inability to offer significant economic advantage 
compared to the preferred FB-CB manufacturing strategy. In a medium-sized 
company (Figure 5.9b) when the economic benefits are 2x as important as 
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the operational benefits (R1 = 0.6, R3 = 0.3) the ATF-CB and FB-CB 
strategies are equally attractive. The ability of the ATF-CB strategy to offer a 
superior ranking as the importance of the economic benefits increases is due 
to superior savings offered in the cost to launch and capital expenditure at 
this company scale. Figure 5.9c illustrates how the high importance placed 
on capital expenditure and cost to launch by the small-sized company, 
results in the ATF-CB becoming the preferred manufacturing choice with 
increasing economic importance. However if the operational benefits are 
more important the FB-CB strategy is still the favoured manufacturing 
strategy. When the operational attribute combination ratio was fixed at 0.1 
and the environmental attribute combination ratio varied with the economic 
attribute combination ratio as shown in Figure A5.1. The FB-CC strategy is 
able to outcompete the FB-CB strategy across all company scales, because 
the higher risk score is countered by the higher significance placed on the 
lower E factor ratings.  The remaining relationships with the ATF-CB able to 
offer superior ranking as the importance of the economic benefits is 
maintained for the medium and small sized companies. 
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Figure 5.9. Sensitivity plots portraying the effect of the economic attribute 
combination ratio (R1) in the overall aggregate scores when the 
environmental combination ratio is constant, for a) the large-sized company, 
b) medium-sized company and c) small-sized company, for the base case 
(solid black line), FB-CB (grey dashed line), ATF-CB (grey dotted line), FB-
CC (black dashed line) and ATF-CC (black dotted line). 
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5.4 Conclusion 
This chapter has evaluated the feasibility of continuous biopharmaceutical 
manufacturing strategies utilising perfusion cell culture and semi-continuous 
chromatography throughout the product life cycle from Pre-Clinical to 
Commercial manufacture. The decision-support framework was configured to 
cope with the continuous nature of the manufacturing strategies. The 
framework was used to provide an in-depth analysis of the potential of mAb 
manufacturing facilities based on the standard batch platform compared to 
the alternate continuous manufacturing strategies across a range of 
manufacturing and company scales so as to represent scenarios of 
relevance to industry. The analysis highlighted the underlying cost drivers for 
each strategy and evaluated the robustness of each strategy via a risk score. 
The derivation of environmental indices not only provided useful benchmarks 
of E factors for continuous processes but also enabled the economic, 
environmental and operational outputs to be assessed simultaneously. The 
tool predicts that the complete continuous strategy (ATF-CC) struggles to 
compete on economic, environmental and robustness fronts for Commercial 
manufacture, but offers saving during product development (Pre-Clinical, 
PoC, Phase III). In contrast the hybrid batch and continuous strategies (FB-
CB & ATF-CB) outperform the continuous strategy for all manufacturing and 
company scales. The FB-CB strategy was shown to be the most consistent 
strategy offering savings at all manufacturing and company scales and is 
always the preferred manufacturing strategy for the large sized company. 
The ATF-CB strategy is predicted to offer superior economic benefits during 
product development that outweigh its lower robustness and increased 
Commercial manufacturing costs for the medium and small sized companies. 
However the analysis highlighted that if the operational feasibility is 
considered more important than the economic benefits the hybrid FB-CB 
strategy is found to be the preferred strategy for all company scales. The 
simulation framework therefore acts as a valuable test bed for assessing the 
potential of novel continuous strategies to cope with different scales of 
operation and decisional drivers. 
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6 Process Validation: Principles & Practices 
 
6.1 A Paradigm Shift in Process Validation 
Over the last two decades the biopharmaceutical industry has 
changed dramatically, with a growth rate out stripping pharmaceuticals sales, 
the establishment of a number of biological blockbusters and more recently 
the emergence of biosimilars (Aggarwal 2011). In contrast the United States 
Food and Drug Administration (FDA) has been supporting the same 
guidance document on process validation for the biopharmaceutical industry 
since 1987. However in January 2011, it released its first major update to its 
original 1987 guidance document. The original 1987 guidance titled 
“Guideline on General Principles of Process Validation” centred on 
instrument testing and qualification, and placed significant emphasis on 
collecting large amounts of data from a number of validation batches to 
demonstrate process robustness and repeatability. In contrast the latest 
guidance document “Guidance for Industry – Process Validation: General 
Principles and Practices” is a significant shift in process validation strategy 
with the guidance concentrating on risk management, quality by design 
(QbD) and the implementation of a continuous improvement process 
(PharmOut 2011; Scott 2011). The new guidance has been the principle 
driver in global drug registration in recent years and as a result has directly 
contributed to a number of quality guidance’s from the International 
Conference on Harmonisation Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) (PharmOut 2011; Scott 2011). The 
ICH brings together multiple regulatory authorities and industrial 
representatives in Europe, the US and Japan to harmonise scientific and 
technical aspects of drug registration.  
The ICHs quality guidelines form the basis for of all drug registrations 
in Europe, the US and Japan, with process validation covered in a number of 
key quality guidance documents: ICH Q7 (Good Manufacturing Practice), 
ICH Q8 (Pharmaceutical development), ICH Q9 (quality risk management), 
ICH Q10 (pharmaceutical quality system) and ICH Q11 (Development and 
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Manufacturing of Drug Substances). These guidelines are directly referenced 
in the new FDA guidance document and highlight the shift from data driven 
process validation to a more holistic risk management derived process 
validation (PharmOut 2011). The new holistic guideline approach is centred 
on the `Products Lifecycle` and as a result can be defined as a three-stage 
approach to process validation: from process design, to process qualification 
followed by continued process verification. This new paradigm is a significant 
shift from the 1987 FDA guidelines, which promoted validation as a one-off 
event prior to product commercialisation. The FDA is keen to stress to 
companies that this thinking is no longer acceptable and states accordingly: 
 
“Focusing exclusively on qualification efforts without also 
understanding the manufacturing process and associated variations may not 
lead to adequate assurance of quality. After establishing and confirming the 
process, manufacturers must maintain the process in a state of control over 
the life of the process, even as materials, equipment, production 
environment, personnel, and manufacturing procedures change.”  
 
This new stance has triggered significant debate within the industry as 
it comes to terms with the long-term impact of the new guidelines. Table 6.1 
highlights the activities a company is now expected to fulfil over the lifecycle 
of the product and process. 
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Table 6.1. Validation stages and expected activities 
Stage Intent Typical Activities 
Process 
Design 
To define the commercial 
process on knowledge gained 
through development and 
scale up activities. 
The outcome is the design of a 
process suitable for routine 
manufacture that will 
consistently deliver product 
that meets its critical quality 
attributes. 
• A combination of product and 
process design (QbD) 
• Product development activities 
• Experiments to determine 
process parameters, variability 
and necessary controls 
• Risk assessments 
• Other activities required to 
define the commercial process 
• Design of experiment testing 
 
Process 
Qualification 
To confirm the process design 
as capable of reproducible 
commercial manufacturing. 
 
• Equipment & utilities 
qualification 
• Process Performance 
Qualification (PPQ) 
• Strong emphasis on the use of 
statistical analysis of process 
data to understand process 
consistency and performance 
 
Continued 
Process 
Validation  
To provide ongoing assurance 
that the process remains in a 
state of control during routine 
production through quality 
procedures and continuous 
improvement initiatives. 
 
• Procedural data collection from 
every batch. 
• Data trending and statistical 
analysis 
• Equipment and facility 
maintenance calibration 
• Management review and 
production staff feedback 
• Improvement initiatives through 
process experience 
Adapted from PharmOut 2011. 
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  The new validation paradigm places significant emphasis on non-
qualification activities (traditional IQ, OQ, PQ activities) such as product 
development and procedural monitoring for on-going process verification 
(PharmOut 2011). This new approach has been described as the “four Ds”: 
Design (for standard requirements & control), Demonstration (by 
experimentation & verification), Documentation (employing Good 
Manufacturing Practices & sound scientific rigour) and Determination (on-
going process monitoring) (PharmOut 2011). This approach requires an 
increasing knowledge of statistics and risk management to realise the 
required linkages between risk management and QbD into process validation 
activities. Figure 6.1 demonstrates how these new approaches and 
requirements will impact a products lifecycle, from early development to 
commercial manufacture. The core risk management theme highlighted in 
Figure 6.1, starts with definition of the products Critical Quality Attributes 
(CQA) in early development. An initial risk assessment then ranks the 
process parameters with respect to potential impact on the products CQA. 
The high-risk parameters are then studied in process characterisation (PC) 
studies and can feedback into the process design. After PC a further risk 
assessment is carried out to evaluate the findings from the PC work and re-
rank the process parameters and confirm expected linkages to product CQA. 
The top parameters are then classified as critical process parameters (CPP) 
to highlight the level of control required to maintain product quality and 
process robustness. The CPP and their controls are documented in the 
process Control Strategy Document (CSD), which also includes the required 
future process monitoring strategy of the product CQA and CPP to 
demonstrate Continuous Process Verification (CPV). The expectation for 
CPV is the continued monitoring and statistical trending of CQA and CPP 
over time. This should allow companies to discover trend shifts, which will 
highlight future problems earlier ideally preventing process failures, product 
losses, regulatory issues and expensive mistakes (Scott 2011). The generic 
development and lifecycle approach shown in Figure 6.1, will not always be 
the same between companies due to their differences in risk management 
and the level of QbD principles they maybe adopting in their products 
registration filing. 
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Figure 6.1. Validation activities throughout a products lifecycle. Adapted from 
Scott 2011. 
 
 
6.2 Validation Concerns for Continuous Processes 
The current drug registration quality guidance regulations are 
surprising silent on designating or even promoting a preference to the mode 
of manufacturing to be used, with respect to batch and continuous 
processing. One the most common concerns cited with continuous 
processing is the regulatory impact of batch/lot definition. The ICH Q7 quality 
guidance document defines a batch/lot as follows: 
 
“A specific quantity of material produced in a process or series of 
processes so that it is expected to be homogeneous within specified limits. In 
the case of continuous production, a batch may correspond to a defined 
fraction of the production. The batch size can be defined either by a fixed 
quantity or by the amount produced in a fixed time interval.”   
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The ICH definition demonstrates that the current regulatory definition 
for both batch and lot are applicable to a continuous process. This definition 
is aligned within all ICH supporters and also in US law, with an analogous 
definition cited in the Code of Federal Regulations (CFR). 
While the regulatory agencies looked primed to accept the idea of a 
complete continuous manufacturing process for biopharmaceutical product 
registration, there are still a number of concerns with validating the individual 
continuous and semi-continuous unit operations employed. For example 
continuous perfusion cell culture unit operations have one principle difference 
to batch cell cultures, which is the longer operating time. The longer 
operating times will raise the risk of genetic or production drift in the cell line, 
bioburden contamination and a higher risk for the introduction and growth of 
viruses (Kozlowski 2013). These regulatory concerns have been answered 
for a number of products in recent years, however these product registrations 
were filed using the 1987 FDA guidance document and as a result no 
continuous perfusion based process has been successfully registered under 
the new regulations. Continuous perfusion cell culture processes are unlikely 
to cause significant regulatory concerns under the new regulations, due to 
historic acceptance by multiple manufactures and products.  
In contrast continuous chromatographic unit operations, which are 
widely seen in the food and chemical industries, have yet to appear in the 
manufacture of a registered biopharmaceutical product. Similarly, the 
principal validation concern for continuous chromatographic unit operations is 
the longer operating time and how it impacts the separation power of the step 
with respect to contaminants and product quality (Kozlowski 2013). Another 
key area of concern is how to validate the viral clearance of a continuous 
chromatography step (Kozlowski 2013). Chapter 4 of this thesis 
demonstrated that in principle the separation power of a protein A continuous 
chromatography unit operation is representative with fresh resin and by 
leveraging a single column lifetime study can demonstrate robust separation 
power for the lifetime of the resin. The use of small-scale cycle studies 
followed by supporting manufacturing scale verification is a widely accepted 
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principle for batch chromatographic operations and therefore should be 
acceptable for continuous chromatographic unit operations as well. Validation 
of the continuous chromatography’s viral clearance will be more of a 
challenge and is likely to one of key hurdles for this technology to overcome if 
it is to be utilised in biopharmaceutical manufacture. Viral clearance for batch 
chromatography systems is established by experimentally deriving the Log 
clearance and the partitioning of the viral panel. Due to the wealth of 
information available to mAb manufacturers due to the use of platform 
manufacturing strategies (constant resin section and operating conditions), 
the likely Log clearance and fraction location of partitioned virus can be 
predicted. However the impact of recycling flow-through and wash volumes 
over a new column with low product concentration may significantly alter how 
the virus is fractionated over the system and therefore the viral log clearance 
of that step. To date there is no official guidance or published data on the 
impact of viral clearance across a continuous chromatographic system.  
There appears to be no significant regulatory roadblocks towards the 
adoption of continuous biopharmaceutical manufacturing, with the concepts 
in ICH Q7, Q8, Q9, Q10 and Q11 all being applicable to continuous 
processing (Kozlowski 2013). There are however, some unit operation 
dependant validation concerns (viral clearance in a continuous 
chromatographic system) that still need to be addressed before the 
technology is widely adopted. To date continuous perfusion cell cultures are 
the only continuous technology to feature in a manufacturing process of a 
successfully registered biopharmaceutical product. Until a more developed 
continuous manufacturing process is successfully registered under ICH 
guidelines there will always remain a degree of uncertainty around 
continuous processing in biopharmaceutical manufacturing. However the 
FDA and EMEA stress in any public disclosure that dialog is always 
encouraged around any regulatory issues, suggesting there is string path 
forward to answer any regulatory compliance concerns around continuous 
technologies. 
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7 Conclusions & Future Work 
  Biopharmaceutical manufactures currently find themselves in very 
challenging environment, with increasing competition, lower reimbursement 
levels and the loss of patent exclusivity for a number of blockbusters. To 
remain competitive in such an environment companies are looking to reduce 
R&D and manufacturing costs by improving their manufacturing platform 
processes whilst maintaining flexibility and product quality. As a result 
companies are now exploring whether they should choose conventional 
batch technologies or invest in novel continuous technologies, which may 
lead to lower production costs. Currently the only way to explore these 
technologies is with proof of concept laboratory scale evaluations, which are 
highly resource intensive. In the last decade, the potential impacts on clinical 
and commercial manufacturing of new technologies has been routinely 
assessed with decision-support tools. However, to date the publication of any 
decision-support tools capable of capturing multiple continuous unit 
operations, or even a continuous biopharmaceutical manufacturing process 
has not been seen. This chapter summarises the efforts made in this thesis 
to create such a dynamic tool as part of a decision-support framework that is 
capable of simulating and optimising continuous monoclonal antibody (mAb) 
manufacturing in this challenging environment. It also points out a number of 
future developments that will increase the understanding of the potential 
benefits and pitfalls of continuous processing in the biopharmaceutical 
sector. 
 
7.1 Overall Conclusions 
 The primary aim of this the thesis has been the design and development 
of a decision-support framework that is capable of simulating and optimising 
continuous mAb manufacturing processes in the challenging environment 
biopharmaceutical manufactures find themselves. The resulting tool 
described throughout this thesis is capable of facilitating more informed 
decision-making when evaluating continuous and semi-continuous 
245 
 
manufacturing strategies, with respect to their economic, environmental and 
operational feasibility. The aim of this body of work was realised through a 
number of objectives that formed the basis of each of the preceding chapters. 
Theses chapters clearly demonstrate that the framework is a powerful test 
bed for assessing the potential of novel continuous technologies and 
manufacturing strategies to cope with future titres, multiple scales of 
operation and key decisional drivers. 
Chapter 2 details the development approach adopted in the 
establishment of the resulting decision-support framework. The framework 
was built to tackle the complex problem domain found in biopharmaceutical 
manufacturing. This was achieved through the utilisation of deterministic 
discrete-event simulation, Multi-Attribute Decision Making and Monte Carlo 
simulation techniques. Hence, the framework is capable of describing a large 
number of scenarios within the industry, highlighting the key economic, 
environmental and operational metrics of the facilities, processes and 
technologies investigated under uncertainty. This was made possible by the 
hierarchal nature of the framework, which simulates the manufacturing 
scenarios of interest on a number of levels of detail ranging from high-level 
process performance metrics to low-level ancillary task estimates. This 
approach made the resource-demand profiles for tasks more realistic, 
allowing the constraining nature of facility resources to be modelled more 
accurately in both deterministic and stochastic simulations. The hierarchal 
approach adopted also aided the development of semi-continuous unit 
operation process models with the addition of a sixth hierarchal layer (sub-
batches) making it possible to track the merging and splitting of batches. This 
allowed the framework to fulfil the primary aim of this work, namely assisting 
decision-making in the evaluation of alternative manufacturing strategies 
employing semi-continuous unit operations. The frameworks ability to capture 
the impact of a number of individual semi-continuous unit operations and 
manufacturing strategies linking multiple semi-continuous unit operations has 
been demonstrated in Chapters 3, 4 & 5. 
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 Chapter 3 presents the utilisation of the framework to assist in cost-
effective bioprocess design in the presence of uncertainty and multiple 
conflicting outputs relating to economic, environmental and operational 
feasibility. The tool was configured to cope with the continuous nature of 
perfusion cultures, the consequences of failures as well as the use of single-
use bioreactors and bags when the scale was appropriate.  The tool was 
used to provide an in-depth analysis of the potential of mAb facilities based 
on fed-batch cell culture systems compared to 1st (spin-filter) and 2nd 
(alternating tangential flow; ATF) generation perfusion systems across a 
range of titres and scales of operation so as to represent different possible 
scenarios of relevance to industry. The analysis highlighted the underlying 
cost drivers for each process and identified the robustness of each strategy 
along with the root causes for the differences. The derivation of 
environmental indices not only provided useful benchmarks of E factors for 
fed-batch and perfusion processes but also enabled the economic, 
environmental and operational outputs to be assessed simultaneously. This 
was achieved using a multi-attribute decision-making technique that provided 
a more holistic approach to managing conflicting outputs. The tool’s 
predictions that the spin-filter perfusion strategy struggles to compete on 
economic, environmental, operational and robustness fronts at most titres 
and scales provides insight into its limited use in industrial processes.  In 
contrast, the ATF perfusion strategy is predicted to offer economic benefits 
that outweigh its lower robustness (versus traditional fed-batch cell culture), 
even when it achieves cell densities that are only 3 fold higher than fed-batch 
strategies for typical titre and demand levels.  However, the analysis 
highlighted that if environmental or operational feasibility (e.g. ease of 
operation and validation) are considered more important than process 
economics savings then the fed-batch strategy is found to be preferred.  
 In Chapter 4 the frameworks capability to simulate multiple downstream 
purification manufacturing strategies was demonstrated by assessing the 
impact of semi-continuous chromatography for product capture across a 
product’s lifecycle from Proof-of-Concept to Commercial manufacture. Semi-
continuous chromatography is a new technology and as such there were no 
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dedicated design and optimisation protocols. Therefore a novel approach 
was adopted linking small-scale single-column experimental studies to the 
framework. The experimental work was key to determining the critical design 
parameters for the periodic counter current system (PCC) investigated, 
through the derivation of mass balance, scale-up and scheduling equations. 
The integrated techno-economic evaluation presented in the chapter predicts 
that semi-continuous chromatography has the ability to offer manufacturing 
cost savings in early clinical phase material generation, which can be 
significant due to the high attrition rates of early phase projects. The analysis 
also demonstrated the obstacles to using such a technology at commercial 
scale and the importance in the selection of the protein A resin employed. 
The framework was then employed to determine the semi-continuous system 
specification required to operate with similar costs to a standard batch 
process while a process change application is pursued for a theoretical 
transition from semi-continuous chromatography in early development to a 
conventional batch chromatography system in commercial manufacture. 
Chapter 5 demonstrates the fulfilment of the primary thesis aim, by 
presenting a feasibility evaluation of multiple continuous biopharmaceutical 
manufacturing strategies utilising perfusion cell culture and semi-continuous 
chromatography throughout the product life cycle from Pre-Clinical to 
Commercial manufacture. The framework was used to provide an in-depth 
analysis of the potential of mAb manufacturing facilities based on the 
standard batch platform compared to the alternate continuous manufacturing 
strategies across a range of manufacturing and company scales so as to 
represent scenarios of relevance to industry. The analysis highlighted the 
underlying cost drivers for each strategy and evaluated the robustness of 
each strategy via a risk score. The derivation of environmental indices not 
only provided useful benchmarks of E factors for continuous manufacturing 
strategies but also enabled the economic, environmental and operational 
outputs to be assessed simultaneously. The tool predicts that the complete 
continuous strategy (ATF perfusion linked to continuous purification train) 
struggles to compete on economic, environmental and robustness fronts for 
Commercial manufacture, but offers saving during product development (Pre-
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Clinical, Proof-of-Concept & Phase III). In contrast the hybrid batch and 
continuous strategies (fed-batch or ATF perfusion linked to a continuous 
capture step, followed by batch polishing steps; FB-CB & ATF-CB) 
outperform the continuous strategy for all manufacturing and company scales 
investigated. The FB-CB strategy was shown to be the most consistent 
strategy offering savings at all manufacturing and company scales and is 
always the preferred manufacturing strategy for the large sized company 
(targeting 2 product launces a year). The ATF-CB strategy is predicted to 
offer superior economic benefits during product development that outweigh 
its lower robustness and increased Commercial manufacturing costs for the 
medium and small sized companies (targeting one product launch every year 
or every two years, respectively). However the analysis highlighted that if the 
operational feasibility is considered more important than the economic 
benefits the hybrid FB-CB strategy is found to be the preferred strategy for all 
company scales.  
In addition to the techno-economic evaluations presented in Chapters 
3, 4 & 5, it was recognized that the potential benefits of the new or alternative 
technologies needed to be balanced against any regulatory concerns. 
Chapter 6 addresses the current state of drug registration and assesses the 
regulatory impact of new continuous technologies and continuous 
manufacturing in general. The chapter highlights that there appears to be no 
significant regulatory roadblocks towards the adoption of continuous 
biopharmaceutical manufacturing, with the concepts in ICH Q7, Q8, Q9, Q10 
and Q11 all being applicable to continuous processing. There are however, 
some unit operation dependant validation concerns (viral clearance in a 
continuous chromatographic system) that still need to be addressed before 
the technology is widely adopted. To date continuous perfusion cell cultures 
are the only continuous technology to feature in a manufacturing process of a 
successfully registered biopharmaceutical product. Until a more developed 
continuous manufacturing process is successfully registered under ICH 
guidelines, there will always remain a degree of uncertainty around 
continuous processing in biopharmaceutical manufacturing. However the 
FDA and EMEA stress in any public disclosure that dialog is always 
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encouraged around any regulatory issues, suggesting there is strong path 
forward to answer any regulatory compliance concerns around continuous 
technologies. 
 
7.2 Future Work 
The objective of this body of work has been the design and 
development of a decision-support framework that is capable of simulating 
and optimising continuous mAb manufacturing processes. The preceding 
chapters have demonstrated how the framework has successfully fulfilled this 
objective. The framework is clearly a powerful test bed for assessing the 
potential of novel continuous technologies and manufacturing strategies, and 
can therefore act as a strong foundation from which future work can build; 
several examples are highlighted and discussed below. 
In addition to the continuous unit operations assessed in this thesis 
there are a further number of new and existing unit operations that could also 
be assessed. A number of alternative continuous cell culture systems exist 
that may not achieve the high cell densities offered by the ATF system, but 
still offer competitive cell densities with potentially lower system failure rates. 
These include gravity settlers, hydrocyclones and centrifugal cell retention 
devices, which do not employ filters to retain cells and therefore are not as 
prone to fouling related failure events (Voisard et al. 2003). Concentrated 
fed-batch cell culture is a new hybrid cell culture technology, which employs 
batch and continuous cell-culture techniques (Clincke et al. 2013a; Clincke et 
al. 2013b). A concentrated fed-batch cell culture is operated in a batch 
manner but is continuously fed fresh media to promote ultra-high cell 
densities and product concentrations. Unlike perfusion cell culture both the 
cells and product are retained in the bioreactor for a similar duration to a 
typical fed-batch culture (12-14 days), resulting in viable cell densities in the 
100s of millions (108) of cells per ml and mAb yields 6 times higher than a 
typical fed-batch culture (Clincke et al. 2013a; Clincke et al. 2013b).  
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The latest continuous unit operations are not just confined to cell 
culture systems, with single pass tangential flow filtration (TFF) (Dizon-
Maspat et al. 2012), continuous precipitation (Jaquez et al. 2010) and 
multicolumn counter current solvent gradient purification (MCSGP) to name a 
few (Müller-Späth et al. 2008).  Single pass TFF allows continuous 
concentration or conductivity reduction of a product stream, offering a 
continuous replacement to batch ultrafiltration (Dizon-Maspat et al. 2012). 
Another technology showing a lot of potential is continuous precipitation, 
which builds on a historical knowledge base of batch precipitation seen in 
early mAb manufacturing and transforms this existing technology into a 
scalable continuous purification approach. Biogen Idec has recently realised 
this potential by demonstrating how continuous precipitation can be 
successfully integrated into a continuous purification train consisting of 
precipitate isolation, precipitate storage, and downstream purification through 
two flow-through chromatography steps (Jaquez et al. 2010). MCSGP builds 
on the recent influx of semi-continuous chromatography systems, but instead 
concentrates on the polishing chromatographic operations instead of the 
initial product capture. The system employs multiple ion-exchange columns 
(3-6) to divide closely related charge variants of a continuous mAb product 
stream into separate product pools, replacing low-throughput batch gradient 
elution chromatographic steps (Müller-Späth et al. 2008). All the prescribed 
technologies have the potential to significantly impact the way mAbs are 
manufactured in the future, and the framework could act as test bed for these 
technologies and be used to visualize their impact in future hybrid and 
continuous manufacturing strategies.  
Chapter 5 highlighted how manufacturing strategies with varied 
combinations of batch and continuous technologies offer different levels of 
economic benefits depending on the scale of production and the company’s 
size. These findings are also supported by conclusions in Chapter 4, which 
highlights the economic benefits of using continuous capture in early clinical 
development to reduce resin costs, but the disadvantage of using such a 
technology during commercial manufacturing. This suggests that a company 
can realise significant economic benefits by adopting various levels of 
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continuous manufacturing technologies throughout their pipeline portfolio. For 
example, the most economical way of producing a new mAb product would 
be to use a hybrid early phase clinical facility employing ATF perfusion cell 
culture linked to a continuous capture step. Before transferring to a large-
scale commercial facility (contract manufacturer or in-house) for late stage 
clinical and commercial manufacturing employing hybrid (fed-batch cell 
culture linked to continuous capture) or conventional batch technologies. To 
establish what the optimal configuration of manufacturing sites and the 
technologies they should employ is currently outside the reach of this version 
of the framework presented in this thesis. However, by adding additional 
hierarchal layers the framework would be able to tackle the next key 
decisional domain of the biopharmaceutical industry; portfolio management. 
A number of tools exist that have demonstrated their ability to optimise a 
company`s product portfolio with respect to site management, contract 
manufacturing and partnering decisions. These approaches can be readily 
combined into this framework to take the current short-term techno-economic 
evaluations presented in this work into long-term capacity planning and 
portfolio management.  
In conclusion, the future work that has been outlined looks to increase 
the scope of continuous technologies the framework can simulate and also 
broaden the level of analysis possible, by building on the existing frameworks 
methods and approaches discussed in this thesis. Over the next decade 
continuous technologies are expected to become more prevalent in 
biopharmaceutical manufacturing, a paradigm shift of this magnitude has not 
been seen since chromatography became a platform technology in the 
1970s. Due the high number of technologies and hybrid manufacturing 
strategies a framework that is capable of relating proof-of-concept technology 
evaluations to portfolio optimisation, will have a significant impact on the rate 
of uptake of continuous technologies. 
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9  Appendices 
9.1 Chapter 2 Appendix 
9.1.1 Tables 
 
Table A2.1. Block Types Employed Within the Simulation Framework 
Block Source Block Function 
Pre-fabricated   
 
Executive 
Manages event scheduling, 
providing simulation control, item 
allocation and attribute 
management. 
 
Item 
Generation 
Creates default items with no 
attribute values. 
 
Set Attribute 
Value 
Sets the attribute properties of an 
item passing through the block. 
 
Get Attribute 
Value 
Displays and outputs the attribute 
properties of an item passing 
through the block. 
 
Item Queue 
Queues items and release them 
based on a user selected algorithm. 
(e.g. first in first out, first in last out 
etc.) 
 
Item Activity 
 
Holds one or more items and release 
them based on a delay time from an 
attribute. 
 
Item Exit Passes items out of the simulation. 
 
Interchange 
(Item & 
Flow) 
Acts as a tank interfacing between 
flow and times 
 
Tank 
(Flow) 
Acts as a source, storage or sink for 
flow. 
 
Valve 
(Flow) 
Controls, monitors and transfers 
flow. 
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Block Source Block Function 
Customised   
 
Item Routing Directs item to specific block based upon attribute or database value. 
 
Resource 
Router & 
Queue 
Checks if a resource is available and 
record its use or holds item until 
resource is available. 
 
Resource 
Recorder & 
Pool 
Records contents of pool and signals 
with resource queue when a 
resource is available. 
Bespoke   
  
Passing 
Block 
Executes bespoke algorithms and 
equations specified in ModL on item 
arrival, sets attribute and database 
values. 
    
Remote 
Generation 
Block 
On remote signal or time trigger from 
executive block. Executes bespoke 
algorithms and equations specified 
in ModL and generates a new item 
and sets attribute and database 
values. 
 
Remote 
Signalling 
Block 
On remote signal or time trigger from 
executive block. Executes bespoke 
algorithms and equations specified 
in ModL updates database values 
and can send remote signals to 
other blocks. 
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Table A2.2. Equipment size, cost and exponential scaling coefficients 
Equipment SizeLow SizeHigh SizeBase 
CostBase 
(USD) Coefficient 
Stainless Steel 
Vessel (m3) 
0.01 1 0.01 31807 0.137 
1 5 1 61119 0.0681 
5 80 5 73207 0.6254 
Stainless Steel 
Bioreactor (m3) 
0.01 0.03 0.02 104000 0 
0.03 0.3 0.1 728000 0 
0.3 0.8 0.1 800000 0 
0.8 20 0.1 54505 0.1882 
Single Use 
Bioreactor Skid 
(m3) 
0.002 0.2 0.2 88000 0 
0.2 0.5 0.5 98000 0 
0.5 1 1 110000 0 
1 2 2 174614 0 
Spin-filter (L) 0 2000 N/A 35000 0 
ATF Skid (L) 
1 3 N/A 20000 0 
4 20 N/A 30000 0 
20 100 N/A 90000 0 
100 200 N/A 130000 0 
200 800 N/A 180000 0 
800 1600 N/A 360000 0 
Centrifuge (L/hr) 100 16000 1800 757500 1.105 
DF Skid (m2) 2 400 5 7500 0.7565 
Chromatography 
Skid (L) 
1 10 50 677174 0 
10 100 50 677174 0 
100 3000 100 677174 0.3133 
VRF Skid (m2) 0.01 1 1 257420 0 1 50 1 257420 0.2216 
UFDF Skid (m2) 0.1 2 1 103250 0 2 100 2 142971 0.4696 
The cost models shown were primarily sourced from the projects 
industrial sponsor (Sa V Ho, Pfizer R&D Global Biologics, MA, USA). Other 
cost models were derived from discussions with Morten Munk, Christoffer Bro 
and Jacob Jensen (CMC biologics, Copenhagen, Denmark) and Karol Lacki 
and Roger Nordberg (GE Healthcare, Uppsala, Sweden). 
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Table A2.3. Consumables costs  
Consumable Description Size Unit Cost (USD) Reuses 
Filter Membranes 
Depth Filter 0.2 250 1 
Viral Retention Filter 0.2 3250 1 
50 kDa UF Filter 0.2 250 30 
Chromatographic 
Resins 
Protein A 1 8000 200 
Anion Exchange 
Resin 1 1500 100 
Cation Exchange 
Resin 1 1500 100 
Disposable Bags 
500L 500 453 1 
200L 200 324 1 
100L 100 360 1 
50L 50 52 1 
Single Use 
Bioreactors 
50L Wave 25 210 1 
100L Wave 50 420 1 
200L Wave 100 462 1 
200L SUB 200 4200 1 
500L SUB 500 5460 1 
1000L SUB 1000 8260 1 
2000L SUB 2000 9800 1 
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Table A2.4. Raw material costs 
Buffer Name Cost (USD per litre) 
Fermentation Media 3.133 
Fermentation Feed 13.070 
Fermentation Flush Buffer 0.044 
Chromatography Packing Buffer 0.376 
Protein A - Equilibrium Buffer 0.842 
Protein A - Wash Buffer 0.067 
Protein A - Elution Buffer 0.067 
Protein A - Regeneration Buffer 0.257 
Protein A - Storage Buffer 2.699 
Protein A - Cleaning Buffer 0.064 
2.0M Acetic Acid 0.440 
2.0M Tris Base 6.763 
CEX - Cleaning Buffer 0.615 
CEX - Equilibrium Buffer 0.072 
CEX - Wash Buffer 0.032 
CEX - Elution Buffer 0.104 
CEX - Regeneration Buffer 0.626 
CEX - Storage Buffer 0.630 
AEX - Cleaning Buffer 0.672 
AEX - Equilibrium Buffer 0.265 
AEX – Wash Buffer 0.044 
AEX - Regeneration Buffer 0.625 
AEX - Storage 0.620 
Nano Virus Flush Buffer 0.065 
Nano Virus CIP Flush Buffer 0.064 
Diafiltration Buffer  0.044 
Final Diafiltration Buffer 0.122 
Caustic Rinse 0.192 
Acid Rinse - 3% w/v Phosphoric acid 0.120 
WFI 0.020 
 
Table A2.5. Consumable unit masses 
Consumable Mass per Unit (kg) Unit 
Chromatography Resin 1.5 litre of resin 
Depth Filter 2 m2 of filter 
Viral Retention Filter 4 m2 of filter 
UFDF Filter 2 m2 of filter 
50L Wave 2 bioreactor bag 
100L Wave 2 bioreactor bag 
200L Wave 2 bioreactor bag 
200L SUB 2.8 bioreactor bag 
500L SUB 3.2 bioreactor bag 
1000L SUB 7 bioreactor bag 
2000L SUB 7 bioreactor bag 
500L Disposable Bag 3.4 bag 
200L Disposable Bag 2.6 bag 
100L Disposable Bag 1.8 bag 
50L Disposable Bag 1.7 bag 
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9.1.2 Equations 
9.1.2.1 Centrifugation 
 !!!"# = !!!!" ∗ !"#$%       (A2.1) !"#!"# = !!!"#!!!" !"#!"         (A2.2) !"#!"#$% = !"#!" − !"#!"#       (A2.3) !"#$!"# = ! !!!"#!"#!"#        (A2.4) 
 
9.1.2.2 Depth Filtration 
 !"#!"# = !"#!" + !"#$!" ∗ !"#$ℎ!"      (A2.5) 
!!"#$%&& = !"#!"#!!"∗!"#$!"        (A2.6) 
!"#$!"# = ! !"#$!"∗!"#!"∗!"#$%!"#!"#        (A2.7) 
 
9.1.2.3 Viral Retention Filtration 
 !!"!"# = !"#!" + !"#$!"# ∗ !"#$ℎ!"#      (A2.8) !!"#$%&& = !"#!"!!"#∗!"#$!"#       (A2.9) !"#$!"# = !"#$!"∗!"#!"∗!"#$%!"#!"#        (A2.10) 
 
9.1.2.4 Concentration and Diafiltration 
 !!"#$%&& = !!"#!$#%&'%("# + !!" + !!"#$%     (A2.11) !"#!"# = !"#!"#"$#%#" ∗ !"#$%      (A2.12) !"#$!"# = !"#$!"#$%        (A2.13) 
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9.1.2.5 Chromatography 
 
!!"!"#$ = !! ∗ !"#!"#!!        (A2.14) !"#!"#$%& = !"#!"#$ ∗ !"#!"#$!!      (A2.15) !!" = ! ∗ !"#!"#$        (A2.16) 
!!"#$%&& = ! !"#!"##$%!!"         (A2.17) 
!!!"#$ = !!"∗!"#$%!!"#$%&         (A2.18) 
!"#$!"# = !!"#$%&∗!!"#$%!"#!"#        (A2.19) 
 
9.1.2.6 Viral Inactivation 
 !"#!"# = !"#!"#$ + !"#!"#$ + !"#!"     (A2.20) 
!"#!!"# = !"#$!"∗!"#!"∗!"#$%!"#!"#        (A2.21) 
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9.2 Chapter 3 Appendix 
9.2.1 Tables 
Table A3.1. Uncompleted qualitative factor questionnaire 
 
1. Please rank the qualitative factors in order of importance, where 1 = the 
most important factor and 5 = the least important factor. 
2. Then rate the impact of each factor, where 1 = low impact, 2 = medium 
impact and 3 = high impact, for each cell culture option (see example factor). 
 
  
Qualitative factors 
Rank of factor 
 
(1 – 5, 1 = most 
important & 5 = 
least important) 
Rating 
(1 = Low, 2 = Medium,  
3 = High) 
FB SPIN ATF 
Example Factor  2 3 3 
Ease of control / operation     
Ease of validation (time / effort)     
Ease of development (time / effort)     
Operational flexibility     
Batch-to-batch variability     
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Table A3.2. Completed qualitative factor questionnaire – Respondent #1 
 
 
Table A3.3. Completed qualitative factor questionnaire – Respondent #2 
 
 
Qualitative factors 
Rank of factor 
 
(1 – 5, 1 = most 
important & 5 = 
least important) 
Rating 
(1 = Low, 2 = Medium,  
3 = High) 
FB SPIN ATF 
Example Factor  2 3 3 
Ease of control / operation 1 1 3 3 
Ease of validation (time / effort) 3 1 3 3 
Ease of development (time / effort) 2 1 3 3 
Operational flexibility 5 1 3 3 
Batch-to-batch variability 4 1 3 3 
Qualitative factors 
Rank of factor 
 
(1 – 5, 1 = most 
important & 5 = 
least important) 
Rating 
(1 = Low, 2 = Medium,  
3 = High) 
FB SPIN ATF 
Example Factor  2 3 3 
Ease of control / operation 3 3 1 3 
Ease of validation (time / effort) 4 3 1 2 
Ease of development (time / effort) 5 3 1 2 
Operational flexibility 2 3 1 2 
Batch-to-batch variability 1 2 1 3 
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Table A3.4. Completed qualitative factor questionnaire – Respondent #3 
 
 Table A3.5. A comparison of the key economic metrics 
* Percentage change relative to the fed-batch process 
+ Disposable bioreactor (maximum volume 2000 Litres) 
 
 
Qualitative factors 
Rank of factor 
 
(1 – 5, 1 = most 
important & 5 = 
least important) 
Rating 
(1 = Low, 2 = Medium, 
3 = High) 
FB SPIN ATF 
Example Factor  2 3 3 
Ease of control / operation 3 1 3 1 
Ease of validation (time / effort) 4 1 3 2 
Ease of development (time / effort) 5 1 3 2 
Operational flexibility 2 1 3 2 
Batch-to-batch variability 1 2 3 1 
   
Number and size of 
fermenters (L)   
Capital 
investment 
(million RMU) 
  COG/g (RMU/g)  
Titre 
(g/L) 
Demand 
(kg/year) FB SPIN ATF FB SPIN* ATF* FB SPIN* ATF* 
           
2 100 1 x 2800 1 x 1440 1 x 430+ 63 -25% -40% 127 0 % -22% 
 500 2 x 6720 4 x 1800 2 x 1080+ 102 -6% -45% 51 +43% -21% 
 1000 2 x 13430 8 x 1800 3 x 1440+ 119 +39% -42% 34 +97% -11% 
           
5 100 1 x 1150+ 1 x 580 1 x 180+ 48 -7% -25% 100 +12% -12% 
 500 1 x 5620  2 x 1440 1 x 860+ 88 -23% -46% 39 +17% -20% 
 1000 2 x 5380 3 x 1920 2 x 860+ 104 -14% -41% 29 +20% -19% 
           
10 100 1 x 570+ 1 x 290 1 x 90+ 43 +2% -19% 92 +16% -9% 
 500 1 x 2810 1 x 1440 1 x 430+ 79 -30% -42% 35 -2% -19% 
 1000 1 x 5620 2 x 1440 1 x 860+ 102 -27% -46% 25 +7% -22% 
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9.2.2 Figures 
 
Figure A3.1. Sensitivity plots showing the effect of the economic attribute 
combination ratio (R1) on the overall aggregate scores when (a) the 
operational attribute combination ratio is constant and (b) the environmental 
attribute combination ratio is constant. For the fed-batch (solid line), spin-filter 
(dashed line), and ATF (dotted line) processes, for 100 kg/year scale of 
production and equivalent titre of 5 g/L. 
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Figure A3.2. Sensitivity plots showing the effect of the economic attribute 
combination ratio (R1) on the overall aggregate scores when (a) the 
operational attribute combination ratio is constant and (b) the environmental 
attribute combination ratio is constant. For the fed-batch (solid line), spin-filter 
(dashed line), and ATF (dotted line) processes, for 1000 kg/year scale of 
production and equivalent titre of 5 g/L. 
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9.3 Chapter 4 Appendix  
9.3.1 Tables 
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Table A4.2. Batch Uptake Experimental Data for the New Resin Sample 
 
Table A4.3. Batch Uptake Experimental Data for the Cycled Resin Sample 
 
  
NEW Eppendorf #1 Eppendorf #2 Eppendorf #3 
Time 
(Seconds) 
Mobile 
Phase 
(mg) 
Stationary 
Phase 
(mg) 
Binding 
Capacity 
(mg/mL) 
C/Co 
Mobile 
Phase 
(mg) 
Stationary 
Phase 
(mg) 
Binding 
Capacity 
(mg/mL) 
C/Co 
Mobile 
Phase 
(mg) 
Stationary 
Phase 
(mg) 
Binding 
Capacity 
(mg/mL) 
C/Co 
0 0 4.67 0 1 0 4.67 0 1 0 4.67 0 1 
120 0.49 4.19 12.15 0.9 0.49 4.19 12.21 0.9 0.4 4.28 9.9 0.92 
240 0.68 3.99 17 0.86 0.8 3.88 19.77 0.84 0.66 4.02 16.39 0.87 
360 0.89 3.79 22.04 0.82 1.1 3.58 27.42 0.77 0.91 3.77 22.51 0.81 
480 1.08 3.6 26.97 0.77 1.15 3.53 28.62 0.76 0.98 3.7 24.46 0.8 
600 1.17 3.51 29.23 0.75 1.33 3.35 33.16 0.72 1.17 3.51 29.09 0.76 
720 1.26 3.41 31.49 0.74 1.41 3.27 35.17 0.7 1.24 3.44 30.91 0.74 
840 1.46 3.22 36.26 0.69 1.5 3.18 37.37 0.68 1.43 3.25 35.55 0.7 
960 1.57 3.11 39.16 0.67 1.59 3.09 39.63 0.67 1.53 3.15 38.12 0.68 
1080 1.69 2.99 42.22 0.64 1.69 2.99 42.1 0.64 1.59 3.09 39.73 0.67 
1200 1.62 3.06 40.47 0.66 1.72 2.96 42.9 0.64 1.69 2.98 42.24 0.64 
2400 n/a n/a n/a n/a 2.18 2.5 54.47 0.54 2.18 2.5 54.45 0.54 
3600 n/a n/a n/a n/a 2.44 2.24 60.76 0.48 2.44 2.24 60.88 0.48 
5400 2.36 2.32 58.82 0.5 2.54 2.14 63.33 0.46 2.61 2.07 65.12 0.45 
7200 2.51 2.17 62.64 0.47 2.7 1.98 67.44 0.43 2.69 1.99 67.18 0.43 
9000 2.56 2.11 64 0.46 2.78 1.9 69.46 0.41 2.76 1.92 68.86 0.42 
10800 2.6 2.08 64.91 0.45 2.77 1.9 69.24 0.41 2.76 1.92 68.88 0.42 
 
Cycled Eppendorf #1 Eppendorf #2 Eppendorf #3 
Time 
(Seconds) 
Mobile 
Phase 
(mg) 
Stationary 
Phase 
(mg) 
Binding 
Capacity 
(mg/mL) 
C/Co 
Mobile 
Phase 
(mg) 
Stationary 
Phase 
(mg) 
Binding 
Capacity 
(mg/mL) 
C/Co 
Mobile 
Phase 
(mg) 
Stationary 
Phase 
(mg) 
Binding 
Capacity 
(mg/mL) 
C/Co 
0 0 4.62 1.44 1 0 4.62 0 1 0 4.62 0 1 
120 0.64 3.98 17.3 0.87 0.49 4.13 13.6 0.9 -0.3 4.92 -6.09 1.07 
240 0.67 3.95 18.09 0.86 0.4 4.22 11.36 0.92 0.11 4.51 4.03 0.98 
360 0.64 3.98 17.41 0.87 0.37 4.25 10.62 0.93 0.27 4.36 7.97 0.95 
480 0.91 3.71 24.05 0.81 0.75 3.87 20.02 0.84 0.47 4.15 13.15 0.9 
600 0.91 3.71 24.1 0.81 0.66 3.97 17.73 0.86 0.55 4.07 15.17 0.89 
720 1.05 3.57 27.53 0.78 0.85 3.77 22.57 0.82 0.66 3.96 17.9 0.86 
840 1.1 3.53 28.73 0.77 0.83 3.8 21.98 0.83 0.75 3.88 19.97 0.84 
960 1.15 3.47 30.09 0.76 0.96 3.66 25.28 0.8 0.85 3.77 22.66 0.82 
1080 1.2 3.42 31.28 0.75 0.95 3.67 25.19 0.8 0.88 3.74 23.4 0.81 
1200 1.33 3.29 34.59 0.72 0.99 3.63 26 0.79 0.9 3.72 23.79 0.81 
2400 1.5 3.12 38.83 0.68 1.3 3.32 33.94 0.72 1.22 3.4 31.79 0.74 
3600 1.6 3.02 41.35 0.66 1.4 3.22 36.43 0.7 1.36 3.27 35.23 0.71 
5400 1.69 2.93 43.61 0.64 1.52 3.1 39.39 0.68 1.49 3.14 38.48 0.68 
7200 1.61 3.02 41.46 0.66 1.6 3.02 41.31 0.66 1.57 3.05 40.54 0.67 
9000 1.69 2.93 43.61 0.64 1.58 3.04 40.85 0.66 1.64 2.98 42.39 0.65 
10800 1.74 2.88 44.94 0.63 1.66 2.96 42.88 0.65 1.67 2.95 43.08 0.64 
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Table A4.4. Batch Uptake Experimental Data for the NaOH Cycled Resin 
Sample 
 
Table A4.5. Isotherm Experimental Data for the New Resin Sample 
 
  
NaOH Eppendorf #1 Eppendorf #2 Eppendorf #3 
Time 
(Seconds) 
Mobile 
Phase 
(mg) 
Stationary 
Phase 
(mg) 
Binding 
Capacity 
(mg/mL) 
C/Co 
Mobile 
Phase 
(mg) 
Stationary 
Phase 
(mg) 
Binding 
Capacity 
(mg/mL) 
C/Co 
Mobile 
Phase 
(mg) 
Stationary 
Phase 
(mg) 
Binding 
Capacity 
(mg/mL) 
C/Co 
0 0 4.73 0 1 0 4.73 0 1 0 4.73 0 1 
120 0.46 4.28 9.92 0.91 0.4 4.34 8.43 0.92 0.08 4.65 0.64 0.99 
240 0.72 4.01 16.5 0.85 0.53 4.2 11.76 0.89 0.12 4.61 1.51 0.98 
360 1.01 3.73 23.73 0.79 0.65 4.08 14.85 0.87 0.54 4.2 11.92 0.89 
480 1.21 3.52 28.89 0.75 0.9 3.83 21.07 0.82 0.79 3.95 18.23 0.84 
600 1.19 3.54 28.4 0.75 1.01 3.72 23.8 0.79 0.82 3.91 19.11 0.83 
720 1.33 3.41 31.71 0.73 1.17 3.57 27.71 0.76 0.99 3.74 23.34 0.8 
840 1.38 3.35 33.07 0.71 1.23 3.5 29.28 0.75 0.99 3.74 23.31 0.8 
960 1.53 3.2 36.79 0.68 1.36 3.38 32.46 0.72 1.23 3.5 29.4 0.74 
1080 1.57 3.17 37.66 0.67 1.4 3.34 33.46 0.71 1.25 3.48 29.89 0.74 
1200 1.64 3.1 39.46 0.66 1.48 3.25 35.63 0.69 1.34 3.39 32.07 0.72 
2400 2.05 2.69 49.67 0.57 1.95 2.78 47.34 0.59 1.82 2.91 44.08 0.62 
3600 2.27 2.46 55.31 0.53 2.16 2.58 52.43 0.55 2.07 2.67 50.21 0.57 
5400 2.35 2.38 57.31 0.51 2.32 2.41 56.59 0.51 2.28 2.45 55.55 0.52 
7200 2.45 2.29 59.67 0.49 2.3 2.43 56.11 0.52 2.39 2.34 58.25 0.5 
9000 2.53 2.2 61.76 0.47 2.38 2.35 58.08 0.5 2.42 2.31 59.02 0.49 
10800 2.48 2.25 60.5 0.48 2.41 2.32 58.87 0.5 2.44 2.29 59.53 0.49 
 
NEW Experiment #1 Experiment #2 Experiment #3 
Challenge 
Load (mg) 
Mobile 
Phase (mg) 
Stationary 
Phase (mg) 
Binding 
Capacity 
(mg/mL) 
Mobile 
Phase (mg) 
Stationary 
Phase (mg) 
Binding 
Capacity 
(mg/mL) 
Mobile 
Phase (mg) 
Stationary 
Phase (mg) 
Binding 
Capacity 
(mg/mL) 
0.23 0 0.23 9.03 0.01 0.23 8.81 0 0.23 9.2 
0.44 0 0.45 17.94 0 0.44 17.41 0 0.43 17.12 
0.66 0 0.7 27.88 0.01 0.71 28.31 0 0.65 25.67 
0.88 0.01 0.9 35.69 0.01 0.93 37.1 0.01 0.83 33.02 
1.09 0.01 1.14 45.27 0.01 1.16 46.29 0.01 1.14 45.39 
1.28 0.04 1.32 52.66 0.02 1.37 54.72 0.01 1.25 49.88 
1.47 0.09 1.48 58.92 0.07 1.56 62.18 0.08 1.53 60.87 
1.76 0.22 1.53 60.82 0.18 1.65 65.65 0.22 1.65 65.61 
1.96 0.37 1.63 65.12 0.32 1.69 67.4 0.39 1.65 65.87 
2.2 0.55 1.66 66.33 0.51 1.69 67.52 0.57 1.76 70.06 
2.42 0.85 1.57 62.51 0.72 1.74 69.32 0.76 1.72 68.59 
2.65 0.99 1.64 65.58 0.95 1.7 67.97 1.04 1.73 68.98 
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Table A4.6. Isotherm Experimental Data for the Cycled Resin Sample 
 
Table A4.7. Isotherm Experimental Data for the NaOH Cycled Resin Sample 
  
Cycled Experiment #1 Experiment #2 Experiment #3 
Challenge 
Load (mg) 
Mobile 
Phase (mg) 
Stationary 
Phase (mg) 
Binding 
Capacity 
(mg/mL) 
Mobile 
Phase (mg) 
Stationary 
Phase (mg) 
Binding 
Capacity 
(mg/mL) 
Mobile 
Phase (mg) 
Stationary 
Phase (mg) 
Binding 
Capacity 
(mg/mL) 
0.24 0 0.22 10.1 0 0.23 10.52 0 0.21 9.49 
0.49 0 0.46 20.91 0 0.48 21.67 0 0.4 18.2 
0.66 0.02 0.61 28.03 0.02 0.57 26.14 0.01 0.63 28.66 
0.87 0.03 0.79 36.03 0.04 0.77 35.42 0.04 0.8 36.52 
1.09 0.19 0.9 41.11 0.15 0.89 40.62 0.19 0.88 40.03 
1.29 0.36 0.92 42.32 0.35 0.88 40.22 0.36 0.91 41.61 
1.47 0.57 0.92 42.18 0.56 0.91 41.42 0.57 0.92 42.03 
1.74 0.77 0.96 43.81 0.76 0.93 42.34 0.8 0.94 43.2 
1.97 1 0.92 41.93 1 0.9 41.35 0.95 0.94 42.84 
2.17 1.12 0.99 45.5 1.1 0.99 45.3 1.05 0.99 45.19 
2.41 1.27 0.98 44.92 1.3 0.98 44.88 1.33 0.98 44.89 
2.65 1.47 0.98 44.74 1.46 0.99 45.35 1.18 0.96 43.71 
 
NaOH Experiment #1 Experiment #2 Experiment #3 
Challenge 
Load (mg) 
Mobile 
Phase (mg) 
Stationary 
Phase (mg) 
Binding 
Capacity 
(mg/mL) 
Mobile 
Phase (mg) 
Stationary 
Phase (mg) 
Binding 
Capacity 
(mg/mL) 
Mobile 
Phase (mg) 
Stationary 
Phase (mg) 
Binding 
Capacity 
(mg/mL) 
0.23 0 0.21 9.66 0 0.21 9.65 0 0.2 8.78 
0.49 0 0.42 19.29 0 0.46 20.87 0 0.45 20.46 
0.67 0.02 0.61 27.84 0.01 0.63 28.7 0.01 0.61 27.95 
0.89 0.03 0.81 36.86 0.02 0.85 38.94 0.01 0.83 38.03 
1.1 0.06 0.98 45.06 0.04 1.19 54.54 0.01 1.05 48.05 
1.29 0.09 1.16 53.18 0.07 1.23 56.22 0.04 1.28 58.71 
1.47 0.21 1.26 57.86 0.24 1.28 58.86 0.11 1.36 62.32 
1.63 0.4 1.27 58.41 0.47 1.28 58.5 0.15 1.15 52.85 
1.97 0.6 1.31 60.15 0.66 1.28 58.76 0.62 1.27 58.19 
2.17 0.73 1.37 62.89 0.88 1.28 58.83 0.71 1.32 60.3 
2.4 0.98 1.36 62.15 1.1 1.3 59.53 0.86 1.25 57.2 
2.64 1.23 1.35 62.02 1.27 1.33 61 1.14 1.16 53.13 
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9.3.2 Figures 
Figure A4.1. Langmuir regression plots for the new resin sample. 
 
 
Figure A4.2. Langmuir regression plots for the cycled resin sample 
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Figure A4.3. Langmuir regression plots for the NaOH cycled resin sample 
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9.4 Chapter 5 Appendix 
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6.1.1. Figures 
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Figure A5.1. Sensitivity plots portraying the effect of the economic attribute 
combination ratio (R1) in the overall aggregate scores when the 
environmental combination rate is constant, for a) the large-sized company, 
b) medium-sized company and c) small-sized company, for the base case 
(solid black line), FB-CB (grey dashed line), ATF-CB (grey dotted line), FB-
CC (black dashed line) and ATF-CC (black dotted line). 
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